Structure-based design of inhibitors of CXCR4. by Meier, Jason Bradley, 1980-
University of Louisville 
ThinkIR: The University of Louisville's Institutional Repository 
Electronic Theses and Dissertations 
12-2011 
Structure-based design of inhibitors of CXCR4. 
Jason Bradley Meier 1980- 
University of Louisville 
Follow this and additional works at: https://ir.library.louisville.edu/etd 
Recommended Citation 
Meier, Jason Bradley 1980-, "Structure-based design of inhibitors of CXCR4." (2011). Electronic Theses 
and Dissertations. Paper 962. 
https://doi.org/10.18297/etd/962 
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's 
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized 
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the 
author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu. 
STRUCTURE-BASED DESIGN OF INHIBITORS OF CXCR4 
By 
Jason Bradley Meier 
B.S., University of Louisville, 2005 
A Dissertation 
Submitted to the Faculty of the 
School of Medicine of the University of Louisville 
In Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
Department of Biochemistry and Molecular Biology 
University of Louisville 
Louisville, Kentucky 
December 2011 
Copyright 2010 by Jason Bradley Meier 















Jason Bradley Meier 
B.S., University of Louisville, 2005 
 
A Dissertation Approved on 
  






By the following Dissertation Committee 
 
 
       
John O. Trent, Dissertation Director 
 
 
       
Thomas C. Geoghegan 
 
 








       
B. Haribabu 
ACKNOWLEDGEMENTS 
I would like to thank my mentor, Dr. John O. Trent, for his guidance, patience and 
gentle prodding which helped me to bring this thesis to a close. 
I would also like to thank my committee, Dr. William Dean, 
Dr. Thomas Geoghegan, Dr. Haribabu Bodduluri, and Dr. Robert Mitchell 
for their advice and assistance. 
I would especially like to thank my wife, Renate, for her understanding, 
patience and her love and my son Noah for his unconditional love which has 
brought a new light into my life. 
I would like to thank my lab mates, Dr. M. Clarke Miller and Dr. Indira Chaudhuri 
for their assistance and for creating a welcoming, family-like lab environment. 
Finally, I would like to thank my mother and father; Barry and Sheryl Meier for 
helping me become the man that I am today. 
iii 
ABSTRACT 
STRUCTURE-BASED DESIGN OF INHIBITORS OF CXCR4 
Jason Bradley Meier 
November 17,2011 
Metastasis is a complex process requiring directed migration of metastatic 
cells to favorable microenvironments. Increased CXCR4 expression has been 
implicated in more invasive, aggressive and metastatic tumor phenotypes and 
poor patient survival in twenty-three forms of cancer. CXCR4 has been linked to 
cancer metastasis and CXCR4 expression on the cell surface of tumor cells has 
been linked to increased migration and homing of neoplastic cells to sites where 
stromal cells express the chemokine CXCL 12 such as the lung and bone 
marrow. In this dissertation, we will utilize structure based drug design to identify 
inhibitors of CXCR4 targeting the extracellular surface of the receptor, as well as 
the intracellular interface between the GPCR and G-protein. Our screens of the 
extracellular surface identified one compound, ECLVS14, which inhibits 
chemotaxis with an IC50 value of 5 j..IM, and is highly selective for CXCR4 
without significant cytotoxicity. Subsequent QSAR analysis of the structure of this 
inhibitor reveals the importance of the 1-[bis (phenyl methyl) amino] methyl moiety 
and the fact that electronegative modifications of the terminal benzene enhance 
activity. Subsequent Molecular dynamics simulations of the compound in 
complex with CXCR4 reveal that the compound induces significant modifications 
iv 
of the receptor structure. Our intracellular screens represent a novel screening 
strategy targeting the intracellular region of CXGR4 interacting with Gai, which 
identified ten compounds selectively inhibiting GXGR4 with IG50 values of 10 IJM 
or less. Three of the most active compounds from the extracellular and 
intracellular screens were tested in an in vivo anti-metastatic animal model, 
successfully demonstrating the anti-metastatic activity of these compounds. In 
total this work demonstrates that structure based drug design utilizing in silico 
analysis in combination with in vitro and in vivo testing can be utilized to develop 
novel lead compounds which can function as anti-metastatics. 
v 
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CHAPTER I: INTRODUCTION 
Metastasis presents an unresolved and difficult clinical problem 
Tumor metastasis represents a significant portion of the morbidity and 
mortality attributable to neoplasia [1]. Axillary lymph node micrometastasis or 
occult metastasis of 2mm or less correlates poorly with disease-free and overall 
survival [2]. Bone metastasis is present in 30-50% of patients with highly 
metastatic cancers such as breast, prostate, and non-small cell lung cancer [3]. 
Development of metastases requires a complex process of cellular 
evolution including several distinct transitions from primary carcinoma in situ to 
cells capable of establishing new metastatic foci, (see Figure 1) [4, 5]. 
Neoplastic cells must proliferate and invade at the primary site. These cells must 
then leave the primary tumor and enter the blood stream, in a process known as 
intravasation. Neoplastic cells extravate from the blood stream and attach to 
surfaces at foci of metastasis [6]. Established by Paget in 1889, the "seed and 
soil hypothesis" stipulates that neoplastic cells only establish metastatic foci in 
favorable microenvironments [6, 7]. 
The diffuse and systemic nature of metastatic disease renders many 
conventional treatment modalities ineffective, presenting a particularly perplexing 
predicament for treatment. Prior to metastasis, neoplasia can be 
effectivelytreated by surgical excision with clear margins and localized radiation. 
Once the neoplastic cell's metastatic capability is disabled, the disease reverts to 
1 
Figure 1: The process of metastasis of neoplastic cells from primary 
tumors to target organs. Neoplastic cells proliferate and invade at their primary 
locus. Selected cells gain the capability of leaving the primary tumor and entering 
the systemic circulation. Tumor cells extravate in target organs such as the lung, 
liver, bone marrow and brain. Once adherent, selected neoplastic cells will 
survive in favorable microenvironments and proliferate to form metastatic foci. 
Reproduced from [6]. 
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Figure 1: The process of metastasis of neoplastic cells from primary 
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an earlier stage, and becomes a cancer that is once again isolated to its primary 
site and any metastatic foci. Neoplastic growth would continue in a linear fashion, 
but without systemic spread, conventional surgery/chemoradiation could have a 
greater probability of success. An anti-metastatic approach largely mirrors the 
clinical reality. For example, 84% of newly diagnosed lung cancer has already 
progressed past early stage disease upon time of diagnosis [8], making treating 
and inhibiting the metastasis of the primary tumor a greater concern than 
inhibition of the growth of the primary tumor. Unfortunately there are no primary 
anti-metastatic treatments approved by the FDA or in clinical trials. 
CXCR4 plays a key role in Tumor metastasis. 
A wide number of molecules such as cytokines, chemokines and their 
receptors and growth factors have been implicated in the metastatic properties of 
cancer cells [9-15]. In 2001 the involvement of chemokine receptors in breast 
cancer metastasis was reported [9]. In a seminal Nature paper, Muller et al 
delineated a theory of metastasis which centered on chemoattraction, a process 
illustrated in Figure 2. Metastatic breast cancer cells displayed increased cell 
surface expression of CXCR4 and CXCR4's ligand CXCL 12 was highly 
expressed in lung, lymph node, bone marrow and liver tissues. Muller found that 
CXCL 12 induced more malignant and metastatic phenotypes with increased 
actin modification and pseudopodia formation in cells expressing CXCR4. 
CXCL 12 and CCL21 also were found to induce metastatic cell migration. Protein 
extracts from several organs were found to induce chemotactic migration by the 
cancer cells, with lung, lymph node, bone marrow and liver tissues inducing the 
4 
Figure 2: Metastatic breast cancer cells migrate to regions of elevated 
CXCL 12 concentration. Reproduced from [16]. MOiler et al. found that 
metastatic breast cancer cells (patient samples and in the MDA-MB-231 cell line) 
express elevated levels of cell surface CXCR4. CXCR4 ligand CXCL 12 
expression was increased in sites of metastatic foci, including lymph nodes, lung, 
liver and bone marrow. Metastatic cells migrated to regions of elevated CXCL 12 
concentration, and cells with elevated CXCR4 surface expression formed stable 
metastatic foci. 
5 
Figure 2: Metastatic breast cancer cells migrate to regions of elevated 






most migration. Finally, metastasic models, using mammary fat pad or tail vein 
injection of metastatic MDA-MB-231 cells, CXCR4 neutralization by antibody was 
found to reduce lung metastasis with a rate of relative suppression of 61-68%. 
CXCR4 has been demonstrated to playa critical role in angiogenesis [17] 
and metastasis [18] of several tumors, including basal cell carcinoma [17], thyroid 
cancer [18], squamous cell carcinoma [19], neuroblastoma [20], ovarian [21], 
melanoma [22], renal cell carcinoma [23], hepatocellular carcinoma [24], breast 
[25], colon [26], lung [25], pancreatic [27] and prostate cancers [25]. Chinni et al 
expanded on the Muller theory by demonstrating that bone metastatic prostate 
cancer cells express cell surface CXCR4, and the CXCR4/CXCL 12 interaction 
was essential to migration and bone marrow invasion [28]. Additional research 
has determined that knockdown or inhibition of CXCR4 impedes growth [29] and 
metastasis [9, 30, 31] of neoplastic breast cancer cells. Phillips et al [32] 
demonstrated that non-small cell lung cancer (NSCLC) tumor specimens and 
NSCLC derived cell lines, (such as A549) express CXCR4 and that these cells 
migrate towards CXCL 12, with increased intracellular signaling in the form of 
increased intracellular calcium mobilization and MAPK activation. They also 
demonstrated that NSCLC metastasis could be prevented in nude mice through 
the application of a CXCR4-specific antibody, with rate of relative suppression of 
around 50% for bone marrow and brain metastasis. 
A recent publication by Karnoub et al [33] suggested an alternative 
mechanism for metastasis. In this report, they demonstrated that mesenchymal 
stem cells (MSCs) within the tumor stroma can induce increased metastasis in 
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primary tumors. Their mechanism for this increased metastasis centered on 
increased CCl5 production by MSCs inducing enhanced AKT phosphorylation 
which resulted in increased tumor motility and invasiveness. While this paper 
would seem to cast some doubt on CXCR4's role in metastasis, several factors 
speak to the importance of CXCR4 in this process. Active MSCs have been 
characterized as retaining enhanced expression of CXCR4 and CXCl12 [34]. 
Also, a more recent study using C090 high expressing cells (a common marker 
for MSCs) found that co-culture or incubation in conditioned medium resulted in 
increased CXCR4 expression in BPH-1 cells [35]. Muelberg et al [36] recently 
demonstrated increased motility, invasion and metastasis in breast cancer cells 
using Adipose tissue derived stem cells. They found this increased metastasis 
was largely effected by BCCs inducing increased secretion of CXCl12 by the 
Adipose tissue derived stem cells, and that the enhanced- metastasis phenotype 
could be abolished by CXCR4 knockdown in tumor cells. 
CXCR4 expression by the tumor cells allows for tumor cell migration, and 
homing of the neoplastic cells to sites where non-malignant stromal cells express 
CXCl12 [37]. This implies that tumor cell metastasis is not a random event, but 
directed by the expression of chemokine receptors and adhesion molecules on 
the neoplastic cells, and their respective ligands in the target organs [9, 16]. 
Tumor cells utilize this mechanism to access microenvironments, such as the 
bone marrow, that provide factors that favor their growth. For example, the 
importance of CXCR4 for breast cancer metastasis to different target organs has 
been demonstrated in vitro and in vivo [9]. leukemia cells from patients with 
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chronic lymphocytic leukemia (Cll) and acute lymphoblastic leukemia utilize 
CXCR4 for homing to marrow stromal cells in vitro [38] and in vivo [39]. 
Moreover, CXCl12 has a direct growth and survival-promoting effect for various 
cancer cells, such as breast cancer cells [40] or Cll cells [41]. CXCl12 
promotes tumor progression by recruiting endothelial progenitor cells to tumors 
for angiogenesis [40]. 
CXCR4 was originally characterized as a co-receptor for T-tropic strains of 
HIV-1. 
Originally dubbed "lESTR", or "leukocyte-derived seven-transmembrane 
domain receptor" [42], CXCR4 was an orphan G-protein coupled receptor 
(GPCR) when it was identified as the co-receptor for T-tropic strains of the 
human immunodeficiency virus-1 (HIV-1) [43]. CXCR4 was offiCially named 
following the identification of its cognate ligand CXCl12, (previously identified as 
stromal derived factor-1) through experiments demonstrating that CXCR4 
interaction with CXCl12 inhibited HIV-1 infection [44, 45]. It was found that the 
N-terminal region of CXCR4 was essential to HIV-1 entry [46] and that complex 
interactions between the N-terminus and second extracellular loop (ECl2) of 
CXCR4, GP120 and CD4 and the V3 loop of HIV-1 are important for HIV-1 
infection, as illustrated in Figure 3 [47-50]. Interaction between gp120 and CD4 
results in a conformational change of gp120, allowing binding of the co-receptor, 
in this case, CXCR4. Interactions between gp120 and CXCR4 induce further 
conformational changes in the complex, resulting in insertion of the fusion 
peptide of gp41 into the cell membrane of the host T-cell membrane [51]. 
9 
CXCR4 and CXCL 12 play essential roles in the physiology of the 
developing embryo. 
CXCR4 is constitutively expressed in many tissues including stomach, 
small intestine, brain, lymphatics, thymus and spleen and serves to direct 
migration for numerous cell types [52]. CXCR4 mediated migration serves a 
variety of functions, from facilitating repair of damaged liver tissue [53] to 
endochondral bone formation [54]. 
CXCR4 also plays an important role in development as CXCR4 deletions 
are lethal in utero, with embryos displaying defects in neuronal and cardiac 
development [55-57] as well as defects in neovascularization [24]. CXCR4 
regulates the migration of primordial germ cells in the formation of the nervous 
system [58]. CXCR4 and CXCL 12 are also essential to the proper migration of 
cells associated with the cerebellum, dentate gyrus and dorsal root ganglia [59-
61]. Finally, CXCR4/CXCL 12 interaction controls cortical interneuron migration 
and positioning [62]. 
CXCR4 mediated signaling is also essential to the formation of the 
primordial gut, known as the cloaca, [63] as well as the formation of the vascular 
10 
Figure 3: Complex interactions between CXCR4, gp120, CD4 and the V3 
loop of HIV-1 guide fusion of the HIV-capsule to the host cell membrane. 
Reproduced from Cohen et al [64]. Interaction between gp120 and CD4 results 
alters the conformation of gp120 resulting in CXCR4 binding of gp120. CXCR4: 
gp120 interaction induces insertion of the fusion peptide of gp41 into the cell 
membrane of the host T-cell membrane [51]. 
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Figure 3: Complex interactions between CXCR4, gp120, CD4 and the V3 
loop of HIV-1 guide fusion of the HIV-capsule to the host cell membrane. 
Tc'" 
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system of the GI tract [65, 66]. The CXCL 12/CXCR4 axis is also responsible for 
maintaining mucosal barrier integrity in the gut by regulating epithelial cell 
migration, barrier maturation, and reconstitution [67]. 
CXCR4 heterozygous mutation can lead to WHIM (warts, 
hypogammaglobinemia, infections, and myelokathexis) syndrome [68]. The 
structural basis of WHIM syndrome pathology stems from a C-terminus deletion 
of CXCR4, most commonly at R334 [69]. This C-terminal deletion produces a 
two-fold increase in signaling, while rendering the GPCR strongly resistant to 
ligand-mediated downregulation [69]. 
Essential role of CXCR4 signaling in cell mediated immunity 
CXCR4 and CXCL 12 signaling is essential to immune physiology. CXCR4 
is widely expressed on leukocytes, and serves to regulate leukocyte 
hematopoesis and trafficking [68] as well as anchoring developing cells to 
specific regions of the bone marrow [70]. NaYve T-Iymphocytes express CXCR4, 
and this expression is essential in directing T-cell migration to the thymus for 
maturation. Once in the thymus, the interaction between CXCR4 and CXCL 12 is 
critical to the intra-thymic migration of immature T-cells [71]. In the spleen, lymph 
nodes, and tonsils, CXCR4 is essential to the formation of properly structured 
lymphoid follicles and population of germinal centers by controlling the trafficking 
of 8-cells, T-cells and plasma cells [72, 73]. In mature neutrophillic leukocytes, 
increased CXCR4 expression has been associated with cell aging, and 
sequestration in the liver, spleen and bone marrow before apoptosis [74]. While 
increased CXCR4 expression and activation has been associated with increased 
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migration in the leukocyte compartment, decreased CXCR4 expression and 
activation has been associated with increased circulating active leukocytes [75], 
and increased activation of T-cell receptors on T -lymphocytes [76]. 
One of the more interesting roles of CXCR4 in the immune compartment 
involves its role in regulation of neutrophil mobilization. Petit et a/ demonstrated 
that neutrophils are maintained in the bone marrow by CXCR4-CXCL 12 
signaling. Specifically, it is the production of CXCL 12 by bone marrow stromal 
cells which maintains the interaction between CXCL 12 and CXCR4, and when 
factors such as granulocyte colony stimulating factor (G-CSF) decrease stromal 
CXCL 12 production by inhibiting CXCL 12 mRNA expression, stem cells are 
mobilized [77, 78]. This effect is seen in a variety of pathological situations, 
including sepsis where depressed marrow CXCL 12 expression combined with 
enhanced CXCL 12 expression in the spleen has been demonstrated to drive 
neutrophil mobilization and leukocytosis in response to overwhelming infection 
[79]. CXCR4's role in sequestration of hematological stem cells in the bone 
marrow is also highlighted by CXCR4 inhibitor AMD3100. Inhibition of CXCR4 
decreases CXCR4-CXCL 12 signaling, producing rapid mobilization of 
hematopoietic stem cells [80-82], a finding that resulted in FDA approval of 
AMD3100 as a mobilization agent for hematopoietic stem cells for autologous 
transplantation in non-Hodgkin's lymphoma and multiple myeloma [80]. 
Because of CXCR4's critical role in immunity some may question the 
wisdom of using it as a chemotherapeutic agent. They may suggest that 
inhibition of immunity at a time when patients are already immunocompromised 
14 
due to elevated tumor burden would be unwise. However, this really isn't the 
case with cancer chemotherapy. One of the most common side effects of 
common chemotherapeutic agents such as cisplatin, adriamycin, 
cyclophosphamide and mercaptopurine is myelosuppresion, which results in a 
nadir 21-28 days after treatment is begun when white blood count can drop to 
almost zero. Several chemotherapy regimens include prednisone, a 
corticosteroid which suppresses the immune system. The counter to 
symptomatic myelosuppression has been treatment with G-CSF, which acts by 
inhibiting CXCR4 signaling. 
G-Protein Coupled Receptors: sensors of external and internal stimuli 
CXCR4 is a seven-transmembrane-helix G-protein coupled receptor 
(GPCR) which binds CXCl12, a CXC chemokine. Structurally, CXCR4 and other 
GPCRs are characterized by seven membrane spanning helical domains, an 
extracellular amino terminus, and an intracellular carboxyl terminus. The seven 
transmembrane (TM) domains are joined by three extracellular (ECl) and three 
intracellular (ICl) loops as illustrated in Figure 4. Humans express 750 GPCRs 
which serve as sensors of external and internal stimuli by transmitting signals 
through the cell membrane and activation of cytoplasmic signaling cascades [83]. 
As seen in Table 1, GPCRs are divided into 6 classes, based on the Vriend 
classification system for GPCRs [84]. Class A GPCRs, which are rhodopsin-like, 
encompass 80% of GPCRs [85]. CXCR4 is a Class A GPCR. Class B, secretin-
like, class C, metabotropic glutamates, class 0, pheromones, class E, cAMP 
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Figure 4: Linear structure of CXCR4. G-Protein coupled receptors are 
characterized by seven transmembrane receptors joined by three extracellular 
and three intracellular loops, with an extracellular N terminus and an intracellular 
C terminus. Adapted from [86]. 
16 




Table 1: GPCR Classifications. Under the Vriend classification system [84] for 
GPCRs, class A GPCRs, which are rhodopsin-like, encompass 80% of GPCRs. 
CXCR4 is a Class A GPCR. Class B, secretin-like, class C, metabotropic 
glutamates, class 0, pheromones, class E, cAMP receptors, and the class F 
frizzled/smoothened family encompass the other 20% of these receptors. 
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Table 1: GPCR Classifications. 
GPCR Family Family Description 
Class A Rhodopsin-Like 
Class B Secretin-Like 
Class C Metabotropic glutamates/pheromones 
Class D Fungal Pheromone 
Class E cAMP receptors 
Class F Frizzled/Smoothened 
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receptors, and the class F frizzled/smoothened family encompass the other 20% 
of these receptors. Phylogenetic analysis has allowed further subclassification of 
the Class A GPCRs into distinct sub-families as depicted in Table 2 [87]. CXCR4 
belongs to subfamily A2 in this classification system, which encompasses the CC 
and CXC chemokines, as well as adrenomedullin and the Duffy antigen. 
GPCR activation triggers coupling with heterotrimeric G-proteins 
consisting of a, ~, and V subunits. Upon interaction with an activated GPCR, 
GOP bound to Ga will be exchanged for GTP, facilitating a separation of the 
heterotrimer into Ga and G~y subunits. These subunits in turn activate 
downstream signaling pathways until intrinsic GTP-ases in Go convert GTP to 
GOP, facilitating the reformation of the G-protein heterotrimer. 
Chemokines: small protein regulators of a variety of physiological 
processes 
Chemokines are a superfamily of small molecule chemoattractive 
cytokines that mediate several cellular functions. Chemokines are classified by 
the conformation of a conserved amino-terminal cysteine residue motif, as 
depicted in Table 3 [88, 89]. Chemokines and their receptors regulate 
chemotaxis and the transendothelial migration of leukocytes were recently 
observed to play an important role in the metastasis of various cancers [90], as 
well as homeostasis, cell proliferation, hematopoesis, angiogenesis and 
neovascularization [88]. Chemokines also have important roles outside the 
hematopoietic compartment, for example, GROa has been shown to be an 
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Table 2: Subclassifications of Class A GPCRs. CXCR4 belongs to subfamily 
A2 in this classification system, which encompasses the CC and CXC 
chemokines, as well as adrenomedullin and the Duffy antigen. The BL T/LTB4 
signaling pathway belongs to the A5 class of receptors. Rhodopsin is classified 
as a class A 16 receptor with the rest of the Opsin receptors. 
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Table 2: Subclassifications of Class A GPCRs. 
Subfamily Representative Receptors 
A1 CC and CX3C Chemokines 
A2 CC, CXC, and IL-8 
A3 Angiotensin and Bradykinin 
A4 Opiod, Somatostatin, Neuropeptides BIW 
A5 Leukotriene B4 receptors, Relaxin, Galanin 
A6 Cholecystokinin, Vasopressin, Orexin 
A7 Bombesin, Endothelin, TRHR 
A8 Anaphylatoxin receptor, Formyl peptide receptores 
A9 Melatonin, Neurokinin, Neuropeptide Y 
A10 FSH receptor, LH Receptor, Thyrotropin receptor 
A11 GPR40 and P2 Purinoreceptor 
A12 P2 Purinoreceptor, Platelet-activating factor 
A13 Cannabinoid receptor, Lysophosphatidic acid receptor, Melanocortin/ ACTH receptor 
A14 Eicosanoid receptor 
A15 Protease-activated receptor, Proton-sensing GPCRs 
A16 Opsins 
A17 5-Hydroxytryptamine (5-HT) receptor, Adrenergic receptor, Dopamine receptor, Histamine H2 receptor 
A18 Histamine Receptor, Adenosine receptor, Muscarinic 
acetylcholine receptor 
A19 5-Hydroxytryptamine (5-HT) receptor 
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Table 3: Chemokines are classified by the conformation of a conserved 
amino-terminal cysteine residue motif. Chemokines serve a variety of 
functions in the regulation of the immune system as well as in control of 
homeostasis, cell proliferation, haematopoiesis, angiogenesis and 
neovascularization in neoplasia. Adapted from [88]. 
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Table 3A: CXC, C, and CX3C Chemokines, and their receptors. 
Chemokine Human ligand Receptor(s) 
CXC Chemokine 
CXCL1 GROa/MGSAa CXCR1, CXCR2 
CXCL2 GROI3/MGSAI3 CXCR2 
CXCL3 GROy CXCR2 
CXCL4 PF4 CXCR3B 
CXCL5 ENA-78 CXCR2 
CXCL6 GCP-2 CXCR1, CXCR2 
CXCL7 NAP-2 CXCR2 
CXCL8 IL-8 CXCR1, CXCR2 
CXCL9 MIG CXCR3, CXCR3B 
CXCL 10 IP-10 CXCR3, CXCR3B 
CXCL 11 I-TAC CXCR3,CXCR3B,CXCR7 
CXCL 12 SDF-1 a/l3 CXCR4, CXCR7 
CXCL 13 BLC/BCA-1 CXCR5 
CXCL 14 BRAK, Bolekine Unknown 
CXCL 15 Unknown Unknown 
CXCL 16 SICB6 CXCR6 
CXCL 17 DMC Unknown 
C chemokines 
XCL1 Lymphotactin/ATAC/SCM-1 a XCR1 
XCL2 SCM-113 XCR1 
CX3C Chemokines 
CX3CL 1 Fractalkine CX3CR1 
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Table 38: CC Chemokines, and their receptors. 
Chemokine Human Ligand Receptor( s) 
CC Chemokine 
CCl1 1-309 CCR8 
CCl2 MCP-1/MCAF/TDCF CCR2 
CCl3 MIP-1a/lD78a CCR1, CCR5 
CCl3l1 lD78~ Unknown 
CCl3l3 lD78~ Unknown 
CCl4 MIP-1~ CCR5 
CCl4l1 AT744.2 Unknown 
CCl5 RANTES CCR1, CCR3, CCR5 
CCl7 MCP-3 CCR1, CCR2, CCR3 
CCl8 MCP-2 CCR1, CCR2, CCR3, CCR5 
CCl11 Eotaxin CCR3 
CCl13 MCP-4 CCR1, CCR2, CCR3 
CCl14 HCC-1 CCR1 
CCl15 HCC-1/lKN1/MIP-1y CCR1, CCR3 
CCl16 HCC-4/lEC/lCC-1 CCR1, CCR2, CCR5, HRH4 
CCl17 TARC CCR4 
CCl18 DC-CK1/PARC/AMAC-1 Unknown 
CCl19 MIP3~/ElC/exodus-3 CCR7 
CCl20 MIP3a/LARC/exodus-1 CCR6 
CCl21 SlC/6Ckine/exodus-2 CCR7 
CCl22 MDC/STCP-1 CCR4 
CCl23 MPIF/CK~8/CK~8-1 CCR1 
CCl24 Eotaxin-2/MPI F-2 CCR3 
CCl25 TECK CCR9 
CCl26 Eotaxin-3 CCR3 
CCl27 CTACKlllC CCR10 
CCl28 MEC CCR3, CCR10 
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autocrine growth factor in melanoma [91]. In addition, decoy chemokine 
receptors bind ligands with high affinity but negligible activity, in order to control 
the availability of chemokine for receptor and fine tune directionality of chemical 
gradients [88, 89, 92]. 
GPCR signal transduction is based on movement of transmembrane 
helixes 
The theory of G-protein function is largely based on the opsin model, 
wherein interaction between ligand and receptor disrupts an ionic lock between 
TM3 and TM6. This in turn disrupts several stabilizing interactions between the 
TM regions allowing the GPCR to shift from an inactive to an active state capable 
of interacting with a G-protein [93-96]. GPCRs are also capable of forming homo 
and hetero dimers and oligomers, allowing protein function to vary with 
quaternary structure [83, 97-103]. 
The lack of insight into GPCR structure is largely due to the difficulty in 
expressing, purifying, and solubilizing the large amounts of protein required for x-
ray crystallography. The original mammalian crystal structure, bovine rhodopsin 
[104] was generated by micelle suspension of rhodopsin, which required 
harvesting the GPCR from a large volume of bovine retinas, a process which 
benefitted from the relatively undynamic structure of rhodopsin when compared 
to other GPCRs [104-107]. Similar large volume purification protocols were used 
in the crystallization of opsin [95]. 
Developing the capability of producing massive volumes of functional 
receptor from baculovirus infected insect cells, coupled with antibody-mediated 
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stabilization methods to stabilize the third intracellular loop (ICL3) region of the 
GPCR allowed initial crystallization of the f32-adrenergic receptor [108]. Higher 
resolution structures of the f32-adrenergic receptor were generated by 
replacement of the ICL3 region with T 4 Lysozyme (T 4L) a soluble and stable 
protein [109, 110] which exchanges a mobile and flexible unit for a solid and 
immobile element which is a desirable characteristic in the development of well-
ordered three dimensional crystals. Utilization of the T 4L replacement technique 
along with replacement of the C-terminal tail with a histidine purification epitope 
allowed successful crystallization of the a2A adenosine receptor [111]. 
Comparison of the rhodopsin, f32-adrenergic receptors and the a2A 
adenosine receptor structures offers some key insights into the functional 
differences between the GPCRs, as depicted in Figure 5. At the extracellular 
surface of the receptors, there are significant differences in the placement of 
ECL2 and the N-terminus. In Rhodopsin, the ECL2 and the N-terminus the 
GPCR combine to form a f3-sheet which covers the binding pocket of the protein 
and prevents cis-retinal hydrolysis. ECL2 in the f32-adrenergic receptor forms an 
a helix which is displaced away from the ligand binding site by two disulfide 
bonds. ECL2 on the a2A adenosine receptor is characterized by formation of an 
a helix restrained by disulfide binding as in the case of the f32-adrenergic 
receptor however in the case of a2A adenosine, there are 2 additional disulfide 
bonds on the helix, and the surface of the binding site displays significantly lower 
electron density than that of the f32-adrenergic receptor. 
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Figure 5: Receptor structures and ligand binding sites for GPCR crystal 
structures. Structures are presented in ribbon format for A) bovine 
rhodopsin/retinal (PDBID: 1 F88), B) ~2-adrenergic receptor/carazolol (PDBID: 
1 F88), C) ~2-adrenergic receptor/timolol (PDBID: 1 F88), and D) a2A-adrenergic 
receptor/ZM241385. Bound ligands are depicted as spheres in the ribbon helix 
format and as stick figures in the ligand binding site images. Modified from [112]. 
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Figure SA: Receptor structures for GPCR crystal structures. 
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Figure 58: Receptor ligand binding sites for GPCR crystal structures. 
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On the intracellular surface of the rhodopsin crystal structure, the second 
intracellular loop (ICL2) is displaced away from the central TM helixes. In the 
crystal structures of 132-adrenergic receptor and a2A adenosine receptor, ICL2 
interacts with the intracellular surfaces of TM2, TM3, TM5 and TM6, specifically 
with the thirtieth residue of TM6, disrupting the formation of the ionic lock formed 
by this glutamate residue as seen in rhodopsin. In addition, ICL2 of the a2A 
adenosine receptor forms a short helical motif not seen in the other receptor 
structures. In the cases of the 132-adrenergic receptor, the a2A adenosine 
receptor replacement of the ICL3 region and removal of the C-terminal tail could 
also explain these differences with the rhodopsin structure. (Reviewed in [93, 
107,112-115]) 
CXCL 12 activity is governed by structure and posttranslational 
modifications 
The structure of CXCL 12 has been identified by crystal structure 
determination. CXCL 12 is a 67 residue polypeptide with an n-terminalloop, 
followed by three anti-parallel l3-strands, and a c-terminal a-helix packed against 
the l3-sheet [116]. CXCL 12 exists in equilibrium between monomeric and dimeric 
structures and the chemokine aggregates at nonacidic pH and in response to 
multivalent anions like phosphate, sulfate, citrate, or heparin [117, 118]. CXCL 12 
activity is regulated by the protein carboxypeptidase N, which cleaves CXCL 12's 
C-terminal lysine, disabling the chemokine's proliferative and chemoattractant 
abilities [119]. A CXCL 12 ligand lacking the C-terminal a-helix can still bind and 
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induce internalization of CXCR4, but does not induce calcium mobilization, ERK 
phosphorylation, or chemotaxis [120]. 
CXCl12 signaling occurs in a two-site / two-step reaction as depicted in 
Figure 6. In this reaction, the N-terminus of CXCR4 interacts with the R-F-F-E-S-
H motif of the N-terminal loop of CXCl12 [121-123]. This triggers a 
conformational change in the CXCR4 N-terminus bringing CXCl12 into contact 
with the extracellular portions of TM2 and TM7 as well as ECl1 and ECl2 [122]. 
The extracellular binding interface of CXCl 12 was described by Brelot et al as 
composed of residues 097 on TMII, 0187 on ECl2, and E288 on TMVII [124]. 
Ligand binding at these points is largely driven by hydrogen bond interactions 
between the highly basic surface of CXCl12 and the acidic residues of CXCR4. 
Interaction between the N-terminus of CXCl12 and extracellular surfaces of the 
TM helixes produces signal transduction [121, 125, 126]. 
CXCR4 signal transduction is determined by CXCR4 structure. 
CXCR4 is characterized structurally by seven membrane spanning helical 
domains, an extracellular amino terminus, and an intracellular carboxyl terminus. 
The seven TM domains are joined by three ECl and three ICl loops. The 
extracellular loop region consists of 4 SUb-regions: the N-terminal strand from 
residues 1 to 39, the ECl1 encompassing residues 98 to 109, the ECl2 
extending from residue 176 to 202, and the ECl3 from 262 to 282. Initial studies 
into the interaction of CXCR4/CXCl12 revealed that the N-terminal strand is 
essential to the interaction of chemokine and receptor, while reduced binding and 
signaling was seen in mutations to the extracellular portions of TM2 and TM7 as 
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Figure 6: Two-site I two-step interaction between CXCL 12 and CXCR4. In 
the two-site / two-step reaction, the RFFESH loop of the N-terminus of CXCL 12 
binds to the N-terminus of CXCR4, and the N-terminus of CXCL 12 subsequently 
interacts with the extracellular surfaces of the transmembrane helixes. Adapted 
from [121]. 
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Figure 6: Two-site I two-step interaction between CXCL 12 and CXCR4. 
A B c 
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well as ECl1 and ECl2. The N-terminus was essential to receptor transport to 
the cell surface [124]. N-terminal deletions of CXCR4 impair CXCl12 binding and 
signaling. Specifically, acidic (Glu14 and Glu15) and tyrosine (Tyr21) residues of 
the n-terminus are required for CXCl12 binding [124]. 
The intracellular loop region consists of 4 SUb-regions: the first intracellular 
loop encompassing residues 64-76, the second intracellular loop extending from 
residue 132 to 155, ECl3 from 223 to 241, and the carboxyl-terminus of the 
protein extending from residue 308 to 352. This region governs signal 
transduction of the receptor, and has multiple interactions to stimulate signaling 
cascades. Mutational analysis of the intracellular surface has defined several 
essential elements to Signal transduction, including the DRY motif of the second 
intracellular loop, which will inactivate receptor signaling if disrupted [124], and 
the N-terminal region of ICl3, disruption of which eliminates CXCl12 mediated 
signaling [124]. 
The interhelical segments are also essential for CXCR4 mediated signal 
transduction. Zhang et al developed a series of mutations focused on the TM3 
residue Asn 119 (N119). N119 mutation to Ser (N119S) or Ala (N119A) produced 
a constitutively active conformation of CXCR4, while mutation to lys (N119K) 
produced a constitutively inactive conformation of the receptor [127]. The N119S 
conformation produced an elevated signaling level which could be further 
stimulated by CXCl12 binding, in contrast to the N119A mutation which although 
constitutively signaling at a level greater than the N119S mutant, could not be 
further stimulated. The constitutively active mutants also both bound G-proteins 
3S 
to a greater extent than the native state of the receptor. In contrast to both of 
these strains, N119K signaled poorly in response to CXCL 12 binding, and did not 
bind G-proteins to any extent greater than the unstimulated native receptor. 
CXCR4/CXCL 12 signaling occurs by a variety of pathways 
CXCR4 signaling occurs primarily via the pertussis toxin-sensitive Gi 
pathway, composed of Gai, G~ and Gy [128]. CXCL 12 interaction with CXCR4 
induces dissociation of Gai from the trimeric G-proteins, and G~y activates 
several phosphorylation pathways, including ERK1/2, JNK, MAPK, and GSK 
3a/~ [129]. Activation of the G~y subunit also results in signaling by the 
Phospholipase C pathway to enhance calcium mobilization as well as signaling 
by the Phosphoinositide-3-kinase pathway to activate AKT. CXCR4 binding of 
CXCL 12 also serves to augment intracellular cAMP levels [130] and activate 
cAMP-dependant signaling pathways, such as PKa or CREB [131,132]. The 
combined activation of these factors results in cell migration [133-135]. 
Activation of these signaling pathways allows CXCR4 to induce several 
changes in the cell phenotype. CXCR4 enhances cell adhesion by enhancing 
binding between integrin couples such as VLA-4 and VCAM-1 [136]. CXCR4 
stimulation produces a phenotype with enhanced invasiveness by increasing 
AKT mediated MMP9 expression. Finally, CXCR4 facilitates cytoskeletal 
rearrangement by stimulating actin polymerization by formation of F-actin [137]. 
CXCR4 expression in cancer cells can be enhanced by several factors including 
demethylation [138], or increased expression of hypoxia inducible factor (HIF) 1a 
[139]. CXCR4 activity can also be down-regulated in several fashions, such as 
36 
internalization on lipid rafts and inactivation by ~-arrestin binding due to excess 
CXCL 12 [139] or repression of CXCR4 DNA by G-CSF [140]. 
CXCR4 internalization is in fact essential to CXCR4 function. Interactions 
between ~-arrestin and the C-terminus of CXCR4 govern receptor internalization 
[141], but coexpression of CXCR4 with overexpression of ~-arrestin has been 
demonstrated to produce a 3-6 fold increase in CXCL 12-induced ERK 
phosphorylation [142], as well as increased sensitivity to CXCL 12 to induce 
chemotaxis [143], effects that could be blocked by knockdown of ~-arrestin 
expression [143]. In addition, once ~-arrestin has internalized CXCR4 it serves to 
prevent degradation of the receptor [144] and modulates endosomal sorting to 
recycle inactivated receptors back to the cell surface [145]. 
This produces a signaling model of CXCR4 based on receptor recycling. 
Interactions between CXCR4 and CXCL 12 produce an active receptor, which 
initiates multiple G-protein mediated signaling cascades. The active receptor 
then interacts with ~-arrestin, which silences CXCR4 by internalization. 
Internalized receptors are then protected from degradation, inactivated and 
recycled to the cell surface. The necessary balance between activation and 
inactivation of CXCR4 is reflected in the activity of the WHIM variant of CXCR4. 
In the CXCR4-WHIM variant, absence of several C-terminus residues impairs ~­
arrestin-2 recruitment and binding, which produces a delay in internalization of 
the receptor. Cells expressing the CXCR4-WHIM variant also displayed delayed 
phosphorylation of Erk 1/2 [146]. This suggests that rapid cycling of CXCR4 
augments the ability of the receptor to detect changes over time in the availability 
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of ligand, producing a mechanism to fine tune the directionality of chemotaxis. 
This explains the poor immune response of WHIM syndrome immune cells, in 
spite of enhanced CXCL 12 mediated chemotaxis in WHIM patient leukocytes 
[147] and lymphocytes [148]. 
There are multiple assays available to assess CXCR4-mediated signaling. 
Some of the most common methods include assessment of CXCL 12-induced 
calcium mobilization [149-151], phosphorylation of secondary Signaling 
molecules such as ERK1/2, JNK, MAPK, and GSK 3a/~ [151-153], and 
internalization assays to assess the activity of ~-arrestin [142-144]. Assessment 
of CXCL 12-induced calcium mobilization involves pretreating cells with Fura-2 or 
Indo-I, fluorescent dyes which alter the ratio of their emissions in response to 
exposure to calcium. Treatment with Triton X-100 releases mitochondrial calcium 
stores providing a consistent measure by which assay results can be normalized, 
thus this method provides a rapid, real time, consistent measure of CXCL 12-
induced signaling which is very amenable to usage in high-throughput processes. 
Western blot analysis can be used to determine the quantity of 
phosphorylated ERK1/2 and PI3K1AKT in a given sample. However, assessment 
of protein phosphorylation requires lysis and purification of the protein samples, 
preventing any assessment of signaling in real time. In addition, variability in 
protein expression and signaling makes translation of this measurement to a 
high-throughput process difficult. 
Internalization assays to assess the activity of ~-arrestin can be performed 
utilizing fluorescently tagged receptor proteins, allowing cell surface expression 
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of the receptor to be detected by fluorescent microscopy. Although receptor 
internalization would be a very qualitative measurement of ~-arrestin activity, the 
results would be difficult to quantify, making comparisons between samples 
different, and making it difficult to translate this method to high throughput 
protocols. 
GPCRs are common targets for pharmaceuticals 
GPCRs account for the majority of the top selling pharmaceuticals and 
roughly 40% of all licensed pharmaceuticals, a partial listing of which is 
presented in Table 4. The serotonin receptor serves as the target for several 
medications such as Resperdal, Zyprexa, Imitrex, Buspar, Prozac, Paxil, Zoloft, 
and Effexor. The histamine receptors serve as targets for many pharmaceuticals 
as well, including Claratin, Allegra, Zantac, Pepcid, and Gaster. Cardura, Flomax, 
Hytrin, and Wellbutrin all function through inhibition of the alpha-adrenergic 
receptor. Tenormin, Ventolin, Toprol-XL, and Serevent all inhibit the beta-
adrenergic receptor. Diovan, Vasotec, and Cozaar all inhibit the angiotensin" 
receptor and the angiotensin-converting enzyme. Several other GPCR receptors 
serve as targets for pharmaceuticals including the GABA (Diprivan), GNRH 
(Lupron), histone deacetylase (Depakote), Leukotriene (Singulair), LHRH 
(Zoladex), Muscarinic acetylcholine (Atrovent), and the prostanoid selective FP 
receptor (Xalatan). 
Several anti-CXCR4 compounds have been developed 
Despite significant research, there is currently only one FDA-approved 
CXCR4 inhibitor on the market, AMD3100, and that compound is designated 
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Table 4: GPCR structures serve as targets for numerous pharmaceuticals. 
Anti-GPCR compounds serve as targets for more than 40% of all licensed 
pharmaceuticals for a wide variety of indications ranging from hypertension, 
gastric esophageal reflux disease, allergy, to psychosis. 
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Table 4: GPCR structures serve as targets for numerous pharmaceuticals. 
Pharmaceutical Receptor target Indication 
Cardura a adrenergic Prostatic Hypertrophy 
Flomax a adrenergic Prostatic Hypertrophy 
Hytrin a adrenergic Hypertension 
Wellbutrin a adrenergic Depression 
Diovan Angiotensin" Hypertension 
Vasotec Angiotensin Converting Enzyme Hypertension 
Cozaar Angiotensin Converting Enzyme Hypertension 
Tenormin 13 adrenergic Angina 
Ventolin 13 adrenergic Bronchospasm 
Toprol-XL 13 adrenergic Hypertension 
Serevent 13 adrenergic Asthma 
Diprivan GABA Anesthesia 
Lupron GnRH Prostate cancer 
Claratin Histamine Allergy 
Allegra Histamine Allergy 
Zantac Histamine GERD 
Pepcid Histamine GERD 
Gaster Histamine GERD 
Depakote Histone Deacetylase Epilepsy 
Singulair Leukotriene Asthma 
Zoladex LHRH Prostate cancer 
Atrovent Muscarinic Acetylcholine Bronchospasm 
Xalatan Prostanoid Selective FP Glaucoma 
Risperdal Serotonin Psychosis 
Zyprexa Serotonin Psychosis 
Imitrex Serotonin Migraine 
BuSpar Serotonin Anxiety 
Prozac Serotonin Depression 
Paxil Serotonin Depression 
Zoloft Serotonin Depression 
Effexor Serotonin Depression 
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solely for stem-cell mobilization and not as adjuvant chemotherapy for cancer or 
HIV-1 infection. AM03100, as depicted in Figure 7, is a bicyclam used as a 
mobilization agent for hematopoietic stem cells [80]. AM03100 exhibited 
antagonistic activity to proliferation and chemotaxis of acute lymphoblastic 
leukemia [154], acute myelogenous leukemia [155], ovarian cancer [156], 
primary brain tumors [157], anaplastic thyroid carcinoma [158], and colo recta I 
cancer [159). However, cardiotoxic side effects limit its utility as a 
chemotherapeutic agent [160). 
There is a long history of bicyclic amine compounds being used to 
modulate the activity of GPCRs, several of which are depicted in Figure 8. 
Zimelidine was one of the earliest selective serotonin antagonists (SSRI) 
prescribed as anti-depressants [161] although it has been withdrawn from the 
market for inducing Guillain-Barre syndrome, a form of peripheral neuropathy 
[162]. Zimelidine, along with citalopram [163-165], represents some of the 
earliest use of bicyclic amines as chemotherapy, and they continued to play an 
important role in the pharmacotherapy of depression through the development of 
subsequent bicyclic SSRls such as venlafaxine [166-168). 
There has been limited success with bicyclam derivatives such as AMO-
070 (Figure 7), which recently completed Phase I clinical trials as anti-HIV-1 
chemotherapy [169). There has also been successful development of in vitro 
CXCR4 inhibitors in the benzimidazole [170] and imidazopiperazine [171] 
analogs of the AMO bicyclams, but these compounds are heavily protein bound 
and suffer from severe protein shift in antiviral assays [170). These bicyclam 
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Figure 7: Anti-CXCR4 compounds. Several compounds have been 
demonstrated to selectively inhibit CXCR4, targeting the extracellular surface of 
the receptor and the interaction between CXCR4 and either its ligand CXCL 12, 
or the interaction between CXCR4, gp120, and the V3 loop of HIV-1. 
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Figure 7: Anti-CXCR4 compounds. 
AMD3100 
rl rl (""") (""") 
U~U 
AMD-070 
- I ~ Q'" ,/ N~N~NH2 
AMD-070 benzamidazole 
derivative 











~I ~ Arg-Arg-Nal-CYS-Tyr-Cit-LY\ U ""s DLys ~ I 




val Leu /Tyr 
""/"" "" Lys-Gly Ser Ser Arg / Lys-NH2 
\ /
val Leu /Tyr 
""/"" "" Lys-Gly Ser Ser Arg 
Figure 8: Bicyclic aromatic compounds inhibit GPCR activity. Bicyclic 
compounds are some of the earliest characterized anti-GPCR compounds. 
These compounds function by inhibiting serotonin receptors. 
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derivatives strongly interact with two residues, Asp171 and Asp262, located on 
the extracellular side of TM4 and TM6, on either end of the CXCL 12 binding 
pocket [172]. 
Other small molecule derivatives, such as the KRH series, depicted in 
Figure 7, can inhibit CXCR4 mediated chemotaxis and intracellular calcium 
mobilization [173], but none of these compounds have entered clinical trials. 
These compounds share a binding site with the AMD bicyclams, targeting the 
aspartate residues in the CXCL 12 binding pocket [174]. 
Peptide compounds represent another family of CXCR4 inhibitors with 
polyphemusin derivatives, such as T140 [175], (outlined below) and CXCL 12 
peptidomimetics such as CTCE-990B (Figure 7) [176] which generate significant 
anti-CXCR4 activity. CTCE-990B is a 17 -amino acid palindromic dimer of the N-
terminal region of CXCL 12, which has been demonstrated to function as a 
CXCR4 antagonist and to decrease metastasis of breast cancer cells [177, 17B], 
osteosarcoma cells [176] and melanoma cells [176]. CTCE-990B has also been 
found to induce mitotic catastrophe in ovarian cancer cells [179], and induce 
apoptosis and inhibit tumor proliferation in prostate tumor cells [1BO]. CTCE-990B 
entered phase Iblll clinical testing and showed efficacy with stable disease in six 
of twenty patients and no serious adverse effects associated with the drug, 
however Chemokine Therapeutics Corp, the parent corporation of CTCE-990B 
filed for bankruptcy in 200B, leaving any further development in limbo. All of 
these compounds have been designed targeting the extracellular surface of 
CXCR4 and their primary objective has been inhibition of interaction with HIV-1. 
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There are no FDA approved chemotherapeutic or anti-metastatic anti-
CXCR4 agents 
AMD3100 is the only anti-CXCR4 agent that has been FDA approved, 
however it is not approved for HIV-1 or cancer chemotherapy, but as a 
mobilization agent for hematopoietic stem cells. There are currently forty clinical 
trials involving CXCR4: seventeen of these are studies observing CXCR4 
expression in a variety of clinical scenarios, such as rheumatoid arthritis or acute 
myocardial infarction. CXCR4 expression in response to pharmaceuticals such 
as atorvastatin or an anti-herpes simplex gel was also assessed. Another ten of 
these studies are exploring the role of anti-CXCR4 compounds AMD31 00 and 
TG-0054 in stem cell mobilization. Two of the studies involve anti-CXCR4 
compound AMD070 and its role as an anti-HIV-1 agent. Two other studies are 
preliminary safety studies of anti-CXCR4 compounds MSX-122 and ALX-0651. 
The remaining nine studies concern CXCR4 and anti-CXCR4 compounds 
AMD3100, BKT140, and BMS-936564 as chemotherapy or as neoadjuvant 
therapy for leukemia, lymphoma, myelodysplasia, or multiple myeloma. All of the 
anti-CXCR4 compounds currently in clinical trials target the extracellular surface 
of the receptor. 
Structure based drug design is an effective technique for identifying new 
pharmaceuticals. 
Structure based drug design (SBDD) has had substantial success in the 
field of drug discovery, with over 50 novel compounds entering clinical trials and 
multiple FDA approvals [181]. SBDD is an empirical method based on developing 
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lead compounds either targeting specific structures of a target molecule, 
mimicking structural features or ligands, or generating new structures derived 
from established active compounds. 
One particularly illuminating example of structure based drug design 
highlights the development of T140 and its subsequent derivatives by SSOO 
based on a successful lead compound. T140 structurally originates from a series 
of antimicrobial 19-mer polypeptide compounds derived from Atlantic horseshoe 
crab hemocytes called polyphemusins [182]. Initial SSOO work generated a 
synthetic 19-mer polypeptide based on the polyphemusin sequence which 
specifically prevents HIV-1 binding, T22, depicted in Figure 9 [183]. Extensive 
study went into identifying the interaction of T22 with CXCR4 on the cell surface 
[184-189], and structure-activity relationships of the polypeptide [190, 191]. The 
N-terminal and C-terminal arginine residues as well as the disulfide rings were 
identified as essential elements of anti-HIV-1 activity. Aromatic substitution of 
Trp3 was found to maintain activity of the compound, while the positive charge of 
the beta turn side chain was found to be essential to strong anti-HIV-1 activity. 
Through quantitative structure activity relationship (QSAR) analysis, 
pharmacophores or regions and properties of the T22 molecular structure which 
were essential to its interaction with CXCR4 were identified and investigated 
through a series of analog peptide structures [192-194], allowing eventual 
downsizing of the original 19-mer polypeptide to a smaller 14-mer peptide, T140 
[195]. Subsequent structure-activity relationship analysis of T140 [127, 175, 196-
200], allowed additional pharmacophore development based on this structure 
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Figure 9: Polyphemusin derivative structures. Polyphemusins act as specific 
inhibitors of CXCR4. Structure based drug design was used to refine the 
structure of the compounds from a 19-mer peptide compound to a 14 residue 
peptide. Further refinement of the T140 structure produced size reductions in the 
form of cyclic pentapeptide compounds, and finally small molecule inhibitors of 
CXCR4. 
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Figure 9: Polyphemusin derivative structures. 
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[30, 201-204]. Basic amino acid residues of T140 were found to produce non-
specific binding and cytotoxicity, and replacement of these residues with Glu and 
L-citrulline was found to produce selective anti-CXCR4 activity with low 
cytotoxicity and high anti-HIV-1 activity [201]. Pharmacophore analysis of T140 
illustrated that four of the fourteen residues (Arg2, Na13, Tyr5, and Arg14) were 
essential to CXCR4 function [196], allowing the 14-mer T140 peptide to be 
reduced to a cyclic pentapeptide with strong anti-CXCR4 activity. A series of 
analogs based on this cyclic pentapeptide, TE14011, identified a 4-F-benzoyl 
derivative with enhanced anti-HIV-1 activity, identifying this group as a novel 
pharmacophore for CXCR4 antagonism [202]. Further size reduction of the T140 
pharmacophore was produced by replacing the Nal-Gly subunit of the cyclic 
pentapeptide with a v-amino acid or pseudopeptides cyclized by disulfide and 
olefin bridges to develop novel cyclic tetrapeptide derivatives of T140 [205]. 
Subsequent QSAR analysis of the cyclic penta peptide derivatives of T140 [206], 
in conjunction with the identification of an enhanced pharmacophore in 
conjunction with identification of an electro-deficient N-terminal aromatic moiety 
helped to develop small-molecule inhibitor based on the cyclic pentapeptide 
derivatives of T140 [204]. 
Lipid bilayer simulations suggest that T140 binding to CXCR4 is mediated 
by interaction with a series of residues, Asp171 on TM4, Arg188 and Tyr190 on 
ECL2, Gly207 on TM5, and Asp262 on ECL3 [200]. Photolabeling studies of 
radiolabeled T140 identified TM4 as the most important segment of CXCR4 
involved in binding [207]. 
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Those of us not fortunate enough to have unlimited access to Atlantic 
horseshoe crabs need to develop our own lead compounds, and rational 
methods for identifying new lead compounds and drug development scaffolds are 
another extension of SBDD. In silico screening methodologies such as virtual 
screening are some of the most promising of these new rational methods for lead 
compound identification. Virtual screening prescreens vast databases, such as 
the Zinc compound library a compound virtual database [208], the 2010 version 
of which contains the refined three dimensional structures of thirteen million 
commercially available compounds. This prescreening is accomplished by 
targeting a three dimensional structure to determine those compound which best 
fit, or dock, into a chosen allosteric binding site or ligand binding site. The theory 
is that by prescreening and identifying compounds with structurally favorable 
features, the total volume of compounds needed to identify a new lead inhibitor 
can be reduced by several orders of magnitude. This database enrichment would 
allow reduced in vitro or in vivo screening of compounds. 
Virtual screening has been successful in determining new lead 
compounds for many different targets such as: carbonic anhydrase II [209], 
Ptp1 b [210], estrogen receptor [211], thrombin [211], factor Xa [211], thymidylate 
synthase [212], retinoic acid receptor [213], farnesyl transferase [214], kinesin 
[215], hypoxanthine-guanine-xanthine phosphoribosyl transferase [216], DNA 
gyrase [217], H IV -1 RNA transactivation response element [218], aldose 
reductase [219], rac GTPase [220], checkpoint kinase-1 [221], alpha amylase 
[222], BCR-ABL tyrosine kinase [223], protein kinase CK2 [224], and alpha-
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reductase [225]. In one documented case virtual screening targeting DNA gyrase 
identified lead compounds where experimental high throughput screening of 
libraries was unsuccessful [181, 217]. 
Docking of compounds into the target structure can occur using a pre-
positioned, or rigid, chemical conformation for the screened compounds or by 
docking compound fragments and constructing the full compound based of 
energetically favorable positions of the initial fragment placements. Docked 
compound conformations are then evaluated based on the electrostatic and 
hydrophobic interactions they would form between the compounds and the target 
site, which in combination with any identified steric conflicts formed can be used 
to derive a ranking of the interaction between the compound and the target, or 
score. There are numerous docking methods employed in virtual screening, the 
most well reviewed of which include DOCK [226], Autodock [227], GOLD [228], 
eHiTS [229], Glide [230, 231], Cdocker [232], MCDock [233] and Surflex [234], 
and while these docking methods employ their own scoring methodologies, 
several outside scoring programs such as PLP1 [235,236], PLP2 [237], Ludi 
[238], PMF [239], FlexX [240], SCORE [226], and Ligandfit [241] also exist. 
Unfortunately, no docking or scoring algorithm has been determined to be 
superior than others, so common practice has been to determine consensus 
scoring for docked ligands using two or more docking programs to identify bound 
molecules identified by one than one scoring methodology [181,242,243]. The 
DOCK [226], Autodock [227], and Surflex [234], have the advantage of being 
designed for performance with large database virtual screening, allowing efficient 
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flexible docking and evaluation of docked conformations at high volumes. One 
important facet of this process is the basis of the virtual screening target itself: 
the target of the virtual screening protocol. In our experience with virtual 
screening we have found that the strongest determinant of identification of active 
compounds instead of false positives has been a well defined target structure, 
and strong experimental and in vivo evidence governing the development of the 
targeted site for the docking. 
Our prior experience with the Surflex-Dock [234, 244] docking program 
has demonstrated that this program is highly amenable to high-throughput virtual 
screening. In unpublished research, benchmarking Surflex-Dock [234, 244] with 
three other common molecular docking programs, MolDock [245], DOCK [226], 
and Autodock [227], we found that Surflex-Dock consistently reproduced 
predicted compound binding modes as illustrated by compound/receptor crystal 
structures to a greater degree than the other docking programs. The Surflex-
Dock [234, 244] method is centered on development of a protomol, a pseudo-
molecule used to virtually define the binding site targeted on the protein 
structure. This proto mol can be generated based on available ligands, inhibitors 
or partner proteins or development can be designed based on a defined series of 
target residues composing an active site. Once the protomol is developed, 
Surflex-Dock conducts flexible docking by fragmenting the compounds into 
components and docking the fragments into the defined site, constructing the 
compound in the active site based on favorable positions for each of the 
compound fragments. Multiple poses of each compound are returned to the user 
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and assigned a score based on binding affinity, degree of inappropriate 
penetration into the protein, and internal structural conflicts. 
Receptor inhibition can be in the form of agonists, antagonists, and inverse 
agonists. 
Compounds targeting a receptor can alter signaling in four primary 
patterns: agonism, partial agonism, antagonism, and inverse agonism. In 
contrast to agonists and superagonists, which bind and activate an inhibitor 
producing equivalent or greater signaling responses, partial agonists bind the 
receptor and result in signaling, but the amplitude of the response is much less 
than that of the full agonist. Effectively, partial agonists cause the receptor to shift 
into a partially active conformation, incapable of full signal transduction, but also 
not in fully inactive states. The degree of signaling can vary with the partial 
agonist, and very weak partial agonists, such as AMD3100 [127], can almost 
completely abolish receptor signal transduction by inducing alterations of the 
intracellular TM regions and the intracellular loops [200]. In contrast to partial 
agonists, inverse agonists do not induce the active conformation of the receptor 
or result in signal transduction. These compounds interact with receptors with 
some basal level of activity, and upon binding, reduce the constitutive signaling 
of a receptor. These compounds, such as T140 [127], preferentially stabilize the 
inactive, or native in the case of CXCR4, conformation of the receptor [200]. 
CXCR4 as a Virtual Screening Target. 
CXCR4 represents an interesting potential target for virtual screening. 
From our prior descriptions of CXCR4 signaling there are five potential 
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mechanisms for inhibiting signal transduction. The natural ligand could be 
intercepted or manipulated in such a manner that it does not interact with the 
extracellular surface of CXCR4 as illustrated by Target 1 in Figure 10. 
Conversely, the extracellular surface where CXCL 12 is bound could be 
manipulated to prevent ligand binding as illustrated by Target 2 as per Figure 10. 
This has been the approach of prior attempts at developing anti-CXCR4 agents, 
and has been the binding site of AMD3100 and T140. Next, the TM helix could 
be restrained preventing movement necessary to transmit the signal from the 
extracellular surface to the intracellular surface as illustrated by Target 3 in 
Figure 10. The intracellular surface itself could be manipulated to either restrain 
the protein's intracellular surface in an inactive conformation, or prevent G-
proteins from interacting with the surface as illustrated by Target 4 in Figure 10. 
Finally, the G-protein heterotrimer could be manipulated in such a manner that it 
does not interact with the intracellular surface of CXCR4 as illustrated byTarget 
5 in Figure 10. Although the majority of anti-CXCR4 inhibition efforts have been 
directed at just the extracellular surface of the receptor, there is a precedent for 
targeting the intracellular components of the signaling process. YM-254890 
(Figure 11) is a specific Gaq/11 inhibitor designed to prevent acute thrombosis 
and neointima formation by preventing signal transduction at the G-protein level 
rather than at the GPCR level like the P2Y12 receptor antagonists ticlopidine and 
clopidogrel [246-251]. M119 (Figure 11) is a G~V inhibitor which modulates the 1-1-
opiod receptor to act as an anti-nociceptive.[252-254] This compound has also 
been found to inhibit metastasis of MDA-MB-231 cells [255]. Covalent 
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Figure 10: There are 5 potential structural targets for inhibiting CXCR4 
signaling: 1) Targeting the ligand CXCL 12 to prevent ligand/receptor interaction, 
2) Targeting the Extracellular ligand binding site as in AMD3100 and T140, 3) 
Stabilizing the transmembrane helixes to prevent ligand induced conformation 
changes, 4) Targeting the Intracellular region of CXCR4 at the G-Protein 
interface, 5) Targeting the G-protein to prevent GPCR-G-protein interaction. 
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Figure 10: There are 5 potential structural targets for inhibiting CXCR4 
signaling 
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Figure 11: Structures for G-protein inhibitors. Specific inhibitors of G-proteins 
have been designed. YM-254S9 is an anti-thrombotic agent that targets the 
Gaq/11 subunit. M 119 is an anti-nociceptive agent targeting the G~y subunit. 
Covalent modification of G~y inhibits G~y function. 
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modification of the GJ3v subunit by selenocystamine (Figure 11) has also been 
found to selectively inhibit GJ3v function [256]. 
A novel crystal structure for CXCR4. 
Five novel crystal structures for CXCR4 were released on November 19, 
2010 [257]. These structures were developed in a manner similar to the crystal 
structures for the J32-adrenergic receptor and the a2A adenosine receptor, with 
replacement of ICL3 with T4L, as well as a stabilizing L 125W mutation, and a C 
terminal tail truncation. Testing of the crystallization protein demonstrated that 
the modified CXCR4 was capable of binding a bis (imidazolylmethyl) amine 
(SIMA) ligand, although at a lower binding affinity than wild-type CXCR4. 
Calcium flux assays using the crystallization protein were ineffective, which the 
authors suggested was due to ineffective G-protein binding due to C-terminal 
truncation and replacement of ICL3. Structures were generated as co-crystals 
with either IT1 t, an isothiourea derivative which has been demonstrated to inhibit 
interaction between CXCR4 and HIV-1 [258], or CVX15, a 16-mer peptide 
derivative of T140 with demonstrated anti-metastatic activity by CXCR4 inhibition 
[30]. Three constructs of CXCR4, CXCR4-1, CXCR4-2, and CXCR4-3, were 
cocrystallized with IT1t with additional cocrystals of the CXCR4-2/IT1t complex 
and CXCR4-2/CVX15. 
The primary description of the structure was for the highest accuracy (2.5 
angstrom, monomer, and bound to IT1t) structure, with the other four 
conformations being described in relation to it. Significant differences between 
the primary CXCR4 structure and other GPCRs involved significant structural 
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deviations by TM1 and TM4 from their expected positions in the ~2-adrenergic 
receptor and the a2A adenosine receptor. A tighter helical turn at Pro 92 
produced an additional 120 degree rotation in TM2, which produces a different 
series of residues facing the binding pocket. TM6 is characterized by a sharp 
kink at residue 254, producing a deviation of the extracellular end of the helix. 
Characterization of the extracellular region links the base of the N-terminal 
segment to the cytoplasmic side of TM7 by a disulfide bond and an additional 
disulfide linkage between TM3 and ECL2. The ligand binding pocket is larger, 
more open, and more superficial than in comparable GPCRs. Characterization of 
the intracellular surface indicates that positioning of the intracellular side of the 
TM helixes is conserved between the CXCR4, ~2-adrenergic receptor, a2A 
adenosine receptor, and rhodopsin structures, while TM7 was one turn shorter 
than expected. 
Differences were noted between the five crystal structures. Construct 
CXCR4-3 contained a T240P mutation which abolished signal transduction 
capability, which was structurally characterized to contain a disruption of the 
intracellular side of TM6 corresponding to a region between Gly231 and Pro240. 
Constructs bound to inhibitors were found to have a larger, more open and more 
shallow cavity on the extracellular surface compared to other GPCRs, and 
constructs were found to have alteration of the position of TM5 by 0.5 angstroms 
from the center of the receptor, TM6 1.5 angstroms towards the center of the 
receptor and TM7 by 1.5 tangential to the receptor. 
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Subsequent investigation of these crystal structures by Indira Chaudhuri, a 
post doctoral fellow in the Trent laboratory, has identified several interesting 
factors concerning the conformation of the receptors and their utility for virtual 
screening. Comparison of the crystal structure to the lipid bilayer structure of 
CXCR4 in Figure 12 reveals that there is a significant truncation of the Nand C 
terminal regions, as well as disruption of ICL3 in the crystal structure of CXCR4. 
In addition, an extreme kink in TM6 corresponding to residue 254 producing a 
sharp deviation of TM6 and TM7. Further, unlike in the homology model and in 
the other available GPCR structures, ECL2 is displaced upwards and outwards, 
extending between TM1 and TM2. Differences are also noted in the N119S 
structures, in that the N terminal region, rather than being more compact in the 
N119S structure seems to be almost completely disordered in the homology 
model based on the crystal structure. 
Several features of the CXCR4 crystal structure represent causes for 
concern if it is to be used as a basis for SBDD and virtual screening in these 
studies. The structure was released on November 19, 2010 [257], well after the 
experiments involved in this structure were completed. Truncations of the C-
terminal segment and replacement of ICL3 with T 4L mean that essential 
intracellular features of the receptor would be absent, precluding investigation of 
the intracellular surface of the protein. Further, the absence of these structures 
could artificially influence movement or rigidity of the TM helix regions especially 
TM5, TM6 and TM7. Truncation of the C-terminal tail could cause the remaining 
portion of the sequence to adopt an unfavorable position, such as the novel kink 
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Figure 12: Comparison of the CXCR4 x-ray crystal determined structure of 
CXCR4 and the CXCR4 homology model. A) On the left, the CXCR4 crystal 
structure, (POS 10: 30EO) is presented in blue ribbon. ICL3 is replaced with T4L 
protein on the cytoplasmic surface of the receptor. Homology model of CXCR4 
illustrated on right in green ribbon presentation. S) CXCR4 crystal structure, 
(POS 10: 30EO) is presented in yellow ribbon for comparison with the homology 
model of CXCR4 on the right in green ribbon. Truncation of the Nand C termini 
as well as loss of the ICL3 loop region are visible in the CXCR4 crystal structure. 
Also, note the displacement of TM6, TM7 and the altered conformation of the 
ECL2100p. 
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Figure 12A: Comparison of the CXCR4 x-ray crystal determined structure of 
CXCR4 and the CXCR4 homolo model. 
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Figure 128: Comparison of the CXCR4 x-ray crystal determined structure of 
CXCR4 and the CXCR4 homol model. 
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at residue 254, by failure to effectively anchor TM7 on the intracellular side of the 
membrane. This could allow TM7 to unnaturally shift towards the extracellular 
side of the membrane distorting ECl3 and TM6. In addition, the author's own 
testing indicated that there were ligand binding deficiencies by the crystallization 
protein, suggesting irregularities in the structure of the ligand binding pocket and 
by extension the extracellular loop structure. Thus, perhaps rhodopsin based 
homology modeling of this receptor would be a more effective in virtual screening 
until more representative crystal structures are completed. 
Dissertation Overview 
This dissertation investigates several potential inhibitors of CXCR4 
identified by virtual screening targeting the ECl and ICl regions of this receptor. 
We hypothesize that we will be able to effectively inhibit CXCR4 mediated 
metastasis by targeting multiple sites of CXCR4. Compounds targeting the 
extracellular portion of CXCR4 will be investigated in the second chapter. Based 
on research by Dr. Kelby Napier, we evaluate compounds targeting the T140 
binding site of CXCR4 for their capacity to inhibit CXCl12-induced chemotaxis. 
We successfully identify one compound, EClVS14, which inhibits chemotaxis 
with an IC50 value of 5 !-1M, and is highly selective for CXCR4 without Significant 
cytotoxicity. Subsequent QSAR analysis of the structure of this inhibitor reveals 
the importance of the 1-[bis (phenylmethyl) amino] methyl moiety and the fact 
that electronegative modifications of the terminal benzene enhance activity. 
Subsequent Molecular dynamics simulations of the compound in complex with 
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CXCR4 reveal that the compound induces significant modifications of the 
receptor structure. 
The third chapter of this dissertation will investigate novel compounds 
targeting the intracellular region of CXCR4 responsible for interaction with Gai. 
Based on in silica studies by Dr. Kelby Napier, we will utilize virtual screening to 
identify compounds which will selectively inhibit CXCR4. Our screens will identify 
thirty-seven compounds, twenty four of which will inhibit CXCL 12-mediated 
chemotaxis at 50 jJ, for an exceptionally high initial hit rate of 65%. Ten of these 
compounds will inhibit chemotaxis at IC50 values of 10 jJM or less and will be 
highly selective for CXCR4. These compounds displayed relatively no 
cytotoxicity, and 3 of the compounds significantly inhibited tumor cell 
proliferation. Molecular dynamics revealed that the compounds acted by a variety 
of mechanisms with some compounds restricting the receptor to the native 
conformation, while others induced an intermediary configuration, and still others 
were incapable of interacting with the native conformation of the receptor. 
The fourth chapter of this dissertation involves validation work for the 
compounds identified in the previous two chapters. We will use in silica docking 
methods to predict the binding mode of the compounds with the receptor. Based 
on these docking simulations, we will conduct additional molecular dynamics 
simulations to examine the effect of mutating these residues on receptor 
structure. Mutagenic analysis will also investigate the effect of mutation on 
receptor function. Finally, three of the most active compounds from the previous 
chapters will be selected and tested in an in vivo anti-metastatic an animal 
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model, successfully demonstrating the anti-metastatic potential of these 
compounds. 
In total this work demonstrates that structure based drug design utilizing in 
silico analysis in combination with in vitro and in vivo testing can be utilized to 
develop novel lead compounds which can function as anti-metastatics. 
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CHAPTER II 
STRUCTURE BASED DRUG DESIGN OF EXTRACELLULAR LOOP 
TARGETED COMPOUNDS BY QUANTITATIVE STRUCTURE ACTIVITY 
RELATIONSHIP ANALYSIS AND MECHANISTIC STUDIES. 
Introduction 
CXCR4 has been extensively linked to cancer metastasis (see recent 
reviews [259-263]). CXCR4 expression by the tumor cell allows for tumor cell 
migration, and homing of neoplastic cells to sites of where non-malignant stromal 
cells express CXCL 12 [37]. This implies that tumor cell metastasis is not a 
random event, but directed by the expression of chemokine receptors and 
adhesion molecules on the neoplastic cells, and their respective ligands in the 
target organs [9, 16]. Elevated CXCR4 expression is also associated with 
increased circulating tumor cells in non-small cell lung cancer [264], as well as 
poor outcomes in advanced cases of this disease [265]. 
It is also important to note that while CXCR4 expression has been 
correlated with increased metastasis of neoplastic cells [9], reductions in CXCR4 
expression, or knockdown, can produce the opposite effect. Knockdown of 
CXCR4 expression has been demonstrated to reduce proliferation and invasion 
of ovarian cancer cells [266], and metastasis in breast cancer cells [267] and 
prostate cancer cells [268]. AMD3100, an anti-CXCR4 inhibitor, has consistently 
inhibited CXCR4 signaling and migration in in vivo experiments in a variety of cell 
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lines [269-271]. It has also exhibited antagonistic activity to proliferation and 
chemotaxis of acute lymphoblastic leukemia [154], acute myelogenous leukemia 
[155], ovarian cancer [156], primary brain tumors [157] , Anaplastic thyroid 
carcinoma [158] , and colo recta I cancer [159]. 
AMD3100 is a bicyclam compound as depicted in Figure 13. Originally 
identified as an impurity on a series of anti-HIV-1 compounds, AMD3100 was 
found to selectively antagonize viral entry [272] by T-tropic strains of the HIV-1 
virus through inhibition of CXCR4 [273-275]. Although AMD31 00, successfully 
completed initial phase I clinical trials [276], poor in vivo Anti-HIV-1 activity and 
cardiotoxic side effects halted phase II trials and limit AMD31 ~O 's utility as an 
anti-HIV-1 therapy [160]. 
In spite of its cardiotoxic side effects, AMD3100 is currently the only FDA-
approved CXCR4 inhibitor on the market, and is only indicated for use in stem-
cell mobilization and not as adjuvant chemotherapy for cancer or as therapy for 
HIV-1 infection. There has been limited success in the development of bicyclam 
derivatives such as AMD-070 (Figure 13), which recently completed Phase I 
clinical trials as anti-HIV-1 chemotherapy [169] . There has also been successful 
development of in vitro CXCR4 inhibitors in the benzimidazole (Figure 13) [170] 
and imidazopiperazine [171] analogs of the AMD bicyclams as anti-HIV-1 agents, 
but these compounds are heavily protein bound and suffer from severe protein 
shift in antiviral assays [170] suggesting that the drug concentration available in 
the systemic circulation would be greatly reduced by circulating albumin proteins. 
These bicyclam derivatives strongly interact with two residues, Asp171 and 
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Figure 13: Anti-CXCR4 compounds. Illustrated compounds specifically 
interfere with CXCR4 activity and are targeted at the extracellular surface of the 
CXCR4 receptor. 
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Figure 13: Anti-CXCR4 compound 
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Asp262, located on the extracellular side of transmembrane helix 4 and 6, on 
either end of the CXCL 12 binding pocket [172] . In reference to the potential 
mechanisms of inhibiting CXCR4 depicted in Figure 10, these compounds target 
Target 2, the extracellular interface of the receptor. 
Other small molecule derivatives, such as the KRH compounds (Figure 
13) KRH-1636 and KRH-3955 are selective CXCR4 inhibitors. KRH-1636 was 
extensively investigated as an anti-HIV-1 entry inhibitor, and was identified as 
selectively binding CXCR4 [277], but development was halted due to poor oral 
bioavailability. KRH-3955 produced greater oral bioavailability, while inhibiting 
HIV-1 entry as well as CXCL 12 binding and intracellular calcium mobilization 
[173]. The compound was found to bind in the extracellular region of the receptor 
and interact with all three extracellular loops [278], sharing a binding site with the 
AMD bicyclams, targeti",g the aspartate residues in the CXCL 12 binding pocket 
[174]. Like the bicyclam derivatives, these compounds also target the 
extracellular surface of the receptor, Target 2 in Figure 10. None of the KRH 
compounds have entered clinical trials. 
Peptide compounds such as polyphemusin derivatives T140 (Figure 13) 
[175] and CXCL 12 peptidomimetics such as CTCE-9908 (Figure 13) [176] 
generate significant anti-CXCR4 activity. CTCE-9908 has been demonstrated to 
function as a CXCR4 antagonist and decrease metastasis of breast cancer cells 
[177, 178], osteosarcoma cells [176] and melanoma cells [176] in vitro and in tail 
vein injection studies of mouse lung metastasis. CTCE-9908 presents an 
especially compelling proof of principle for anti-CXCR4 agents in that it 
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demonstrates that inhibition of CXCR4 can effect a reduction in tumor cell 
metastasis. 
The peptide CXCR4 inhibitors have been designed targeting the 
extracellular surface of CXCR4. CTCE-9908 mimics the ligand binding 
mechanism of CXCL 12, primarily interacting with the N-terminus of CXCR4. Lipid 
bilayer simulations suggest that T140 bind ing to CXCR4 is mediated by 
interaction with a series of residues, Asp171 on transmembrane helix 4, Arg188 
and Tyr190 on extracellular loop 2, Gly207 on transmembrane helix 5, and 
Asp262 on extracellular loop 3 [200]. Photolabeling studies of radiolabeled T140 
identified transmembrane helix 4 as the most important segment of CXCR4 
involved in binding [207]. 
SBDD is an empirical method of drug design based on developing lead 
compounds either targeting specific structures of a target molecule, mimicking 
structural features or ligands, or generating new structures derived from 
established active compounds. One of the earliest examples of utilization of this 
method for targeting CXCR4 activity utilized synthetic peptides based on the 
transmembrane domains of CXCR4 [279]. Peptides correlating to TM2 were 
capable of completely abolishing CXCL 12-induced calcium mobilization at 
0.2IJM. Elimination of the acidic apex and basal amino acids was demonstrated 
to improve potency 1 O-fold, while replacement with positively charged lysine 
residues improved potency 100-fold. 
As seen in the description of the evolution of the polyphemusin 
compounds in Chapter 1, drug discovery and development is an iterative, 
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cyclical, and evolutionary process, illustrated in Figure 14. In the first step of this 
process, initial lead compounds are identified through a screening assay. 
Compounds which demonstrate activity in the screening assay are then further 
characterized through in vitro biological assays to identify their impact on cell 
signal transduction, homeostasis, cytotoxicity, and possible identification of their 
molecular mechanism. Active compounds are then subsequently modeled, and 
derivatives are generated to test a hypothesis of interaction based on the model. 
The activity of initial derivatives in in vitro assays is used to perform quantitative 
structure activity relationship analysis and determine the essential elements of 
the active compound and methods by which activity could be increased. 
Compounds are then tested in animal models for toxicity and efficacy, and 
subsequent generations of derivatives are generated to test hypotheses of 
interaction. 
We will be applying this model of SBDD to designing inhibitors targeting 
the extracellular surface of CXCR4. The initial step of identifying a lead 
compound was carried out in previous research by Dr. Napier. His work used a 
N119S structure of XCR4 derived from homology modeling and developed 
through solvated lipid bilayer molecular dynamics, as a target for identifying anti-
CXCR4 compounds targeting the extracellular surface of the receptor, at the 
binding site for T140 [200]. N119S was chosen as the original virtual screening 
target because the inverse agonist T140 was one of the docking targets, and this 
inverse agonist could not bind to the inactive native conformation of the receptor. 
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Figure 14: Structure-based drug design is an iterative and cyclical process. 
After initial identification of a structural basis for pathology and identification of an 
active site , initial compounds are screened for toxicity and functionality. The 
activity of functional compounds is then rationalized by in silico methods. 
Compounds will then be tested in in vivo models. Successful lead compounds 
will then be subjected to QSAR analysis and derivation and testing of derivatives 
in functional screens will identify active pharmacophores for further testing 
rationalization and derivation. 
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Figure 14: Structure-based drug design is an iterative and cyclical process. 
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An initial rigid docking protocol, DOCK [226], was used to prescreen the 
Zinc library database, and the FlexX (Tripos) program was used to flexibly dock 
the top 2100 compounds from the rigid body analysis, with the top 100 
compounds from the FlexX analysis scored and ranked by energy (DOCK) and 
Cscore (FlexX). Dr. Napier was then able to use chemotaxis experiments to 
identify 10 compounds which inhibited CXCR4-mediated chemotaxis. One of 
these compounds, designated compound 14, selectively inhibited CXCR4-
mediated chemotaxis, but not CCR5-mediated chemotaxis. Because of the 
selective anti-CXCR4 activity of compound 14, it was chosen as the lead 
compound to be used as a scaffold for development of subsequent derivatives. 
In this chapter, we will describe the continuation of the SBDD process by 
further characterizing the anti-CXCR4 activity of compound 14 as well as the 
other identified CXCR4 inhibitors. We will further characterize the nature of 
compound 14's activity on CXCR4 by designing a series of inhibitors to 
investigate important regions of the compound 14 structure. Finally, the 
interaction between compounds with anti-CXCR4 activity will be investigated 
through molecular dynamiCS simulations to analyze the interaction between 
identified inhibitors and CXCR4. 
This chapter will highlight the following results: Compound 14 (renamed 
EClVS14) selectively inhibits CXCR4-mediated chemotaxis, but not intracellular 
calcium flux without significant cytotoxicity. QSAR will be used to identify terminal 
benzene modifications in conjunction with acetamide derivation of the ECl VS 14 
structure as a potential mechanism for increasing anti-CXCR4 activity. Molecular 
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dynamics simulations demonstrated that ECl VS 14 induces a more closed 
extracellular position of the extracellular loops (ECl) but an intermediately open 
position for the intracellular loops, suggesting that ECl VS 14 could act as a 
weak-partial agonist. In total, this work will provide an extensive characterization 
of EClVS14 through in vitro analysis and investigation of multiple derivative 
structures, as well as dynamic simulation of compound binding, producing 




The prior virtual screening studies by Napier et al identified ten compounds as 
both specific and non-specific inhibitors of CXCR4 mediated chemotaxis, which 
will be referred to as ECl VS compounds after "ExtraCellular hOoP Virtual 
Screen". EClVS14 was the most promising identified compound with specific 
inhibitory activity of CXCR4-mediated chemotaxis. The other nine EClVS 
compounds also exhibited significant inhibition of CCR5-mediated chemotaxis. 
Of the ten compounds displaying activity towards CXCR4, all were selected for 
testing except ECl VS48 and ECl VS88. As these compounds displayed 
significant cytotoxicity in the original research, they were excluded from these 
studies. 
As ECl VS 14 displayed significant specific inhibition of CXCR4 activity, it 
was selected to perform QSAR analysis in order to identify modifications that 
could alter the activity of the compound in respect to CXCR4. Twenty three 
ECl VS 14 derivatives were synthesized by our organic chemistry collaborators 
led by G. B. Hammond, Dept. of Chemistry, University of louisville, and prepped 
for analysis in human CXCR4 expressing cell lines, which will be referred to with 
the prefix EVS14 and a numerical designation. These derivatives explored the 
role of the bis (phenyl methyl) amino methyl moiety and effects of modification of 
this group, as well as exploring the effect of lengthening the hydrazine-linked 
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alkyl moiety or converting it to an acetamide and modifying the terminal benzyl 
group. 
Fourteen compound EVS 14-2 derivatives were also synthesized for 
testing, with an EVS14-2 prefix and an alphanumeric designation. These 
compounds retained ECLVS14-2's conversion of the hydrazine-linked alkyl to a 
propylhydrazine and demonstrated modification or replacement of the bis 
(phenylmethyl) amino methyl moiety. 
Transfeetion and generation of RBL-2H3 and 300.19 stable eel/lines 
expressing hCXCR4-GFP 
To fully evaluate the effects of the potential inhibitors we stably transfected 
overexpressing CXCR4 cell lines in collaboration with Dr. Haribabu Bodduluri. 
CXCR4-GFP was generated in Dr. Bodduluri's lab by in frame cloning of the 
entire coding region of CXCR4 ahead of the GFP coding regions. RBL-2H3 and 
300.19 cells were obtained from our co-investigator, Dr. Haribabu Bodduluri. 
RBL-2H3 cells are maintained as monolayer cultures in DMEM supplemented 
with 15% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 Ilg/ml 
streptomycin. 300.19 cells are maintained as suspension cultures in RPMI 
supplemented with 10% FBS, 100 U/ml penicillin and 100 Ilg/ml streptomycin, 
and 55 IlM of ~-mercaptoethanol. Transfections are performed by 
electroporation. The RBL-2H3 and 300.19 stable single cell lines expressing GFP 
were derived with pEGFPN2 vectors. The stable cell lines are maintained in the 
presence of 1 mg/ml of G418, an aminoglycoside antibiotic which inhibits 
polypeptide synthesis [280] in the absence of a resistance gene present on the 
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pEGFPN2 vector. Cells are cultured in complete medium for 24 hrs after 
transfection and used for microscopy. The cell surface expression of hCXCR4 is 
also determined by incubating receptor or parental cells with 12G5 Ab followed 
by PE labeled secondary Ab, and analyzed by FACS (BD Biosciences). 
300.19 lymphocyte derived cells will be used for the majority of described 
experiments. This line was selected because as a non-adherent cell line, greater 
cell populations could be acquired quickly, allowing higher-throughput screening 
of the investigated compounds. Also, as a lymphocyte derived cell line, these 
cells retained stronger basal chemotactic capabilities than even highly metastatic 
tumor derived cell lines. In a chemotaxis experiment this would make the 
difference between normalizing migration to a control value of 150-300 cells per 
counted field in the 300.19 cell line, or 150-300 migrated cells total. 
Chemotaxis analysis 
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4-
GFP or BL T1 was performed as previously described [151, 281]. In brief, 24 well 
Transwell chambers (Corning Costar, Cambridge, MA) with pore diameter 8.0 IJm 
were used. CXCL 12 (Peprotech) was added to chemotaxis buffer (RPMI media + 
10% FBS + 1 mM Hepes) and added to the lower chamber. Cell variability 
required that CXCL 12 concentration be optimized for each run, and results were 
normalized to the CXCL 12 alone control. Inhibitor was then added to the 
CXCL 12 + Chemotaxis buffer solution. 1,000,000 Cells were resuspended in 
Chemotaxis buffer and added to the upper chamber. Cells were then allowed to 
migrate for 3 hours at 37 DC. Migrated cells in the bottom chamber were then 
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counted via hemocytometer. Each run featured positive and negative controls run 
in duplicate and each compound was run in duplicate. Negative controls lacked 
CXCL 12 in the bottom chamber, while positive controls included both CXCL 12 
alone chambers and CXCL 12 + DMSO to account for the suspension medium of 
the inhibitors. 
Cell signaling analysis 
Cell signaling by CXCR4 was investigated by assessment of intracellular 
calcium mobilization. Intracellular calcium mobilization was performed using both 
300.19 cells as described previously [149-151]. Briefly, cells were suspended in 
loading buffer (1xPBS +1 % FBS) and loaded with INDO-I for 30 minutes at 37 
°C. Cells were then washed with washing buffer (1 x PBS +0.1 % FBS) and 
resuspended in assay buffer (1XHBSS +1%FBS). Cells were then loaded into 
fluorimeter cuvettes (Sigma-Aldrich) and assessed for fluorescence by 
FACScaliber (BD Biosciences). Cells were allowed to equilibrate in the chamber 
for 60 seconds, after which compound was added. Cells were allowed to 
equilibrate for another 60 seconds, after which response to CXCL 12 addition was 
assessed. Cell variability required that CXCL 12 or other chemokine 
concentration be optimized for each run, and results were normalized to the 
CXCL 12 or other chemokine alone control. Positive and negative controls and 
compounds were assessed in duplicate for each run. Negative controls were 
assessment of untreated cells, while positive controls included CXCL 12 alone 
and CXCL 12 + DMSO samples. 
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Class A GPCR selectivity for non-family member BL T1 
The selectivity of the compounds for CXCR4 was assessed by 
investigating their effect on the Class A GPCR BL T1. Assays for chemotaxis and 
intracellular calcium mobilization, as described earlier, were used to assess 
compound activity in 300.19 cells expressing BL T1 [149] grown in Dr. Bodduluri's 
laboratory. 
Determination of nonspecific cytotoxicity 
The potential cytotoxic effects of the compounds were investigated in our 
own hCXCR4-GFP expressing 300.19 cells. Cytotoxicity was investigated using 
a modified cytotoxicity protocol [282]. In brief: 300.19 cells are plated into a 24 
well plate at 100000 cells/ml in a total volume of 600 III and exposed for 3 hours 
to OMSO, inhibitor compounds or camptothecin (positive control). Cells were 
then collected by centrifugation at 8000xg, washed with PBS, and resuspended 
in 0.2 ml PBS + 0.1 % BSA. Cell suspension was mixed with 2 IJI 100 IJg/ml PI 
(Sigma) incubated for five minutes at room temperature in the dark and then 
analyzed by FACScaliber (BO Biosciences). PI emission is detected through a 
600 nm long-pass filter and a 615 nm short-pass filter on FL2 channel, counting 
10,000 events per sample. 
Compound Screening And Dose Response Analysis 
Compounds identified in the Napier virtual screens (ECLVS) and the 
subsequent ECLVS14 derived compounds were tested in vitro using the above 
assays. CXCR4 response to the compounds was initially evaluated at a 
screening concentration of 50 IlM. 50 IlM is a high initial screening concentration 
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for a drug discovery effort when concentrations of 10 to 20 ).lM are typically used 
[173, 283]. However, for a conventional compound screening protocol, the 
compounds are usually derived from structurally similar lead compounds, for 
which there is established EC50 data. Screening of compounds exhibiting activity 
at 50 ).lM or derivatives at 10 ).lM underwent dose-response assays to eliminate 
any potential false-positives produced by the elevated screening concentration. 
Molecular dynamics modeling of CXCR4 and ECL VS complexes 
Complexes of active ECl VS compounds and CXCR4 were investigated 
by molecular dynamics. The highest scoring conformations of the ECl VS 
compounds were utilized as a guide to initial placement of the inhibitor. As the 
initial virtual screens for the active compounds were targeted at the N 119S 
conformation of CXCR4 and the interface surface of Gai , the compounds were 
re-docked into the native structure using Surflex-Dock [234, 244] . A novel 
protomol was generated for the native CXCR4 structure using the residues 
identified in Table 5, which adequately provided docking coverage to the N-
terminus and extracellular loops two and three. Surflex-Dock [234, 244] was used 
to dock EClVS compounds with anti-CXCR4 activity at 10 IJM or less into the 
defined extracellular surface of the native structure of CXCR4. All compounds 
were successfully docked into the structure. The top scoring conformation for 
each compound was utilized in generating the CXCR4 compound complexes. 
Fully solvated lipid bilayer molecular dynamics simulations of native 
CXCR4 bound with active ECl VS compounds were performed using the AMBER 
suite of programs using the parm99 force field [284]. Restraints were initially 
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Table 5: Protomol generated for docking of ECLVS and EVS14 compounds 
into native structure of CXCR4. Surflex-Dock [234, 244] will be used to 
generate a novel residue based protomol, based on the amino acids within 8 
angstroms of the T140 binding site residues, Asp171 on TM4, Arg188 and 
Tyr190 on ECL2, Gly207 on TM5, and Asp262 on ECL3 identified in lipid bilayer 
simulations [200]. 
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Table 5: Protomol generated for docking of ECLVS and EVS14 compounds 
into native structure of CXCR4. 















used to guide conformation of the receptors as previously described in [285]. In 
brief, an initial 5000 step steepest decent minimization was conducted with 
Protein and compound restrained (100 kcal mor1 A -1), followed by another 5000 
step steepest decent minimization with no protein or compound restraints. This 
was followed by a 25 ps MD (T=100 K) holding protein fixed (100 kcal mor1 A-1), 
and another unrestrained 5000 step steepest decent minimization without 
restraints. The temperature of the system was then increased from an initial point 
of 1 OOK to 300K while maintaining 100 kcal mor1 A -1 restraints. An additional 
three 25 ps steps of minimization were then conducted to gradually decrease the 
restraints from 100 kcal mor1 A -1 to 10 kcal mor1 A -1 and finally to 1 kcal mor1 
A-1. Ten production runs of 500 ps were then conducted free of restraints for a 5 
ns total production run. 
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Results 
ECLVS compounds significantly inhibit CXCR4 mediated chemotaxis. 
Our goal was to assess the identified ECl VS compounds targeting the 
extracellular surface of CXCR4 in order to discover novel small molecules which 
could selectively inhibit receptor function and be used as scaffolds for 
development of clinically active anti-metastatic compounds. The ECl Vs 
compounds are depicted in Figure 15, and listed in Table 6. We sought to 
evaluate the compounds by chemotaxis assays which quantitatively examined 
the capability of cells to migrate towards a ligand gradient. Initial screening of the 
eight EClVS compounds at 50 !-1M identified two compounds which significantly 
inhibited chemotaxis as depicted in Figure 16. Results were normalized to the 
CXCl12 alone control. In contrast to treatment with CXCl12 alone treatment 
with DMSO, the vehicle used to suspend the compounds, induced no 
chemotaxis. At the initial screening concentration of 50 !-1M, EClVS14 reduced 
CXCl12-induced chemotaxis by 79% while ECl VS58 reduced CXCl12-induced 
chemotaxis by 94%. Dose response analysis was used to determine the 
concentration of the active compounds ECl VS 14 and ECl VS58 where 
chemotaxis was inhibited by 50% in reference to the CXCl12 alone control 
(IC50). Results of the dose response analysis are depicted in Figure 17. 
EClVS14 inhibited chemotaxis with an IC50 value of 5 !-1M , while EClVS58 had 
an IC50 value of 20 !-1M. 
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Figure 15: ECLVS compounds. Compounds identified by virtual screening 
using Ludi [238] molecular docking software targeting the T140 binding site of the 
extracellular surface of CXCR4. 
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Table 6: ECLVS compounds. Compounds from the ECLVS series are listed 
below with chemical name, supplier, and molecular weight. 
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Table 6: ECLVS compounds. 
Compound NAME Supplier MW 
(Z)-2-( ((E)-benzylideneamino )oxy)-N'-( 1- TimTec ECLVS14 (( dibenzylamino )methyl)-2-oxoindolin-3- Stock Library 531.6 ylidene )acetohydrazide 
ECLVS43 methyl 4-(2,3-di(pyridin-2-yl)quinoxaline- ChemBridge: 461.47 6-carboxamido )benzoate 
ECLVS44 N-( (3-( oxazolo[4,5-b ]pyridin-2- ChemBridge: 40.45 yl)phenyl)carbamothioyl)cinnamamide 
N-( 4-( 2, 5-d ioxo-3-( (pyrid i n-3-
ECLVS55 ylmethyl)amino )pyrrolidin-1- ChemBridge: 339.36 
yl)phenyl)acetamide 
ECLVS58 (3E,5E)-1-methyl-3,5-bis(pyridin-3- ChemBridge: 291.35 ylmethylene)piperidin-4-one 
(E)-3-amino-N'-cyano-4-(4-
ECLVS59 methoxyphenyl)-6-phenylbenzo ChemBridge: 398.48 
[b ]thiophene-2-carboximidamide 
4-((5,7-bis(trifluoromethyl)-1,8- Bionet ECLVS72 naphthyridin-2-yl)oxy)-N-(pyridin-3- Research 528.43 ylmethyl)benzenesulfonamide 
ECLVS82 N,N'-(1,10-phenanthroline-2,9- Specs 418.45 diyl)dibenzamide 
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Figure 16: ECLVS Compounds Inhibit CXCR4 Mediated Chemotaxis. 
Compounds ECLVS14 and ECLVS58 Significantly inhibit CXCR4-mediated 
chemotaxis in response to CXCL 12. DMSO alone did not significantly induce 
chemotaxis in hCXCR4-GFP expressing 300.19 cells. 
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Figure 17: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis. 
Concentrations which inhibited 50% of chemotaxis in relation to CXCl12 alone 
signaling (IC50) were determined for active EClVS compounds. Vertical axis is 
presented in terms of IC50 of chemotaxis in jJM. Of the original ECl VS 
compounds, only EClVS14 had an IC50 value less than 10 jJM. 
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We then sought to determine the specificity of the ECl VS compounds for 
CXCl12-induced chemotaxis. To do this, chemotaxis assays were carried out 
using 300.19 cells expressing the class A GPCR Bl T1 which mediates 
chemotaxis in response to the chemokine l TB4. Initial screening of EClVS14 
and ECl VS58 revealed that both compounds significantly inhibited l TB4-
mediated chemotaxis in cells expressing Bl T1 at 50 ~M. However, as can be 
seen in Figure 18, dose response analysis of the ECl VS compounds revealed 
that while ECl VS58 inhibited Bl T1 chemotaxis to a greater degree than CXCR4 
mediated chemotaxis (IC50 of 20 ~M vs. 5 ~M), EClVS14 produced significantly 
greater anti-CXCR4 activity at 5 !-1M than anti-Bl T1 at 25 !-1M. This suggests that 
the inhibitory effects produced by EClVS14 are somewhat specific for CXCR4. 
Division of ECLVS compounds into inhibitors and non-inhibitors of CXCL 12 
induced calcium mobilization 
Intracellular calcium mobilization is a common method for assessing 
GPCR receptor activation and signaling. Thus, we investigated the impact of 
ECl VS compounds on CXCl12-induced calcium mobilization. CXCl12-induced 
signaling was assessed by the change in amplitude of the calcium signal and 
deviation from baseline produced by CXCl12 administration, and results were 
normalized to the CXCl12-alone control. Initial screening of the eight EClVS 
targeted compounds at 50 !-1M for inhibition of calcium mobilization identified five 
ECl VS compounds which produced significant reductions in calcium release, as 
depicted in Figure 19. Interestingly, the two compounds which produced 
significant reduction in CXCR4 mediated chemotaxis had no effect on calcium 
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Figure 18: ECLVS14 selectively inhibits CXCR4 Mediated Chemotaxis. 
Specificity screening of active ECl VS compounds in Bl T1 expressing cells 
revealed that both compounds inhibited chemotaxis in both systems. ECl VS58 
inhibited Bl T1 chemotaxis to a greater degree than CXCR4 mediated 
chemotaxis. EClVS14 produced significantly greater anti-CXCR4 activity at 5 !-1M 
than anti-Bl T1 at 25 !-1M. 
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Figure 19: ECLVS compounds inhibit CXCR4 mediated Intracellular 
Calcium Mobilization. Calcium Mobilization assays performed with ECl VS 
compounds at a concentration of 50 IJM. Vertical axis is presented in terms of 
normalized calcium signal, wherein the amplitude of the calcium response to the 
CXCl 12-alone control corresponds to 1. Decreased signal amplitude correlates 
with inhibition of calcium mobilization. Five of eight tested ECl VS compounds 































mobilization. The final compound ECl VS72 significantly enhanced calcium 
release (data not shown). Subsequent dose response analysis conducted to 
determine the IC50 of the active compounds revealed that two of the five active 
compounds, EClVS59 (5 IJM) and EClVS82 (2.5 IJM) had calcium mobilization 
IC50 values of 10 IJM or less as seen in Figure 20. 
We then sought to determine the specificity of the ECl VS compounds for 
CXCl12-induced intracellular calcium mobilization. To do th is, calcium 
mobilization assays were carried out using 300.19 cells expressing Bl T1 and 
signaling was assessed in response to l TB4. Initial screening of the five EClVS 
compounds which inhibited CXCl12-induced calcium mobilization revealed that 
all five compounds significantly inhibited l TB4-induced intracellular calcium 
mobilization. Subsequent dose response analysis, depicted in Figure 21 , 
revealed that the IC50 of four of the five ECl VS compounds were comparable 
between CXCR4 and Bl T1 mediated calcium mobilization: EClVS43 (42 IJM vs. 
50 IJM) , EClVS44 (47.5 IJM vs. 50 IJM), ECl VS55 (47.5 IJM vs. 50 IJM) and 
EClVS82 (2 .5 IJM vs. 3.5 IJM). In contrast EClVS59 produced very specific 
inhibition of CXCR4 mediated calcium mobilization, with anti-CXCR4 activity of 5 
IJM compared to 40 IJM for inhibition of Bl T1-mediated calcium mobilization, 
suggesting that anti-calcium mobilization activity in EClVS59 is selective for 
CXCR4. 
As inhibition of chemotaxis and calcium mobilization by the ECl VS 
compounds could be due to nonspecific toxic side effects, the ECl VS 
compounds were screened for cytotoxicity. Mimicking the conditions in the 
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Figure 20: ICSO of ECLVS compound mediated inhibition of calcium 
mobilization. Concentrations which inhibited 50% of calcium mobilization in 
relation to CXCl 12 alone signaling (IC50) were determined for active ECl VS 
compounds. Vertical axis is presented in terms of IC50 of calcium mobilization in 
IJM. Two of the five active compounds exhibited significant inhibition of calcium 
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Figure 21: ECLV559 selectively inhibits CXCR4 Mediated Calcium 
Mobilization. The five ECl VS compounds which inhibited CXCl12-induced 
calcium mobilization were tested for specificity in Bl T1 expressing cells, 
revealing that all five compounds inhibited calcium mobilization in both systems 
at a 50 !-1M screening concentration. Four of the five compounds produced Bl T1 
mediated calcium mobilization equivalent to CXCR4 mediated calcium 
mobilization. ECl VS59 was selective for CXCR4 mediated calcium mobilization. 
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chemotaxis assay, 300.19 cells were cultured in the presence of ECl VS 
compounds at the initial screening concentration of 50 IJM and cytotoxicity was 
assessed using propidium iodide (PI) based flow cytometry. PI is unable to 
penetrate the cell membrane in viable cells, so cells staining positive for PI do not 
have intact membranes. Cytotoxicity values are presented as percentage of cells 
staining positive for PI in Figure 22. Of the nine ECl VS compounds only two 
produced displayed elevated cytotoxicity when compared to untreated cells or 
cells treated with DMSO only control. Compounds EClVS44 (88.3%) and 
EClVS59 (99.8%) displayed significant increases in cytotoxicity above that of 
untreated (3.5%) and DMSO-treated (3.7%) controls. 
Three of the EClVS compounds possess anti-CXCR4 activity at less than 
10 IJM, EClVS14 with a chemotaxis IC50 of 5 IJM, and EClVS59 and EClVS82 
with calcium mobilization IC50s of 5 IJM and 2.5 IJM respectively. Both EClVS14 
and ECl VS59 were demonstrated to selectively inhibit CXCR4, while ECl VS82 
was non-selective. In addition, while EClVS14 produced relatively little 
cytotoxicity, ECl VS59 produced almost 100% cytotoxicity after 3 hours. Thus, 
because EClVS14 selectively inhibited CXCR4-mediated chemotaxis and 
produced no non-specific cytotoxicity, this compound was chosen as a parent 
compound for subsequent derivation and for the development of QSAR analysis. 
Development of ECLVS14 derivatives for QSAR analysis. 
EClVS14 derivatives were developed targeting specific modifications of the 
compound structure as depicted in Figure 23. Modifications of the central chain 
could introduce greater flexibility between the terminal benzylidenemethanamine 
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Figure 22: ECLVS compounds produce relatively little non-specific 
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI, 
a marker for membrane disruption and non-viable cells. Only two of the eight 
Eel VS compounds with exhibited significant cytotoxicity. These compounds 
produced greater than 80% cytotoxicity at 50 IJM. 
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Figure 23: Modifications of ECLVS14 for QSAR analysis. ECLVS14 
derivatives will be designed with several modifications in mind. Acetamide 
derivatives will be developed. The central chain will be lengthened. The 
benzylidenemethanamine moiety will also be modified to include additional 
electronegative or polar substituents. The necessity of the 1-
[bis(phenylmethyl)amino]methyl (1-BPMAM) moiety will be assessed in 
compounds lacking this moiety. The phenylmethanamine moiety will also be 
assessed by addition of electronegative or polar substituents or replacement with 
a less aromatic substituent. 
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Figure 23: Modifications of ECLVS14 for QSAR analysis. 
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moiety and the imidazole, thus the effect of increasing chain length on this group 
will be assessed. Loss of the acetamide moiety could result in loss of hydrogen 
bonding between the compound and the receptor thus derivatives based on this 
moiety will be developed. Increasingly electronegative or polar substituents 
targeting the benzylidenemethanamine moiety could facilitate increasing ionic or 
hydrogen bonding interactions between compound and receptor, while the 
addition of aliphatic elements or decreasing the aromatic characteristics of the 
group could modulate binding as well. Modifications of the 1-
[bis(phenylmethyl)amino]methyl (1-BPMAM) moiety could facilitate compound 
binding in a manner similar to that of modifications of the 
benzylidenemethanamine moiety, while removal of the entire group could 
facilitate greater and deeper binding of the compound in the binding site . 
EVS14 compounds significantly inhibit CXCR4 mediated chemotaxis. 
Twenty-three ECLVS14 derivatives assigned the deSignation EVS14 
(illustrated in Figure 24 and listed in Table 7) were synthesized by our organic 
chemist collaborators led by G. B. Hammond, Dept. of Chemistry, University of 
Louisville and prepped for analysis in human CXCR4 expressing cell lines by 
suspending the compounds in DMSO to a concentration of 20 mM. These 
derivatives explored the role of the bis (phenyl methyl) amino-methyl moiety and 
effects of modification of this group, as well as exploring the effect of lengthening 
the hydrazine-linked alkyl moiety or converting it to an acetamide and modifying 
the terminal benzyl group. 
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Figure 24: EVS14 compounds. Derivatives of ECLVS14 were generated 
focusing on conversion of the hydrazine alkyl linker moiety to an acetamide alkyl 
linker moiety, as well as investigating the effects of lengthening the hydrazine 
alkyl linker, and assessing the effect of presence or absence of the 1-BPMAM 
moiety. 
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Table 7: EV514 compounds. Compounds from the EVS14 series are listed 
below with chemical name, supplier, and molecular weight. 
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Table 7: EVS14 compounds. 
Compound NAME MW 
(Z)-3-(((E)-benzylideneamino )oxy)-N'-(1-
EVS14-1 (( dibenzylamino )methyl)-2-oxoindolin-3- 545.63 
ylidene )propanehydrazide 
(Z)-4-(((E)-benzylideneamino )oxy)-N'-(1-
EVS14-2 (( dibenzylamino )methyl)-2-oxoindolin-3- 559.66 
ylidene )butanehydrazide 
(Z)-5-(((E)-benzylideneamino )oxy)-N'-( 1-
EVS14-3 (( dibenzylamino )methyl)-2-oxoindolin-3- 573.68 
ylidene)pentanehydrazide 
EVS14-4 (Z)-2-( ((E)-( 4-fluorobenzylidene )amino )oxy)-N-(2- 325.29 
oxoindolin-3-ylidene )acetamide 
EVS14-5 (Z)-2-( ((E)-( 4-chlorobenzylidene )amino )oxy)-N-(2- 341.75 
oxoindolin-3-ylidene )acetamide 
EVS14-6 (Z)-N-(2-oxoindolin-3-ylidene )-2-( ((E)-( 4- 375.3 (trifluoromethyl)benzylidene )amino )oxy)acetamide 
EVS14-7 (Z)-2-( (cyclohexylideneamino )oxy)-N-(2-oxoindolin- 299.32 3-ylidene )acetamide 
EVS14-8 (Z)-2-( ((E)-( 4-methoxybenzylidene )amino )oxy)-N- 337.33 (2-oxoindolin-3-ylidene )acetamide 
EVS14-9 (Z)-2-( ((E)-( 4-methylbenzylidene )amino )oxy)-N-(2- 321.33 
oxoindolin-3-ylidene )acetamide 
EVS14-10 (Z)-2-( ((E)-( 4-nitrobenzylidene )amino )oxy)-N-(2- 352.3 
oxoindolin-3-ylidene )acetamide 
EVS14-11 (Z)-2-( ((E)-(2,4-dimethoxybenzylidene )amino )oxy)- 367.36 N-(2-oxoindolin-3 .. ylidene )acetamide 
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Table 7, continued: ECLVS Compounds 
Compound NAME MW 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2- oxoindolin-3-
EVS14-12 ylidene )-2-( ((E)-( 4-(trifluoromethyl) 599.6 
benzylidene )amino )oxy) acetohydrazide 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3-
EVS14-13 ylidene )-2-( ((E)-( 4-methylbenzylidene) 545.63 
amino )oxy)acetohydrazide 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3-
EVS14-14 ylidene )-2-(((E)-( 4- 549.59 
fluorobenzylidene )amino )oxy)acetohydrazide 
(Z)-2-(((E)-( 4-chlorobenzylidene)amino )oxy)-N'-(1-
EVS14-15 (( dibenzylamino )methyl)-2-oxoindolin-3- 566.05 
ylidene )acetohydrazide 
(Z)-2-(( cyclohexylideneamino )oxy)-N'-(1-
EVS14-16 (( dibenzylamino )methyl)-2-oxoindolin-3- 523.63 
ylidene )acetohydrazide 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3-
EVS14-17 ylidene )-2-( ((E)-(2,4-dimethoxybenzylidene) 591.66 
amino )oxy)acetohydrazide 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3-
EVS14-18 ylidene )-2-( ((E)-( 4-nitrobenzylidene) 576.6 
amino )oxy)acetohydrazide 
EVS14-19 (Z)-N'-(2-oxoindolin-3-ylidene )-4-( ((E)-( 4- 418.37 (trifluoromethyl)benzylidene )amino )oxy)butanehydrazide 
EVS14-20 (Z)-2-( ((E)-benzylideneamino )oxy)-N'-(2-oxoindolin-3- 322.32 ylidene )acetohydrazide 
EVS14-21 (Z)-N'-(2-oxoindolin-3-ylidene )-2-( (( E)-(2- 390.32 (trifluoromethyl)benzylidene )amino )oxy)acetohyd razide 
EVS14-22 (Z)-N'-(2-oxoindolin-3·-ylidene )-2-( ((E )-(3- 390.32 (trifluoromethyl)benzylidene )amino )oxy)acetohydrazide 
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3-
EVS14-23 ylidene )-4-( ((E)-( 4-(trifluoromethyl)benzylidene) 627.66 
amino)oxy) butanehydrazide 
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Chemotaxis analysis was pursued using the EVS14 compounds to identify 
structural elements which could enhance anti-CXCR4 activity. The chemotaxis 
values of ECLVS14 and the EVS14 compounds are presented in Table 8. Of the 
twenty-three EVS14 compounds tested, ten significantly inhibited CXCR4 
mediated chemotaxis. Initial screening chemotaxis at SO IJM is depicted in Figure 
2S. Dose response analysis depicted in Figure 26, was pursued to identify the 
ICSO values of the nine EVS 14 compounds which inhibited chemotaxis. Two of 
the EVS14 compounds produced ICSO values of less than 10 IJM; EVS14-21 and 
EVS14-22 exhibited ICSO values of S IJM and 7.S IJM respectively. 
Specificity screening of active EVS compounds in BL T1 expressing cells 
revealed that eight of the ten compounds inhibited chemotaxis in both systems. 
Dose response analysis revealed that of the eight compounds with anti-BL T1 
activity, only EVS14-4 and EVS14-S produced inhibition of chemotaxis at greater 
than the screening concentrations for BL T1, as depicted in Figure 27. All of the 
compounds other than EVS14-S produced significantly greater anti-CXCR4 
activity than anti-BLT1activity. EVS14-S produced significantly greater reduction 
in BL T1 mediated chemotaxis than CXCR4-mediated chemotaxis. 
EVS 14 compounds were further evaluated for their capability of inhibiting CXCR4 
mediated intracellular calcium mobilization. The EVS14 compounds frequently 
precipitated at higher concentrations during the intracellular calcium mobilization 
experiments. As such, screening of these compounds was carried out at 10 IJM. 
At this concentration precipitation of the compound was not noted in the 
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Table 8: Table of ECLVS14 and EVS14 compound chemotaxis activity. 
Chemical characteristics of parent compound ECLVS14 and the EVS14 
derivatives are listed below along with chemotaxis index listings and the ICSO of 
active compounds. 
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Table 8: Table of ECLVS14 and EVS14 compound Chemotaxis activity. 
Compound Linker Terminal Phenyl 1-BPMAM Chemotaxis Compound length Moeity index ICSO 
ECLVS14 1 phenyl 1-BPMAM 0.21 ± 0.16 5IJM 
EVS14-1 2 phenyl 1-BPMAM 0.24 ± 0.11 40 IJM 
EVS14-2 3 phenyl 1-BPMAM 0.46 ± 0.23 Not Active 
EVS14-3 4 phenyl 1-BPMAM 0.39 ± 0.20 Not Active 
EVS14-4 acetamide 4-fluorophenyl H 0.10±0.12 15IJM 
EVS14-5 acetamide 4-chlorophenyl H 0.18 ± 0.24 20 IJM 
EVS14-6 acetamide 4- trifluroro H 0.15±0.24 15 IJM methyl phenyl 
EVS14-7 acetamide Cyclohexylidene H 0.53 ± 0.26 Not Active 
amino 
EVS14-8 acetamide 4-methoxy H 0.38 ± 0.21 Not Active phenyl 
EVS14-9 acetamide 4-methylphenyl H 0.23 ± 0.22 35IJM 
EVS14-10 acetamide 4-nitrophenyl H 0.64 ± 0.08 Not Active 
EVS14-11 acetamide 2,4-dimethoxy H 0.72±0.14 Not Active phenyl 
EVS14-12 1 4-trifluroro 1-BPMAM 0.39 ± 0.24 Not Active 
methylphenyl 
EVS14-13 1 4-methylphenyl 1-BPMAM 0.73 ± 0.16 Not Active 
EVS14-14 1 4-fluorophenyl 1-BPMAM 0.73 ± 0.24 Not Active 
EVS14-15 1 4-chlorophenyl 1-BPMAM 0.59 ± 0.24 Not Active 
EVS14-16 1 Cyclohexylidene 1-BPMAM 0.82 ± 0.03 Not Active amino 
EVS14-17 1 2,4-dimethoxy 1-BPMAM 0.53 ± 0.13 Not Active phenyl 
EVS14-18 1 4-nitrophenyl 1-BPMAM 0.57±0.19 Not Active 
EVS14-19 3 4-trifluroro H 0.28 ± 0.11 25IJM methyl phenyl 
EVS14-20 1 phenyl H 0.09 ± 0.07 25IJM 
EVS14-21 1 2-trifluroro H 0.28 ± 0.10 5IJM methylphen~ 
EVS14-22 1 3-trifluroro H 0.02 ± 0.02 7.5 IJM 
methyiphenJli 
EVS14-23 1 4-trifluroro 1-BPMAM 0.21 ± 0.08 27.5 IJM methyl phenyl 
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Figure 25: ECLVS14 Derivative Compounds Inhibit CXCR4 Mediated 
Chemotaxis. Ten of the twenty three (43.5%) ECLVS14 derived compounds 
significantly inhibited CXCR4-mediated chemotaxis. Chemotaxis assays 
performed at a concentration of 50 !-1M. 
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Figure 26: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis. 
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone 
signaling (IC50) were determined for active EVS14 compounds. Vertical axis is 
presented in terms of IC50 of chemotaxis in !-1M. Of the EVS compounds, EVS14-
21 and EVS14-22 had IC50 values less than 10 !-1M. 
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Figure 27: EVS14 compounds selectively inhibit CXCR4 Mediated 
Chemotaxis. Specificity screening of active EVS compounds in BL T1 expressing 
cells revealed that eight of the ten compounds inhibited chemotaxis in both 
systems. Only EVS14-4 and EVS14-5 produced inhibition of chemotaxis at 
greater than the screening concentrations for BL T1 . All of the compounds other 
than EVS 14-5 produced significantly greater anti-CXCR4 activity than anti-
BL T1 activity. EVS14-5 produced significantly greater reduction in BL T1 mediated 
chemotaxis than CXCR4-mediated chemotaxis. 
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spectrophotometer cuvette. None of the compounds significantly inhibited 
CXCR4 mediated intracellular calcium mobil ization, as can be seen in Figure 28. 
In all, the EVS14 compounds maintain the characteristics of their parent 
compound EClVS14. Several of the derivatives selectively inhibit CXCR4-
mediated chemotaxis, while maintaining EClVS14's inability to modulate 
CXCR4-mediated calcium mobilization. 
aSAR analysis reveals essential pharmacophores of ECLVS14 
Specific analysis of the EVS 14 compounds reveals several specific factors 
of EClVS14 involved in its anti-CXCR4 activity. One of the most obvious 
modifications of the parent compound involved extension of the hydrazine-linked 
alkyl moiety. Modifications of the hydrazine-linked alkyl moiety to ethyl (EVS14-
1), propyl (EVS14-2), and butyl (EVS14-3) derivatives revealed that as the 
hydrazine-linked alkyl group was lengthened, activity decreased, as can be seen 
in Figure 29. When the hydrazine-linked alkyl moiety is the only modification from 
ECl VS 14, neither the propyl or butyl derivatives significantly inhibited 
chemotaxis. The ethyl derivative significantly inhibited chemotaxis, but the IC50 
was much lower than the hydrazine-linked alkyl parent compound (40 IJM vs. 5 
IJM). 
Several of the EClVS14-derived compounds are comparable, in that they 
were modified in the same manner at the terminal benzene as depicted in Figure 
30. These compounds differ in that some retain the 1-BPMAM moiety and the 
hydrazine-linked alkyl of the parent compound, while their counterparts lack this 
moiety and have converted the hydrazine-linked alkyl into an acetamide. When 
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Figure 28: EV514 compounds do not inhibit CXCR4 mediated calcium 
mobilization. Calcium Mobilization assays performed with EVS14 compounds at 
a concentration of 10 !-1M. Vertical axis is presented in terms of normalized 
calcium signal, wherein the amplitude of the calcium response to the CXCL 12-
alone control corresponds to 1. Decreased signal amplitude correlates with 
inhibition of calcium mobilization. None of the tested EVS14 compounds 
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Figure 29: Increasing length of the hydrazine-linked alkyl moiety decreases 
activity. Sequential modifications of the hydrazine-linked alkyl moiety of 
ECl VS 14, depicted as X in the figure, increased the length from the hydrazine 
(EClVS14) to ethyl (EVS14-1), propyl (EVS14-2) and butyl (EVS14-3) 
derivatives, with decreasing chemotaxis activity with increasing chain length. 
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Figure 29: Increasing length of the hydrazine-linked alkyl moiety decreases 
activity. 
o H 
N",,)l /0"" # 




x = CH2 : IC50 5 IJM 
X = CH2CH2 : IC50 40 IJM 
X = CH2CH2CH2 : No Significant Inhibition 
X = CH2CH2CH2CH2 : No Significant Inhibition 
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Figure 30: Effect of terminal benzene modifications on anti-CXCR4 activity. 
Acetamide derivatives lacking the 1-BPMAM moiety with terminal benzene 
modifications with greater electro negativity have greater anti-chemotaxis activity 
than their hydrazine-linked alkyl counterparts which retain the 1-BPMAM moiety. 
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Figure 30: Effect of terminal benzene modifications on anti-CXCR4 activity. 
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comparing these two groups, we find that the absence of the 1-BPMAM moiety 
and the conversion to an acetamide confers a significant increase in chemotaxis 
index. None of the compounds which retained the 1-BPMAM moiety 
accompanied by terminal benzene modifications significantly inhibited 
chemotaxis. 
Identifying which alteration was responsible for this change is difficult to 
tease out with the available compounds. The structure of compound EVS14-20 
mimics parent compound ECLVS14 except that it lacks the 1-BPMAM moiety as 
can be seen in Figure 31 . Although both compounds significantly inhibit 
chemotaxis, the ICSO of the parent compound retaining the group is significantly 
less than the derivative lacking the group (S !-1M vs. 2S !-1M). Compounds EVS14-
6, EVS14-12, EVS14-21 , EVS14-22, all are modified at the terminal benzene 
with a trifluoromethyl group, but are variably altered at the hydrazine-linked alkyl 
and 1-BPMAM moiety. All three compounds lacking the 1-BPMAM moiety 
significantly inhibited chemotaxis while the compound retaining the moiety did 
not. However, among the compounds lacking the moiety, the two compounds 
which retained the hydrazine-linked alkyl group both had ICSO values which were 
less than the compound with the acetamide group (S !-1M and 7.S !-1M vs. 1S !-1M). 
This comparison must be qualified in that the three position of the trifluoromethyl 
substituent differs in ortho/meta/para position in all three compounds. 
Unfortunately there was no compound which was modified solely in terms of the 
hydrazine-linked alkyl group, so a direct comparison of this modification to the 
parent compound is not available from this data. 
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Figure 31: Absence of the 1-BPMAM moiety alone decreases anti-
chemotaxis activity. A comparison of ECLVS14 which retains the 1-BPMAM 
moiety and EVS 14-20 which lacks it reveals that the presence of this moiety 
confers greater anti-chemotaxis inhibitory activity. 
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With 1-BPMAM moeity: IC50 5 ~M 
Without 1-BPMAM moeity: IC50 25 ~M 
Further modification of the compounds lacking the 1-BPMAM moiety and 
converting to the acetamide group reveals that activity of the compounds is 
related to the electro negativity of the terminal benzyl group modifications. A 
parabolic relationship governs chemotaxis activity. There was no significant 
inhibition in the least electronegative methoxy and dimethoxy derivatives, and the 
most electronegative nitro derivatives. However, as electro negativity increased 
from the methyl derivatives to the chloro , trifluoromethyl and fluoro derivatives, 
the ICSO of the compounds decreased, suggesting that electronegativity of the 
terminal group modifications significantly influences the inhibition of chemotaxis. 
The influence of terminal benzene electro negativity can be seen in the 
relationship between compounds EVS14-2, EVS14-19, and EVS14-23. All three 
of these compounds retain the propylhydrazine modification, however, where the 
terminal benzene on EVS14-2 is unmodified, that of EVS14-19 and EVS14-23 is 
modified to a trifluoromethyl derivative, as illustrated in Figure 32. Whereas 
EVS14-2 did not significantly inhibit chemotaxis, both EVS14-19 and EVS14-23 
did significantly inhibit this activity. And while the ICSO values of the compounds 
are very similar, (2S !-1M and 27.S !-1M respectively) they have a significant 
structural difference in that EVS14-19 lacks the 1-BPMAM moiety. This suggests 
that terminal benzene electro negativity confers a greater influence over activity 
than the presence or absence of the 1-BPMAM moiety. 
Development of EVS14-2 derivatives for QSAR analysis 
Based on preliminary chemotaxis results and a desire to further evaluate 
the effects of extension of the hydrazine-linked alkyl moiety, Dr. Hammond 
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Figure 32: Terminal benzene electronegativity confers greater influence 
over anti-chemotaxis activity than the presence or absence of the 1-
BPMAM moiety. Comparison of EVS14-9 with EVS14-23 reveals that both 
compounds with modification of the terminal benzene have roughly equivalent 
inhibition of chemotaxis despite differing in the presence or absence of the 1-
BPMAM moiety. 
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Figure 32:Terminal benzene electronegativity confers greater influence 
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25 ~M 
27.5 ~M 
developed an additional series of ECLVS14 derivatives based on the 
propylhydrazine derivative EVS14-2. Fourteen compound EVS14-2 derivatives 
were synthesized for testing. These compounds, illustrated in Figure 33 and 
listed in Table 9, retained EVS14-2's conversion of the hydrazine-linked alkyl to a 
propylhydrazine and demonstrated modification or replacement of the 1-BPMAM 
moiety. 
Chemotaxis analysis was pursued using the EVS 14-2 derivative 
compounds to identify structural elements which could enhance anti-CXCR4 
activity. The chemotaxis values of the EVS14-2 derivatives are presented in 
Table 10. Of the fifteen compounds tested , ten significantly inhibited CXCR4 
mediated chemotaxis. Initial screening chemotaxis at 50 IJM is depicted in Figure 
34. Dose response analysis depicted in Figure 35, was pursued to identify the 
IC50 values of the five EVS 14-2 derivative compounds which inhibited 
chemotaxis. Compound EVS14-2-AB was the sole compound to exhibit an IC50 
less than 10 IJM 
Specificity screening of active EVS1 4-2 derivatives, depicted in Figure 36, 
in BL T1 expressing cells revealed that five of the seven compounds inhibited 
chemotaxis in both systems. All of the compounds produced significantly greater 
anti-CXCR4 activity than anti-BL T1 activity. 
EVS 14-2 derivatives were further evaluated for their capacity for inhibiting 
CXCR4 mediated intracellular calcium mobilization. Much like their parent 
compound , the EVS14-2 derivatives frequently precipitated at higher 
concentrations during the intracellular calcium mobilization experiments and 
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Figure 33: EV514 -2 derivative compounds. Derivatives of EVS14-2 were 
generated focusing on modification of the benzene groups of the 1-BPMAM 
moiety while maintaining the propylhydrazine modifications of EVS14-2. 
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Figure 33: EVS14-2 derivative compounds 
EVS14-2-B EVS14-2-J 





Table 9: EVS14-2 derivative compounds. Derivatives of EVS14-2 were 
generated focusing on modification of the benzene groups of the 1-BPMAM 
moiety while maintaining the propylhydrazine modifications of EVS14-2. The 
following table lists compound name and molecular weight. 
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Table 9: EVS14-2 derivative compounds 
Compound NAME MW 
(Z)-N'-( 1-((benzyl( 4-methylbenzyl)amino )methyl)-2-
EVS14-2-B oxoindolin-3-ylidene )-4-( ((E)- 573.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-( (benzyl(3-methoxybenzyl)amino )methyl)-2-
EVS14-2-C oxoindolin-3-ylidene )-4-(((E)- 589.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-( (benzyl( 4-methoxybenzyl)amino )methyl)-2-
EVS14-2-D oxoindolin-3-ylidene )-4-(((E)- 589.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-( (benzyl(2,4-dimethoxybenzyl)amino )methyl)-2-
EVS14-2-E oxoindolin-3-ylidene )-4-(((E)- 619.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-((benzyl( 4-chlorobenzyl)amino )methyl)-2-
EVS14-2-J oxoindolin-3-ylidene )-4-( ((E)- 594.1 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-((benzyl(2-fluorobenzyl)amino )methyl)-2-
EVS14-2-K oxoindolin-3-ylidene )-4-( ((E)- 577.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-((benzyl( 4-fluorobenzyl)amino )methyl)-2-
EVS14-2-L oxoindolin-3-ylidene )-4-( ((E)- 577.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-( (benzyl( 4-(trifluoromethyl)benzyl)amino )methyl)-
EVS14-2-N 2-oxoindolin-3-ylidene )-4-( ((E)- 627.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-(1-((benzyl( 4-nitrobenzyl)amino )methyl)-2-
EVS14-2-P oxoindolin-3-ylidene )-4-(((E)- 604.7 
benzylideneamino )oxy)butanehydrazide 
(Z)-N'-( 1-( (benzyl(pyridin-4-ylmethyl)amino )methyl)-2-
EVS14-2-T oxoindolin-3-ylidene )-4-(((E)- 560.7 
benzylideneamino )oxy)butanehydrazide 
EVS14-2-AA (Z)-N'-( 1-((benzyl( ethyl)amino )methyl)-2-oxoindolin-3- 497.6 ylidene )-4-( ((E)-benzylideneamino )oxy)butanehydrazide 
EVS14-2-AB (Z)-N'-( 1-((benzyl(vinyl)amino )methyl)-2-oxoindolin-3- 495.6 ylidene )-4-( ((E)-benzylideneamino )oxy)butanehydrazide 
EVS14-2-AD (Z)-4-( ((E)-benzylideneamino )oxy)-N'-(2-oxo-1-(piperidin- 447.5 1-ylmethyl)indolin-3-ylidene )butanehydrazide 
(Z)-4-(( (E)-benzylideneamino )oxy)-N'-( 1-
EVS14-2-AE (morpholinomethyl)-2-oxoindolin-3- 449.5 
~Iidene )butanehydrazide 
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Table 10: Table of EVS14-2 compound Chemotaxis activity Chemical 
characteristics of the EVS 14-2 derivatives are listed below along with chemotaxis 
index listings and the ICSO of active compounds. 
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Table 10: Table of EVS14-2 and EVS14-2-AD compound Chemotaxis activity 
Compound Terminal 1-BPMAM Moeity Chemotaxis Compound Phenyl index IC50 
EVS14-2-B phenyl N-benzyl-N-( 4- 1.59 ± 0.30 Not Active 
methylbenzyl)ethanamine 
EVS14-2-C phenyl N-benzyl-N-(3- 1.09 ± 0.29 Not Active 
methoxybenzyl)ethanamine 
EVS14-2-D phenyl N-benzyl-N-( 4- 0.20 ± 0.05 17.5 IJM 
methoxybenzyl)ethanamine 
EVS14-2-E phenyl N-benzyl-N-(2,4- 1.34 ± 0.37 Not Active dimethoxybenzyl)ethanamine 
EVS14-2-J phenyl N-benzyl-N-( 4- 0.44 ± 0.13 Not Active 
chlorobenzyl)ethanamine 
EVS14-2-K phenyl N-benzyl-N-(2- 1.43 ± 0.18 Not Active fluorobenzyl)ethanamine 
EVS14-2-L phenyl N-benzyl-N-( 4- 0.23 ± 0.05 22.5 IJM fluorobenzyl)ethanamine 
N-benzyl-N-( 4-
EVS14-2-N phenyl (trifluoromethyl) 1.45 ± 0.19 Not Active 
benzyl)ethanamine 
EVS14-2-P phenyl N-benzyl-N-( 4- 0.66 ± 0.20 Not Active 
nitrobenzyl)ethanamine 
EVS14-2-T phenyl N-benzyl-N-(pyridin-4- 0.17 ± 0.01 40 IJM ylmethyl)ethanamine 
EVS14-2-AA phenyl N-benzyl-N-ethylethanamine 0.22 ± 0.09 20 IJM 
EVS14-2-AB phenyl N-benzyl-N-ethylethenamine 0.36 ± 0.22 Not Active 
EVS14-2-AD phenyl 1-ethylpiperidine 0.03 ± 0.01 Not Active 
EVS14-2-AE phenyl 4-ethylmorpholine 0.21 ± 0.07 22.51JM 
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Figure 34: EVS14-2 derivative compounds Inhibit CXCR4 Mediated 
Chemotaxis. Seven of the fifteen EVS 14-2 derived compounds significantly 
inhibited CXCR4-mediated chemotaxis. Chemotaxis assays performed at a 





























Figure 35: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis. 
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone 
signaling (IC50) were determined for active EVS14-2 derivatives. Vertical axis is 
presented in terms of IC50 of chemotaxis in I-IM. Of the EVS14-2 compounds, 
EVS14-2-AB had an IC50 value of less than 10 I-IM. 
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Figure 36: EVS14-2 derivatives selectively inhibit CXCR4 Mediated 
Chemotaxis. Specificity screening of active EVS14-2 derivatives in BL T1 
expressing cells revealed that five of the seven compounds inhibited chemotaxis 
in both systems. All of the compounds other than EVS 14-5 produced greater 
anti-CXCR4 activity than anti-BL T1 activity. 
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screening was carried out at 10 IJM. At this concentration precipitation of the 
compound was not noted in the spectrophotometer cuvette. None of the 
compounds significantly inhibited CXCR4 mediated intracellular calcium 
mobilization, as can be seen in Figure 37. 
In all, some of the EVS14-2 derivatives improve on their predecessor. 
Several of the derivatives selectively inhibit CXCR4-mediated chemotaxis, while 
maintaining ECLVS14's inability to modulate CXCR4-mediated calcium 
mobilization. 
QSAR analysis of EVS14-2 derivatives illustrates the effects of alteration of 
the 1-BPMAM moiety. 
The majority of the EVS 14-2 derived compounds deal with replacement or 
modification of the 1-BPMAM moiety, as illustrated in Figure 38. It is difficult to 
identify relationships between different modifications of the benzene elements of 
the 1-BPMAM moiety. Only two of the modifications significantly inhibited 
chemotaxis, the methoxy and fluoro derivatives. Replacement of the 1-BPMAM 
moiety seemed to offer greater alteration of chemotaxis and seemed to correlate 
with size. Replacement of one benzene substituent with a pyridine significantly 
inhibited chemotaxis, and inhibition increased as the substituents shrank in size, 
from pyridine to ethyl to ethenyl (40 IJM vs. 20 IJM vs. 5 IJM). Wholesale 
replacement of the 1-BPMAM moiety with a piperidine or morpholine substituent 
conferred a similar enhancement of inhibition compared to the EVS14-2 parent 
compound (20 IJM and 22.5 IJM). 
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Figure 37: EVS14-2 derivatives do not inhibit CXCR4 mediated calcium 
mobilization. Calcium Mobilization assays performed with EVS14-2 derivatives 
at a concentration of 10 I-IM. Vertical axis is presented in terms of normalized 
calcium signal, wherein the amplitude of the calcium response to the CXCL 12-
alone control corresponds to 1. Decreased signal amplitude correlates with 
inhibition of calcium mobilization. None of the tested EVS14-2 derivatives 
significantly inhibited calcium mobilization. 
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Figure 38: EVS14-2 derivatives modify or replace the 1-BPMAM moiety. The 
EVS 14-2 derived compounds deal with replacement or modification of the 1-
BPMAM moiety. Seven of the fourteen modifications significantly inhibited 
chemotaxis. Replacement of one benzene substituent with a pyridine significantly 
inhibited chemotaxis, and inhibition increased as the substituents shrank in size, 
from pyridine to ethyl to ethenyl (40 !-1M vs. 20 !-1M vs. 5 !-1M). Wholesale 
replacement of the 1-BPMAM moiety with a piperidine or morpholine substituent 
conferred a similar enhancement of inhibition compared to the EVS14-2 parent 
compound (20 !-1M and 22.5 !-1M). 
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Compound Substitution ICSO X 
EVS14-2-D N-benzyl-1-(4- 17.5 IJM \ N 
methoxyphenyl)-N- C)~ methylmethanamine 
N-benzyl-1-(4-fluorophenyl)- \ 0--
EVS14-2-L N-methylmethanamine 22.51JM N OJ 
N-benzyl-N-methyl-1- \ F 
(pyridin-4-yl)methanamine N EVS14-2-T 40 IJM (}~ 
\ 
N-benzyl-N- \ 
EVS14-2-AA methylethanamine 20 IJM crN\ \ !J 
N-benzyl-N- \ 
EVS14-2-AB methylethenamine 5IJM crN~ 
\ !J 
EVS14-2-AD 1-methylpiperidine 20 IJM "0 
"Nl 
EVS14-2-AE 4-methylmorpholine 22.5 IJM ~O 
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Acetamide derivatives of ECLVS14 are associated with elevated levels of 
non-specific cytotoxicity. 
As inhibition of chemotaxis by the EClVS14 derivative compounds could 
be due to nonspecific toxic side effects, the ECl VS compounds were screened 
for cytotoxicity. Mimicking the conditions in the chemotaxis assay, 300.19 cells 
were cultured in the presence of IClGa compounds at the initial screening 
concentration of 50 IJM and cytotoxicity was assessed using propidium iodide 
(PI) based flow cytometry. PI is unable to penetrate the cell membrane in viable 
cells, so cells staining positive for PI do not have intact membranes. Cytotoxicity 
values are presented as percentage of cells staining positive for PI in Figure 39. 
Of the thirty seven EVS 14 and EVS 14-2 compounds only six produced elevated 
cytotoxicity when compared to untreated cells or cells treated with DMSO only 
control. Interestingly, four of the eight acetamide derivatives of EClVS 14 
displayed elevated cytotoxicity, suggesting that modification of this group 
adversely affects the capability of CXCR4 to exhibit specific anti-CXCR4 activity. 
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Figure 39: Acetamide ECLVS14 derivatives produce elevated non-specific 
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI, 
a marker for membrane disruption and non-viable cells. Four of the eight 
acetamide derivatives of Eel VS 14 exhibited significant cytotoxicity. 
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Analysis of anti-CXCR4 compound mechanism through molecular 
dynamics simulations 
To test the hypothesis that compound binding will result in structural 
changes associated with inactivation of CXCR4, the conformational differences 
between native CXCR4, the constitutively active N119S mutant [286, 287], and 
bound CXCR4 inhibitors were investigated. 
The initial native CXCR4 and N119S mutant structures were developed by 
Dr. Kelby Napier via homology modeling util izing the high resolution rhodopsin 
crystal structure [288]. When this work was conducted , the x-ray crystal structure 
for CXCR4 had not yet been released , so th is structure was not a viable option 
for these studies. Also, the rhodopsin structure was chosen rather than the new 
131-adrenergic, 132-adrenergic, or a2a-adrenergic receptors, because these 
structures were generated with significant modifications of the intracellular loop 3 
and the C-terminal region. Homologies developed based on these structures 
would have required rhodopsin based modeling of intracellular loop 3 and the C-
terminal region , making this method redundant. 
Molecular modeling of CXCR4 
Fully solvated lipid bilayer molecular dynamics simulations of native 
CXCR4 bound with active ECl VS compounds were performed using the AMBER 
suite of programs using the parm99 force field [284]. Anti-CXCR4 compounds 
were docked into the T140 binding site [200, 207] of CXCR4 using Surflex-Dock 
[234]. Restraints were initially used to guide conformation of the receptors as 
previously described in [285]. In brief, an initial 5000 step steepest decent 
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minimization was conducted with protein and compound restrained (100 kcal 
mor1 A -1), followed by another 5000 step steepest decent minimization with no 
protein or compound restraints. This was fo llowed by a 25 ps MD (T=100 K) 
holding protein fixed (100 kcal mor1 A-1) , and another unrestrained 5000 step 
steepest decent minimization without restraints. The temperature of the system 
will be increased from an initial point of 1 OOK to 300K while maintaining 100 kcal 
mor1 A -1 restraints. An additional three 25 ps steps of minimization will be 
conducted gradually decreasing the restraints from 100 kcal mol-1 A -1 to 10 kcal 
mor1 A -1 and finally to 1 kcal mol-1 A - 1. Ten production runs of 500 ps were then 
conducted . The impact of the ECl VS and EVS 14 compounds on CXCR4 
structure has not yet been determined. 
Some of the ECLVS and EVS14 compounds do not bind the native 
conformation of CXCR4 in molecular dynamics simulations. 
The final averaged structures of native CXCR4 in complex with each of 
the anti-CXCR4 compounds from the 5 ns molecular dynamics simulation are 
shown in Figure 40. Of the seven docked compounds, stable CXCR4: compound 
complexes were generated for compounds EClVS14, EClVS58, EClVS59, 
EClVS82 and EVS14-2-AB. Compounds EVS14-21 and EVS14-22 did not form 
stable complexes with the native conformation of CXCR4. Neither of these 
compounds possessed the 1-BPMAM moiety, suggesting that this element is 
essential for interacting with the extracellular surface of the receptor. 
The molecular dynamics simulation maintained equilibrium throughout the 
production run , as can be seen in Figure 41 . All energy values were noted to be 
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Figure 40: Final averaged structure of Native CXCR4 dynamically bound to 
compounds. Average structure of CXCR4 presented in ribbon format. 
Compounds are bound to dynamically determined binding position. Interacting 
residues are highlighted in stick conformations. 
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Figure 40: Final averaged structure of Native CXCR4 dynamically bound to 
compounds. 
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Figure 41: Energy plot of ECLVS compounds bound to native CXCR4 
versus time. Energy values across the trajectory for total energy (blue), kinetic 
energy (red) and potential energy (green) are presented. CXCR4 was found to 
be energetically stable and maintained equil ibrium across the production run. A) 
ECLVS14, B) EVS14-2-AB, C) ECLVS58, D) ECLVS59, E) ECLVS82 
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Figure 41: Energy plot of compounds bound to native CXCR4 versus time. 
A) EClVS14, B) EVS14-2-AB, C) EClVS58, D) EClVS59, E) EClVS82 
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stable, indicating that the simulation was well equilibrated prior to production 
analysis. Conformational stability of the CXCR4-compound complexes was 
investigated using root RMSD analysis, presented in Figures 42. RMSD values 
remained stable for the majority of the production runs, with the final average 
structure representative of the trajectory after approximately 1.5 ns. The helical 
domains were highly stable throughout the production run , while the majority of 
the structural variation was seen in the loop regions. The RMSD of the EClVS14 
complex from the native conformation of CXCR4 was 3.1 , compared to RMSD 
values of 3.0 angstroms for EVS14-2-AB, 3.8 angstroms for EClVS58, 3.7 
angstroms for EClVS59 and 3.6 angstroms for EClVS82. 
The dynamic binding site of EClVS1 4, shown in Figure 43 consists of the 
N-terminus and ECl2 posterior to the compound . One of the benzene 
substituents of the 1-BPMAM moiety of ECl VS 14 interacts with the aliphatic lIe6 
side chain as well as the backbone of the Ser5, Tyr7, and Thr8 residues. The 
terminal benzene of the compound interacts with Val197 and Va1198. The 
indolin-2-one moiety interacts with the side chain of Trp195 through TT-TT stacking 
interactions as well as with the leu194 side chain. 
The dynamic binding site of EVS14-2-AB, shown in Figure 44 consists 
anteriorly of the C-terminus and ICl2, and superiorly and posteriorly of ICl2. The 
side chain of Ser144 interacts with the ethenamine moiety of the compound, 
while the indoleine moeity interacts with the guanidine of Arg148 by TT-TT 
stacking. The hydrazine linker region interacts with the backbone of Pro147, as 
well as the side chain of Asn143. The terminal benzene is bound anterior and 
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Figure 42: RMSD values of CXCR4 bound to ECLVS compounds across 5 
ns of the production trajectory. Total RMSD calculated at the Co position 
presented in green. Helical domains are presented in blue, and loop regions are 
presented in red. The CXCR4 structure was noted to be stable, and the average 
structure was noted to represent the conformation present in the trajectory after 
0.5 ns of simulation time. A) ECLVS14, B) EVS14-2-AB, C) ECLVS58, D) 
ECLVS59, E)ECLVS82 
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Figure 42: RMSO values of CXCR4 bound to ECLVS14 across 5 ns of the 
production trajectory. A) ECLVS14, B) EVS14-2-AB, C) ECLVS58, D) 
ECLVS59,E)ECLVS82 
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Figure 43: Dynamic binding site of ECLVS14 to native CXCR4. Critical 
residues for ECLVS14 binding to CXCR4 are highlighted. ECLVS14 is depicted 
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as cyan ribbon. ECLVS14 interacts with the N-terminus and ECL2 
regions of the extracellular surface. 
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Figure 43: Dynamic binding site of ECLVS14 to native CXCR4. 
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Figure 44: Dynamic binding site of EVS14-2-AB to native CXCR4. Critical 
residues for EVS14-2-AB binding to CXCR4 are highlighted. EVS14-2-AB is 
depicted in red ball-stick representation , while CXCR4 residues within 3 
angstroms of the compound are presented in stick representation and 
superstructure of CXCR4 is presented as magenta ribbon. EVS 14-2-AB interacts 
with the C-terminus and ICL2 regions of the Intracellular surface. 
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Figure 44: Dynamic binding site of EVS14·2·AB to native CXCR4. 
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posterior by side chain of Ser352 to the anterior surface of the aromatic ring, and 
by the guanidine of Arg146 by TT-TT stacking posterior to the compound. As the 
original docked conformation placement of EVS 14-2-AB was on the extracellular 
surface of the receptor, the fact that the compound stably and dynamically bound 
to the intracellular surface of the receptor came as a surprise. However, the 
compound structure of EVS14-2-AB was sufficiently different from the parent 
compound to suggest that it may bind in a separate conformation than EClVS14. 
The dynamic binding site of ECl VS58, shown in Figure 45 consists of the 
N-terminus posterior to the compound, ECl2 inferior to the compounds and 
ECl3 anterior to the anterior of the compound. The methyl end of the methyl 
piperidin-1-one moiety is stabilized by interaction with the aliphatic elements of 
the side chain of Glu32 and the backbone of Glu31 . One of the pyridine moieties 
interacts with the aliphatic portion of Tyr12 as well as with anterior and posterior 
cysteine residues 274 and 28. The carboxyl end of the methyl piperidin-1-one 
moiety interacts with the guanidine elements of the Arg183 side chain. The other 
pyridine moiety interacts with the aliphatic elements of the Arg183 side chain as 
well as the side chain of his 281. 
The dynamic binding site of ECl VS59, shown in Figure 46 consists of 
ECl3 posterior to the compound , ECl2 inferior to the compound and the N-
terminus anterior to the compound. The methoxybenzene moiety is stabilized by 
interaction with the aliphatic elements of the phe276 and Val280 side chains. The 
cyanoacetimidamide is stabilized by multiple hydrogen bonds, between the 
backbones of Cys274, Thr279 and His281 as well as the guanidine of Arg 183. 
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Figure 45: Dynamic binding site of ECLVS58 to native CXCR4. Critical 
residues for EClVS58 binding to CXCR4 are highlighted. EClVS58 is depicted 
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as yellow ribbon. ECl VS58 interacts with the N-terminus, ECl2 and 
ECl3 regions of the extracellular surface. 
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Figure 45: Dynamic binding site of ECLVS58 to native CXCR4. 
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Figure 46: Dynamic binding site of ECLVS59 to native CXCR4. Critical 
residues for ECLVS59 binding to CXCR4 are highlighted. ECLVSS9 is depicted 
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as orange ribbon. ECLVS59 interacts with the N-terminus and ECL2 
regions of the extracellular surface. 
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Figure 46: Dynamic binding site of ECLVS59 to native CXCR4. 
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The dynamic binding site of EClVS82, shown in Figure 47 consists of 
ECl3 and the proximal portion of the N-terminus lateral to the compound, and 
the distal portion of the N-terminus posterior to the compound. One of the 
benzamide elements is stabilized by interaction with the aliphatic elements of the 
Phe276 side chain, as well as the backbones of the Glu275 and Cys274 residues 
inferior to the compound, and the backbones of the Glu31 and Glu32 residues. 
The phenanthroline element of the compound interacts with the side chain of 
Glu32 to the anterior of the compound, and with aliphatic elements of the Met6 
and Thr13 side chains posterior to the compound, and the Asn11 and Tyr12 side 
chains lateral to the compound. 
These dynamics determined structures shed light on the potential 
mechanism of the activity of the ECl VS compounds. The compounds primarily 
interacted with the N-terminal and the second extracellular loop regions. 
Stabilization of these regions could allosterically disrupt the conformation of the 
CXCl12 binding site, or prevent movement of TM7 necessary for effective signal 
transduction. Interaction between the compounds and ECl2 could also directly 
interfere with CXCl12 ligand binding. Interaction with the intracellular surface of 
the receptor could produce effects similar to those seen with the ICl VS 
compounds (described in Chapter III). Interaction by the compounds with the C-
terminal region could potentially stabilize TM7, or interfere with the interface 
between the C-terminus and Gai. Interposition of the compound between the C-
terminus and ICl2 could prevent effective formation of the cleft which would be 
occupied by bound Gai. 
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Figure 47: Dynamic binding site of ECLVS82 to native CXCR4. Critical 
residues for ECLVS82 binding to CXCR4 are highlighted. ECLVS82 is depicted 
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as orange ribbon. ECLVS82 interacts with the N-terminus and ECL3 
regions of the extracellular surface. 
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Figure 47: Dynamic binding site of ECLV582 to native CXCR4. 
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ECLVS compound binding alters the conformation of the extracellular and 
intracellular surfaces of CXCR4. 
Given the interactions of the EClVS compounds with the extracellular 
surface of CXCR4, we sought to investigate what effect inhibitor binding could 
have on overall receptor conformation. To do this, we sought to compare the 
structure of the ECl VS complexed conformations of CXCR4 to the inactive 
native conformation and the constitutively active N119S conformations of the 
protein. 
The comparison between the structures of the EClVS14-bound, native 
CXCR4, and the N119S conformation is characterized by differences in loop 
positioning. Although the structure of the loops is conserved between the three 
conformations, there are several differences in positioning. In the N-terminal 
region, the anti-parallel ~-sheet is more compact and the distance between ECl1 
and the N-terminal region is decreased, mimicking the N119S conformation by 
movement of ECL. The entire region N-terminal is displaced away from the 
extracellular surface of the TM regions and towards ECl3. ECl3 is outwardly 
displaced from the center of the receptor. At the intracellular surface of CXCR4, 
ICl1 and the C-terminus of the protein retain the native conformation and 
position, while ICl2 is shifted opposite that of the N119S conformation and 
towards the center of the molecule and ICl1. ICl3 adopts the shape of the native 
conformation, while the apex of the loop is shifted towards the C-terminus. 
The comparison between the structures of the EVS14-2-AB, native CXCR4, and 
the N119S conformation is characterized by differences in loop positioning. 
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Although the structure of the loops is conserved between the three 
conformations, there are several differences in positioning. In the N-terminal 
region, the anti-parallel ~-sheet is preserved, but more linear than in either the 
native or N119S conformations. The region is also shifted away from ECl2 and 
towards the ECl3. ECl1 and ECl largely adopt the native conformation, while 
ECl3 is outwardly displaced from the center of the receptor. At the intracellular 
surface of CXCR4, ICl1, ICl2 and the C-terminus essentially adopt the native 
conformation of the receptor. The conformation of ICl3 is shifted such that the 
apex of the loop is shifted towards the C-terminus and the center of the receptor. 
The comparison between the structures of the ECl VS58, native CXCR4, and the 
N119S conformation is characterized by differences in loop positioning. In the N-
terminal region, the anti-parallel ~-sheet is more compact and the distance 
between ECl1 and the proximal portion of the N-terminal region is decreased, 
mimicking the N119S conformation by movement of ECl 1. The anti-parallel ~­
sheet is also shifted away from ECl2, resulting in a conformation significantly 
different from either the native or N119S conformations. At the intracellular 
surface of CXCR4, ICl1 retains the native conformation and position, while ICl2 
is shifted opposite that of the N119S conformation and towards the center of the 
molecule and ICl1. ICl3 adopts the shape of the native conformation, but a mild 
flexion of TM6 shifts the region towards the center of the molecule and ICl3. 
More significant differences characterize the comparison of the structures 
of the EClVS59, native CXCR4, and the N119S conformation. In the N-terminal 
region, the anti-parallel ~-sheet is preserved, but more compact than the native 
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conformation. In addition, the proximal portion of the region is much more 
disordered adopting a more extended loop structure than in either the native or 
N119S conformations. ECL 1 is shifted towards the N-terminal region, and the 
ECL2 region is shifted away from the extracellular surface of the TM helices. The 
apex of the ECL3 loop is shifted away from the N-terminus. At the intracellular 
surface of CXCR4, ICL 1 and the C-terminus essentially adopt the native 
conformation of the receptor. ICL2 is shifted opposite that of the N119S 
conformation and towards the center of the molecule and ICL 1 while the 
conformation of ICL3 is shifted such that the apex of the loop is shifted towards 
the C-terminus and the center of the receptor. 
The comparison between the structures of the ECLVS82, native CXCR4, 
and the N119S conformation is characterized by conservation of the native 
CXCR4 structure. In the N-terminal region, each of the ECL loops and the N-
terminal region adopt the native conformation of the receptor. At the intracellular 
surface of CXCR4, ICL 1 is shifted slightly downward away from the surface of 
the TM regions, while ICL2 is shifted opposite that of the N119S conformation 
and towards the center of the molecule and ICL 1. The apex of ICL3 is displaced 
away from that of the native conformation and away from the C-terminus and the 
TM surface. The C-terminus is displaced slightly downward from the 
conformation, while the distal portion of the loop is more extended and 
disordered than in the native structure. 
These compound:CXCR4 complex conformations suggest that the 
receptors adopt intermediary conformations of the native and N119S 
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conformation, characterized by movement of the N-terminal regions and 
movement of the ICl loops towards the center of the receptor. 
ECLVS compound binding alters the conformation of the transmembrane 
helixes of CXCR4. 
Given the alterations of the ECl VS compounds of the surface of CXCR4, 
we sought to investigate what effect inhibitor binding could have on the structure 
of the transmembrane helixes. We compared the reduced representations of the 
transmembrane helices for each of the ECl VS complexed conformations of 
CXCR4 to the inactive native conformation and the constitutively active N119S 
conformation of the protein. Multiple receptor conformations were compared 
using the helixanal program developed by Dr. Trent. 
The structure of the ECl VS 14 transmembrane helixes is presented in 
Figure 48a. TM1, TM2 and TM3 structure and positioning is conserved between 
the complexed conformation and the native form. The TM4 kink at Pro170 and 
flexion at lIe173 aligned with the native conformation of the receptor, although 
the helix is shifted towards TM5. The TM5 bulge present in the native structure 
between Met205 and lIe213 is present in the complexed structure. TM6 helix is 
more compact in conformation than native, and the apical turn of the helix is 
displaced towards the plasma membrane. The apex of TM7 is less flexed at 
Glu288 than in the native conformation , displacing the apex of the helix towards 
an intermediate position between N119S and native. 
The structure of the EVS 14-2-AB transmembrane helixes is presented in 
Figure 48b. TM1 adopts the conformation of the native helix other than a flexion 
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Figure 48: Transmembrane regions of the ECLVS compounds complexed 
with CXCR4 adopt a similar conformation to native CXCR4. Reduced 
representations of receptor transmembrane helices are presented: native CXCR4 
in green, N119S in red , EClVS14 conformation in teal , EVS14-2-AB 
conformation in violet, ECl VSS8 conformation in yellow, ECl VSS9 conformation 
in orange, ECl VS82 conformation in blue. 
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Figure 48: Transmembrane regions of ECLVS compounds complexed with 
CXCR4 adopt a similar conformation to native CXCR4. 
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of lIe44 displacing the apex of the helix towards TM2. TM2, TM3, TM4, TM5 and 
TM6 structure and positioning is conserved between the complexed conformation 
and the native form. Angularity at the apex of TM7 align with native structure, 
while the base of the helix is more linear than in the native conformation, lacking 
the kink at leu301 , which results in an outward displacement of the base of the 
helix. 
The structure of the ECl VS58 transmembrane helixes is presented in 
Figure 48c. TM1 is more linear in conformation than native and lacks a kink at 
Val54 present in the N119S conformation. TM2, TM3 and TM4 adopt the 
structure and positioning of the native conformation of the receptor. The although 
the apical position of the TM5 helix matches the native conformation, the apical 
portion of the bulge more closely resembles the more extended structure of the 
N119S mutant. Torsion of the helix shifts the apex of the bulge outward from the 
center of the receptor, while a decreased flexion at the base of the bulge shifts 
the base of the helix away from the center of the receptor. TM6 helix is more 
linear than native, without bowing of N119S, apical turn is intact. TM7 apical 
flexions align with native structure, whi le the base of the helix is more linear than 
in the native conformation, lacking the kink at leu301 , which resu lts in an 
outward displacement of the base of the helix. 
The structure of the ECl VS59 transmembrane helixes is presented in 
Figure 48d . TM1 is more linear in conformation than native and lacks a kink at 
Val54 present in the N119S conformation , producing an outward displacement of 
the apex of the receptor. TM2, TM3, TM4 and TM6 structure and positioning is 
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conserved between the complexed conformation and the native form. The TMS 
bulge present in the native structure between Met20S and lIe213 is present in the 
complexed structure, but the bulge is more extended than in the native structure. 
Angularity at the apex of TM7 aligns with native structure, while the base of the 
helix is more linear than in the native conformation, lacking the kink at leu301 , 
which results in an outward displacement of the base of the helix. 
The structure of the ECl VS82 transmembrane helixes is presented in 
Figure 48e. TM1 is more linear in conformation than native and lacks a kink at 
ValS4 present in the N119S conformation, resulting in displacement of the apex 
and base of the helix. The remaining helices adopt the structure and positioning 
of the native conformation. 
Further examination of the transmembrane helixes involved assessment 
of the distances between the intracellular and extracellular termini of the 
interhelical segments. At the extracellular surface, as seen in Table 11 , the 
compounds adopted several specific conformations. EClVS14 produced similar 
interhelical distances to the native conformation of the receptor aside from the 
TM1-2, TM2-3, TM1-6, and TM2-6 distances, which were all increased compared 
to the native conformation for the receptor. EVS 14-2-AB produced increases in 
the TM1-7 and TM1-6 interhelical distances when compared to the native 
conformation , while the TM-1S distance was comparable to the N119S distance. 
EClVSS8 produced increased interhelical distances between TM1-2 and TM1-7, 
while the interhelical distance between TM2-3 was decreased, and the TMS-6 
distance was intermediate between native and N119S. EClVSS9 produced 
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Table 11: ECLVS compounds modulate the distance between the 
extracellular termini of the transmembrane helixes of CXCR4. Interhelical 
distances measured at extracellular termini of transmembrane domains of native 
CXCR4, constitutively active N119s, and compound docked structures. 
Distances measured at the extracellular termini of reduced representations of the 
averaged structures. Illustrated interhelical distances demonstrate 1.5 angstrom 
or greater deviation from either the Native or N 119S structure. 
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Table 11: ECLVS compounds modulate the distance between the 
extracellular termini of the transmembrane helixes of CXCR4. 
ECLVS EVS14- ECLVS ECLVS TMA TMB Native N119S 2-AB 14 58 59 
1 2 6.5 7.6 7.3 7.0 7.9 9.4 
5 6 11.2 13.1 11.3 11.1 12.3 10.5 
6 7 12.1 13.1 12.4 12.2 12.0 13.2 
1 7 15.8 14.6 16.2 16.9 16.7 18.2 
2 3 18.3 18.6 19.4 18.2 17.3 18.1 
2 7 19.1 19.3 19.9 19.5 20.5 19.4 
1 3 20.9 22.2 21.9 21.6 20.5 22.9 
1 4 21.9 23.3 22.4 22.9 21.2 24.9 
1 6 26.0 25.4 27.0 27.8 26.3 27.8 
2 6 28.7 28.0 30.3 29.6 29.2 29.5 















increases in the interhelical distances ofTM1-2, TM1-4, and TM1-6, while 
decreasing the interhelical distance between TM5-6. TM6-7 and 1-5 adopted an 
interhelical distance comparable to the N119S conformation. Finally, EClVS82 
decreased the interhelical distances between TM1-2, TM1-7, TM1-6, Tm 1-5 and 
TM2-6. 
At the intracellular surface, as seen in Table 12, the compounds adopted 
several specific conformations. EClVS14 produced an increased distance 
between TM6-7 when compared to native, while the distances between TM2-6, 
TM3-4, and TM4-6 were intermediate between the native and N119S 
conformations. EVS14-2-AB produced an increased distance between TM2-7, 
Tm3-7 and TM6-7 when compared to native, while the distances between TM3-4 
and TM5-7 were intermediate between the native and N119S conformations. 
ECl VS58 produced an increased distance between TM3-6 when compared to 
native, while the distances between TM2-6 were intermediate between the native 
and N119S conformations. The interhelical distances between TM1-3, TM1-5, 
TM2-5, and TM2-7 were decreased when compared to the native conformation. 
EClVS59 produced an increased distance between TM2-7, TM3-7, TM4-5, Tm4-
7 and TM6-7 when compared to native, while the distances between TM2-5, 
TM3-4, TM-3-5 and TM5-7 were intermediate between the native and N119S 
conformations. The interhelical distances between TM1-3 were decreased when 
compared to the native conformation. ECl VS82 produced an increased distance 
between TM6-7 when compared to native, while the distance between TM3-4 
was intermediate between the native and N119S conformations. 
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Table 12: ECLVS compounds modulate the distance between the 
intracellular termini of the transmembrane helixes of CXCR4. Interhelical 
distances measured at intracellular termini of transmembrane domains of native 
CXCR4, constitutively active N119S, and compound docked structures. 
Distances measured at the intracellular termini of reduced representations of the 
averaged structures. Illustrated interhelical distances demonstrate 1.5 angstrom 

















Table 12: ECLVS compounds modulate the distance between the 
intracellular termini of the transmembrane helixes of CXCR4. 
ECLVS EVS14 ECLVS ECLVS ECLVS 
TMB Native N119S 
14 -2-AB 58 59 82 
6 10.7 12.9 11.1 10.8 10.3 11.1 10.6 
5 11.5 16.5 10.9 11.3 11.9 13.2 11.6 
7 11.7 12.3 11.9 14.4 11.0 13.7 11.7 
6 12.0 13.4 11.5 11.5 12.5 11.2 11.0 
7 12.3 11.8 13.4 16.5 11.5 15.5 13.9 
4 16.0 12.6 15.6 15.2 15.6 15.5 16.4 
6 19.5 17.6 18.8 18.7 19.1 19.5 19.0 
7 21.5 22.2 21.9 25.4 21.0 23.8 22.0 
7 22.3 21.0 22.2 24.9 21.6 24.2 22.1 
5 22.5 25.3 22.6 22.3 21.6 23.7 22.6 
3 24.6 25.7 24.3 24.6 24.6 22.9 24.1 
7 24.8 23.7 25.3 27.8 21.8 27.7 25.4 
5 26.6 26.8 25.5 25.7 26.3 28.0 27.1 
5 32.2 33.9 31.7 31.5 29.8 32.2 31.6 
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The overall representation of these interhelical distance measurements 
and the reduced representation analysis speaks to a difference in activity 
between the anti-CXCR4 compounds. EClVS14 binding seemed to alter the 
interhelical distances by modulating TM2 and TM6 position at the extracellular 
surface producing a more open conformation of the receptor on this surface, and 
seemed to modulate the interaction between TM6 and the other helices at the 
intracellular surface to produce a similarly open conformation at this surface. This 
suggests that EClVS14 may drive the receptor towards an intermediate 
conformation, more open than the native, but not as open as the constitutively 
active N119S conformation. 
EVS14-2-AB binding alters TM1 interaction with the other helices at the 
extracellular surface, and TM? at the intracellular surface, primarily through its 
interactions with the C-terminus. ECl VS58 and ECl VS59 primarily increased 
intrahelical distances at the extracellular surface and decreased intrahelical 
distances at the intracellular surface, suggesting that binding of these 
compounds could drive the intracellular surface of the receptor towards a more 
closed conformation which would be less receptive to G-protein binding. 
EClVS82 on the other hand, decreased intrahelical distances at the extracellular 
surface, suggesting that it was driving the receptor to a more closed 




There is been a dearth of successful compounds which are capable of 
acting as neoadjuvant chemotherapies for anti-metastasis. We have utilized 
SBDD to target CXCR4 with homology modeling and virtual screening to develop 
novel inhibitors of CXCR4. In this work, non-peptide CXCR4 antagonists were 
structurally characterized through QSAR analysis of structural derivatives. 
These compounds represent an investigation into the structural 
determinants of activity and the role that the subgroups of EClVS14 play in 
determining its anti-CXCR4 activity. Retesting of the original ECl VS compounds 
identified ECl VS 14 as a selective inhibitor of CXCR4-mediated chemotaxis and 
EClVS58 as a non-selective inhibitor of CXCR4-mediated chemotaxis, neither of 
which inhibited CXCR4-mediated intracellular calcium flux. This is an important 
distinction to make, as there are multiple signaling pathways that could 
potentially influence CXCR4-mediated chemotaxis. Cell migration due to CXCR4 
activation is the result of activation of multiple signaling pathways[133-135], 
including the ERK1/2, JNK, MAPK, and GSK 3a/~ phosphorylation systems, 
[129] activation of phospholipase C to enhance calcium mobilization [130], 
activation of the phosphoinositide-3-kinase pathway to activate AKT [130], and 
activation of PKa or CREB [131, 132]. Thus anti-chemotaxis activity of ECl VS 14 
and EClVS58 could be due to inactivation of multiple signaling pathways outside 
of calcium mobilization. 
Derivatives of the parent ECl VS 14 structure revealed several important 
structural-activity relationships governing ECl VS 14 activity, seen in Figure 49. 
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Figure 49: Structural modifications of ECLVS14 and their effects on 
activity. Data from chemotaxis and cytotoxicity assays were analyzed to 
correlate the chemical structure of available analogs to inhibitory activity. 
204 
Figure 49: Structural modifications of ECLVS14 and their effects on activity 
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Analysis of the 1-[bis (phenyl methyl) amino] methyl moiety revealed that absence 
of this group diminished anti-CXCR4 activity as confirmed by EVS14-20. 
However, comparison between compounds EVS14-19 and EVS14-2-1 which 
differed solely in the presence or absence of the 1-BPMAM moiety revealed no 
significant difference in anti-CXCR4 activity. 
Modifications of the hydrazine-alkyllinker moiety to ethyl, propyl, and butyl 
derivatives revealed that as the hydrazine-alkyllinker is lengthened, activity 
decreases, as seen with compounds EVS14-1, EVS14-2, and EVS14-3. There 
was no direct comparison available between the parent compound with a 
hydrazine-alkyl linker moiety and one which was altered to the shortened 
acetamide moiety. However, several compounds had modified 1-BPMAM 
moieties and acetamide along with comparable terminal benzene modifications. 
In each case the compound with the modified 1-BPMAM moiety and acetamide 
demonstrated increased anti-CXCR4 activity. And as the absence of the 1-
BPMAM moiety has been shown to have either a negligible or negative effect on 
anti-CXCR4 activity it would stand to reason that shortening the hydrazine-alkyl 
linker moiety of the parent compound to an acetamide would increase anti-
CXCR4 activity. The benefits of this alteration would have to be balanced by the 
increased potential for cytotoxic side effects of conversion of the compound to an 
acetamide. 
Modification of the terminal benzene by halogenation, methylation, 
nitroxylation or conversion to a cyclhexylideneamine disrupted the activity of the 
parent compound, as seen in compounds EVS14-12, EVS14-13, EVS14-14, 
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EVS14-15, EVS14-16, EVS14-17, and EVS14-18. However, increases in anti-
CXCR4 activity were seen in compounds with increasing electronegativity as well 
as acetamide replacement and removal of the 1-BPMAM moiety. 
It is important to note that ECl VS 14 did not significantly impair intracellular 
calcium mobilization. In fact, the vast majority of the EClVS14 derivatives were 
incapable of inhibiting this signal transduction mechanism. The relative 
insensitivity of calcium mobilization to compound Eel VS 14 suggests that this 
compound may allow selective inhibition of CXCR4-mediated chemotaxis without 
modification of calcium signaling. EClVS14 is very unique in its inability to 
modify calcium signaling, a characteristic that is not shared by any other CXCR4 
inhibitors [289-291], including T140 [195] and AMD3100 [275]. 
Our 5 ns molecular dynamics simulations have allowed us to gain a finer 
mechanistic understanding of the interaction between CXCR4 and EClVS14. We 
have found that ECl VS 14 drives CXCR4 into a unique conformation. It seems to 
be a more open extracellular surface than seen in the native conformation, but 
less open than seen in the N119S conformation. 
This work represents a significant examination of the activity and 
development of an anti-CXCR4 lead compound with direct application to the 
inhibition of cancer metastasis as a neoadjuvant chemotherapeutic agent. 
Investigation of multiple generations of EClVS14 derivatives as well as extensive 
molecular dynamics simulations have allowed us to carry forward the structure 
based drug design program and gain greater insight into the function of CXCR4 
and its interaction with a potent inhibitor. 
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CHAPTER III 
DISCOVERY OF INTRACELLULAR LOOP TARGETED COMPOUNDS BY 
VIRTUAL SCREENING 
Introduction 
As depicted in Figure 50, there are 5 sites where signal transduction by 
CXCR4 can be disrupted. One could attempt to bind or sequester CXCL 12 to 
prevent CXCR4 from interacting with its cognate ligand. One could attempt to 
inhibit the interaction of CXCL 12 and the extracellular surface of the receptor by 
blocking the interaction pOints between CXCL 12 and CXCR4 on the extracellular 
surface of the receptor. One could attempt to stabilize the transmembrane 
helices in an effort to prevent extracellular to intracellular signal transduction. 
One could attempt to prevent the interaction of G-proteins with the intracellular 
surface of CXCR4 by attempting to block the interaction points between CXCR4 
and the G proteins. Finally, one could attempt to bind and sequester the G 
protein in such a manner that it will not interact with CXCR4. 
Although CXCL 12 knockdown has been demonstrated to inhibit tumor cell 
proliferation and migration [292, 293], these genetic therapies are not yet 
applicable to the clinical setting. In addition, in the face of rising concentrations of 
CXCL 12, as would be expected in favorable microenvironments by CXCR4 
expressing neoplastic cells [34-36], inhibition by binding and sequestering 
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Figure 50: There are 5 potential structural targets for inhibiting CXCR4 
signaling: 1) Targeting the ligand CXCL 12 to prevent ligand/receptor interaction, 
2) Targeting the Extracellular ligand binding site as in AMD3100 and T140, 
3)Stabilizing the transmembrane helixes to prevent ligand induced conformation 
changes, 4)Targeting the Intracellular region of CXCR4 at the G-Protein 
interface, 5) Targeting the G-protein to prevent GPCR-G-protein interaction. 
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Figure 50: There are 5 potential structural targets for inhibiting CXCR4 
signaling 
Target 1 Chalcones 
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CXCL 12 would become increasingly difficult. In spite of this, as series of 
compounds has been designed which selectively bind CXCL 12. These 
compounds, chalcones (Figure 51 ), inhibit intracellular calcium mobilization, 
ligand binding and chemotaxis mediated by CXCL 12 at an IC50 of 100 nM [294]. 
The majority of anti-CXCR4 drug discovery efforts have been targeted at 
the extracellular surface of the receptor, or Target 2 in Figure 50. CTCE-9908 is 
a palindromic 17-amino acid cyclic peptide analog of CXCL 12 as depicted in 
Figure 52, which features dual 8 amino acid repeats which mimic the 8 amino 
acid N-terminus of CXCL 12 [176]. Binding of CTCE-9908 is purported to mimic 
the CXCL 12 binding model, primarily interacting with the N-terminal region of 
CXCR4. Identified initially as anti-HIV agents, many other anti-CXCR4 
compounds act at the extracellular surface of CXCR4 including AMD31 00 and 
T140 which are depicted in Figure 52. AMD3100 strongly interacts with residues 
Asp171, Asp262 and Glu288, located on the extracellular side of TM4, TM6 and 
TM7 [295-297]. T140 utilizes a similar binding mechanism interacting with 
residues Asp171 , Arg188, Tyr190, Gly207 and Asp262 [200]. The net effect of 
these interactions is that although some of the specific residues may be different, 
both AMD3100 and T140 interact at the CXCL 12 binding site, and inhibit signal 
transduction, CXCL 12 -CXCR4 interactions, and stabilizing the conformation of 
the native receptor or driving the conformation into an intermediate position 
which does not effectively transmit signal [200]. 
Direct targeting of the TM region of CXCR4 would be a difficult task. 
Unlike many GPCRs, CXCR4 lacks a central channel leading to an 
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Figure 51: Chalcones inhibit CXCR4 signaling by selectively binding 
CXCL 12. Chalcones are small molecules which neutralize CXCL 12. These 
compounds effectively and selectively inhibit CXCL 12 mediated CXCR4 
internalization, chemotaxis, and calcium mobilization in addition to 
CXCR4:CXCL 12 ligand binding. 
212 









Figure 52: Anti-GPCR compounds. Two different classes of compounds are 
illustrated in Figure 69. Those in Column A interact with CXCR4 at the 
extracellular surface of the GPCR. Those in Column B interact with GPCRs at 
the G-protein level, inhibiting Ga and Gj3V. 
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intramembranous rhodopsin-like binding pocket, rather the pocket is larger, more 
open and located more superficially in the extracellular surface of the receptor 
than in other GPCRs [257]. Structural studies of CXCR4 have also suggested 
that movement of TM7 compared to the rhodopsin structure reduces the size of 
the intramembrane region which would correspond to a retinal binding site [200]. 
Drug development targeting G-proteins 
The intracellular surface of CXCR4 is largely undiscovered country for 
drug development, in that there have been no prior attempts to inhibit CXCR4 
function by targeting the intracellular surface of the receptor, and only a handful 
of attempts to target G-proteins as a method for inhibiting GPCRs. G-proteins 
transmit GPCR mediated signals through a series of reactions. G-proteins are 
heterotrimers composed of Ga, GJ3 and Gy. Upon interaction with an activated 
GPCR, GOP bound to Ga will be exchanged for GTP, facilitating a separation of 
the heterotrimer into Ga and GJ3y subunits. These subunits in turn activate 
downstream signaling pathways until intrinsic GTP-ases in Ga convert GTP to 
GOP, facilitating the reformation of the G-protein heterotrimer. 
Antagonism of the interaction between Ga and GPCRs has been 
demonstrated to modul~te receptor function. Peptides based on the C-terminal 
residues of Gai and Ga01 have been found to inhibit agonist binding and signal 
transduction in A 1 adenosine receptors [298]. YM-254890 depicted in Figure 52 
is a specific Gaq/11 inhibitor [299] designed to prevent acute thrombosis and 
neointima formation. YM-254890 was purified from Chromobacterium sp. 
OS36666 [251], and inhibits Gaq/11 function by preventing GOP/GTP exchange 
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by the Ga subunit [300]. YM-254890 mediated effects on thrombosis and 
response to vascular injury were compared to other antithrombotic 
compounds:P2Y12 receptor antagonists ticlopidine and clopidogrel [246-251] 
and was found to have greater inhibitory potency than the anti-GPCR 
compounds. This makes for an interesting proof of principle in that it 
demonstrates that inhibition of GPCR function can be as effective at the G-
protein level as it is at the GPCR level. 
More substantial efforts have targeted G~y as a method of inhibiting 
GPCR signal transduction. BIM-46174 (Figure 52) has been developed as an 
inhibitor of the heterotrimeric G-protein complex, and effectively inhibits GPCR 
signaling in these cells while inhibiting the growth and proliferation of several 
cancer cell lines, although this activity also extended to non-tumor cell lines such 
as HEK-293 [301]. The G~y subunit has been successfully targeted by virtual 
screening for the development of anti-G~y compounds, which actively inhibit G-
protein mediated signaling including calcium mobilization [253]. Covalent 
modification of the G~y subunit by selenocystamine (Figure 52) has also been 
found to selectively inhibit G~y function [256]. Unfortunately, non-specific 
modulation of G~y function would produce widespread failures in GPCR function , 
with potentially devastating outcomes in the immune compartment such as 
myelosuppresion. 
However, a selective G~y inhibitor could potentially have great therapeutic 
utility. M119K, depicted in Figure 52, is one such compound which inhibits G~y 
and acts as an anti-pain medication by modulating the I..l-opiod receptor [252-
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254]. Additional use of this compound has expanded its scope to potentially 
include treatment of metastatic disease. M119K was found to inhibit migration 
and invasion of MDA-MB-231 and MDA-MB-436 cells, but perhaps most 
importantly, M119K was found to selectively inhibit CXCR4 mediated migration 
and chemotaxis by selectively inhibiting G~y functions, while Gai functions 
remained intact [255]. This compound demonstrates that CXCR4 function can be 
successfully inhibited by targeting the intracellular portion of the signaling 
apparatus. 
Development efforts targeting the interface between GPCRs and G-
proteins has been especially sparse, with the only efforts tied to development of 
small molecule inhibitors of the interaction between rhodopsin and its G-protein 
transducin [302, 303]. The first of these studies utilized a reduced intracellular 
loop representation of the rhodopsin crystal structure to identify a series of 
compounds which inhibited transducin binding to rhodopsin [303]. In the second 
study, a portion of the transducin a subunit was used as a pharmacophore model 
to identify compounds which stabilized the active state of Rhodopsin [302]. 
Heterotrimeric G-proteins only interact with active CXCR4 in metastatic 
breast cancer cell lines. 
One of the origins of this work was in a finding by Dr. Kelby Napier. Dr. 
Napier had generated a series of molecular dynamics structures featuring 
mutants of the TM3 residue asparagine 119 (N119). This series of mutants was 
based on findings by Zhang et al which found that N119 mutation to Ser (N119S) 
or Ala (N119A) produced a constitutively active conformation of CXCR4, while 
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mutation to Lys (N119K) produced a constitutively inactive conformation of the 
receptor [127]. One of Dr. Napier's objectives was to attempt to recreate the 
interaction between CXCR4 and a heterotrimeric G-Protein, but he found that he 
was unable to generate a structure with a viable interaction between the native 
CXCR4 conformation and the heterotrimeric G-Proteins. While he was also 
unable to produce a viable interaction structure using the N119K conformation of 
CXCR4, CXCR4 did interact with the G-protein when the N119S and N119A 
structures were used. This suggested that the heterotrimeric G-proteins only 
interacted with activated CXCR4 conformations. This finding is supported by 
clinical data. Holland et al demonstrated that although the Ga and G~y subunits 
could interact individually with CXCR4 in both metastatic and non-metastatic 
breast cancer cell lines, the heterotrimer Ga~y only interacted with CXCR4 in the 
meta static cell lines [137]. This data in combination with the proof of principle 
studies demonstrating that the G~y inhibitor M119 can inhibit migration and 
invasion of MDA-MB-231 and MDA-MB-436 breast cancer cells [255], suggests 
that inhibition of CXCR4 targeting the intracellular surface of the receptor is a 
viable target to inhibit CXCR4 mediated metastasis. 
Virtual screening as a method for drug discovery 
Identification of new small molecule inhibitors begins with identification of 
novel lead compounds. Virtual screening presents the capability to prescreen 
vast databases, such as the Zinc compound library, a 13 million compound 
virtual database [208], by targeting a three dimensional structure to determine 
those compound which best fit, or dock, into a chosen allosteric or ligand binding 
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site. This method has proven successful in the identification of a wide variety of 
targets [209-225]. 
This method is dependent on the development of an accurate three-
dimensional structure. GPCR crystal structures other than bovine rhodopsin [104] 
have only recently become available so the majority of virtual screening targeting 
GPCRs has been accomplished using homology modeling, in spite of the fact 
that there is often low sequence similarity between rhodopsin and the target 
GPCR. Although new high resolution crystal structures of the 132-adrenergic 
receptor [108] and the a2A adenosine receptor [111] have been released, in 
each of these structures intracellular loop 3 has been replaced with T 4 lysozyme 
and the C-terminus has been truncated and replaced with a histidine purification 
epitope. Thus, use of these structures would have required homology modeling 
based on rhodopsin to generate structures for these two regions. Novel crystal 
structures for CXCR4 were released on November 19, 2010 [257], too late to be 
used in any of these studies. These structures carried the same T4 Lysozyme 
and C-terminal substitutions as seen in the 132-adrenergic and a2A adenosine 
receptors. Thus modeling of CXCR4 focusing on the intracellular surface of the 
receptor based on these crystal structures would require extensive homology 
modeling to develop a workable model. Further, such drastic modifications of 
ICL3 and the C-terminus could have dramatic implications on the positioning and 
structure of their attached transmembrane helixes, TM5, TM6 and TM7. 
One method of performing virtual screening is Surflex-Dock [234, 244]. 
This docking program utilizes protomols, or pseudo-molecules, to virtually define 
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binding sites targeting the protein structure. Protomol development can be based 
on ligands, inhibitors or partner proteins acting at the targeted site, or residues of 
the protein itself which comprise or surround an active site can be used to define 
the protomol. The target protein can be screened by attempting to dock 
compounds into the defined protomol site. Surflex-Dock conducts flexible docking 
by fragmenting the compounds into components and docking the fragments into 
the defined site, constructing the compound in the active site based on favorable 
positions for each of the compound fragments. Multiple poses of each compound 
are returned to the user and assigned a score based on binding affinity, degree 
of inappropriate penetration into the protein, and internal structural conflicts. 
In this chapter, we have used SBDD to identify inhibitors of the CXCR4 by 
targeting the intracellular surface of the receptor. As illustrated in Figure 53, we 
have used Surflex-Dock to virtually screen the interface between constitutively 
active N119S CXCR4 and the heterotrimeric G-protein. We identified compounds 
which interacted with either the CXCR4 or the Ga side of the interface, and 
several of these compounds significantly inhibited chemotaxis for an 
exceptionally high initial hit rate of sixty-two percent. Two of these compounds, 
ICLGa28 and ICLGa36, produced IC50 values of 1 IJM. Two other compounds, 
ICLGa9 and ICLGa25, specifically inhibited CXCL 12-induced calcium 
mobilization with an IC50 value of 1 IJM. These compounds exhibited almost no 
cytotoxicity, and several were also capable of inhibiting tumor cell proliferation. 
These compounds represent the first successful attempt to target the intracellular 
interface of a non-rhodopsin GPCR for drug development and drug discovery. 
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Figure 53: SBOO of inhibitors of the intracellular surface of CXCR4. Surflex-
Dock was used to virtually screen the interface between constitutively active 
N119S CXCR4 and the heterotrimeric G-protein. We identified thirty-seven 
compounds which displayed interacted with either the CXCR4 or the Go side of 
the interface, and eleven of these compounds significantly and specifically 
inhibited CXCR4 with an IC50 value of 1 0 ~M in either chemotaxis or calcium 
mobilization. The interaction between the compounds and CXCR4 was further 
rationalized by molecular dynamics. 
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Figure 53: SBOO of inhibitors of the intracellular surface of CXCR4. 
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The lipid-bilayer simulation of the CXCR4 N 119S mutant docked with the 
G-protein heterotrimer was used to identify residues on the interaction surfaces 
of both proteins. The interface between two proteins occurred primarily between 
CXCR4 and the Gai subunit of the heterotrimer. Specific structural considerations 
came into play in designing the protomol files. CXCR4 residues within 8 A of Gai 
and vice-versa were identified using a distance assessment PERL script, and 
these residues (Table 13) were used to produce residue based protomol files 
targeting both proteins. In addition, an a-helix of Gai came into close contact with 
the intracellular surface of CXCR4. This structure was used to develop a ligand-
based proto mol targeting CXCR4. A portion of the third intracellular loop of 
CXCR4 composed of residues 234-239 came into close contact with the surface 
of Gai. This structure was used to define a ligand-based protomol targeting Gai. 
In evaluating the protomols targeting CXCR4, the ligand-based protomol 
best defined the interface surface on intracellular loops 1-3 and the c-terminus 
without positioning itself toward the transmembrane helices and away from Gai, 
as was seen with the residue based protomol. The ligand and residue based 
protomols targeting Gai both identified portions of the interaction surface with 
CXCR4, but neither completely covered the interface. As there was relatively little 
overlap between the protomols, they were combined into a single file and this 
combined proto mol provided excellent coverage of the entire interface surface. 
The virtual screen was set up using the ZINC compound library, which in 2006 
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Table 13: Residues of CXCR4 and Gai used in Protomol development in 
Surflex. Residues on CXCR4 within 8 A of Gai and residues on Gai within 8 A of 
CXCR4 were identified using a distance assessment PERL script to evaluate the 
interaction structure of CXCR4 and Gai. These residues were used to produce 
residue based protomol files targeting both proteins. 
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Table 13: Residues of CXCR4 and Gai used in Protomol development in 
Surflex. 
CXCR4 Gai 
Residue AA Residue AA 
71 Ser 670 Glu 
72 Met 671 lie 
140 His 691 Val 
141 Ala 693 Asp 
143 Asn 694 Val 
144 Ser 696 lie 
234 Lys 697 Lys 
235 Arg 698 asn 
236 Lys 700 Leu 
237 Ala 701 Lys 









comprised a data set of 2.5 million compound structures. These were individually 
docked, scored and ranked by Surflex-Dock using the Dataseam GRID 
distributed computing system (Dataseam [304]). The top 500 compounds were 
re-run as a separate subset using higher accuracy parameters (including 
randomized conformations in multiple starting positions) in Surflex-Dock. 
Transfection and generation of RBL-2H3 and 300.19 stable cell lines 
expressing hCXCR4 and hCXCR4-GFP 
To fully evaluate the effects of the potential inhibitors we have stably 
transfected overexpressing CXCR4 cell lines in collaboration with Dr. Haribabu 
Bodduluri, as described in chapter 2. 
Chemotaxis analysis 
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4-
GFP or BL T1 was performed as previously described in Chapter 2 [151, 281] . 
Cell signaling analysis 
Cell signaling by CXCR4 was investigated by assessment of intracellular 
calcium mobilization as described in Chapter 2. 
Class A GPCR selectivity for non-family member BL T1 
The selectivity of the compounds for CXCR4 was assessed by 
investigating their effect on the Class A GPCR BL T1 as described in chapter 2. 
Determination of nonspecific cytotoxicity 
The potential cytotoxic effects of the compounds were investigated in our 
own hCXCR4-GFP expressing 300.19 cells as described in chapter 2. 
Cell proliferation MTT assay 
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Anti-proliferative effects of the potential inhibitors were investigated using 
tissue derived cell lines. Control non-neoplastic human skin fibroblast (HS27) 
cells as well as lung (A549) and breast (MDA-MB-231 and MCF7) carcinoma cell 
lines were used in a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) assay [305] with our protocols [306-309]. In brief, 102 cell per well were 
plated in 96 well plates, allowed to grow for one day prior to the addition of small 
molecules. Concentrations of the small molecules at 100IlM, 10IlM, 1 IlM, and 
1 OOnM were screened for activity. Four days after treatment, 125 IJg MTT 
(Sigma) was added to each well and incubated for 4 h at 37 C. Cells were then 
lysed with 100 IJllysis buffer (20% sodium dodecyl sulfate, 50% N,N-
dimethylformamide, and 0.8% acetic acid, pH 4.7) incubated for another 22 hand 
finally absorbance at 490 nm was determined. Samples were run in triplicate with 
untreated and DMSO-alone controls. Samples involving ICL compounds were 
normalized to average absorbance of the untreated samples [310-312]. 
Molecular modeling of CXCR4 and ICLGa complexes 
Complexes of active ICLGa compounds and CXCR4 were investigated by 
molecular dynamics as described in chapter 2. 
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Results 
Virtual screening identifies thirty-seven commercially available compounds 
targeting the CXCR4:Gai interface 
Virtual screening targeting the CXCR4:Gai interaction site was conducted 
utilizing structures of CXCR4 and Gai initially developed by Dr. Napier. These 
structures were derived from molecular dynamics simulations of CXCR4 in a fully 
solvated lipid bilayer. As constitutively active mutants of CXCR4 were the only 
configurations of this receptor that were capable of interacting with the G-protein 
heterotrimer and interaction between the heterotrimer and CXCR4 primarily 
occurred at the Gai subunit, the dynamically-refined models of the N119S-mutant 
CXCR4 and Gai were used in virtual screening to identify small molecule 
antagonists targeting the CXCR4:Gai interface. Use of an active conformation of 
a receptor for virtual screening has been demonstrated to be beneficial for drug 
development, with active conformation of the 132-adrenergic receptor enriching 
screening studies by 38% when compared to similar studies using an inactive 
conformation of the receptor [313]. 
Surflex-Dock [234, 244] was conducted in a two stage process. First, the 
ZINC compound library [208] was individually docked, scored and ranked by 
Surflex-Dock using GRID (Dataseam [304]). The top 5000 compounds were re-
run as a separate subset using five starting positions and ten randomized initial 
compound conformations. The top 37 commercially-available compounds, (Table 
14 and Figure 54) were assayed using human CXCR4 expressing cell lines. This 
is the first virtual screen to target the intracellular surface of CXCR4. 
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Table 14: Virtual screening identifies thirty-seven commercially available 
compounds targeting the interface of CXCR4 and Gai. In one of the first 
virtual screens to target the GPCR:G-protein interface, 37 commercially available 
compounds sere selected based on virtual screening scores and assessment by 
"Upinski's rule of five" for drug-like characteristics. 
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Table 14: Virtual screening identifies thirty-seven commercially available 
compounds targeting the interface of CXCR4 and Gai. 
Target NAME Supplier MW 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-
ICLGA1 CXCR4 2-hydroxy-3-(4-nitrophenoxy) Maybridge 347.3 
propan-1-aminium 
ICLGA2 Gai (E)-1-( naphthalen-2-yl)-5-(2- Maybridge 291.4 (pyrrolidin-1-yl)vinyl)-1 H-tetrazole 
1-( 4-nitrophenyl)-2-( (5-( 4-
ICLGA3 CXCR4 pentylphenyl)-4H-1,2,4-triazol-3- Maybridge 410.5 
yl)thio )ethanone 
ICLGA4 Gai N-(2-( 4-ethylphenoxy)ethyl)-5-(3- Chemical 384.5 
methylpiperazin-1-yl)-2-nitroaniline Block 
1-( 4-chlorophenoxy)-3-(2-imino-3-
ICLGA5 Gai (2-(piperidin-1-yl) ethyl) -2,3- Chem 429.0 dihydro-1 H-benzo[d]imidazol-1- Bridge 
yl)propan-2-01 
N 1-(3-( dimethylamino )propyl)-
ICLGA6 Gai N3, N3-dimethyl-N1-(( 4-(prop-1-en- Chem 321.5 2-yl)cyclohex-1-en-1- Bridge 
yl)methyl)propane-1,3-diamine 
4-methoxy-N-( (1-(2-( 0-
ICLGA7 CXCR4 tolyloxy)ethyl)-1 H-benzo[d] Specs 387.5 
imidazol-2-yl)methyl)aniline 
4-ethoxy-N-( (1-(2-phenoxyethyl)-
ICLGA8 CXCR4 1 H-benzo[d]imidazol-2- Specs 387.5 
yl)methyl)aniline 
N4-(benzo[g]quinolin-4-yl)-N1-(6-
ICLGA9 CXCR4 methoxyquinolin-8-yl)pentane-1,4- Specs 436.6 
diamine 
N-((1-methyl-1 H-benzo[d]imidazol-
ICLGA10 Gai 2-yl)methyl)-1-propyl-1 H- Specs 319.4 
benzo[d]imidazol-5-amine 
1-((( 4-( 4-((2,5-dioxopyrrolidin-1-yl) 
ICLGA11 Gai (methyl)amino )benzyl)phenyl) Asinex 420.5 
amino )methyl) pyrrolidine-2,5-dione 
ICLGA12 CXCR4 2-((3-cyano-5, 7 -dimethylquinolin-2- Asinex 375.4 yl)amino )ethyl 2-methoxybenzoate 
N-(2-((3-cyano-5,7-
ICLGA13 CXCR4 dimethylquinolin-2- Asinex 296.5 
yl)amino )ethyl)propionamide 
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Table 14, continued: Virtual screening identifies thirty-seven commercially 
available compounds targeting the interface of CXCR4 and Gai. 
Target NAME Supplier MW 
1-(3,4,5-trimethoxybenzyl)-




ICLGA15 CXCR4 -3-methyl-1-oxo-1 ,5- Asinex 416.5 
dihydrobenzo[4,5 
]imidazo[1,2-a]pyridine-4-carbonitrile 
ICLGA16 CXCR4 1-(9H-carbazol-9-yl)-3-( (4- Asinex 360.5 
ethoxyphenyl)amino )propan-2-ol 
2-(3-(3-( dimethylamino )propyl)-2-
ICLGA17 CXCR4 imino- Asinex 338.5 2,3-dihydro-1 H-benzo[d]imidazol-1-
yl)-1-phenylethanol 
N-((2,3-dihydrobenzo[b][1,4] 
ICLGA18 CXCR4 dioxin-2-yl)methyl)-2-hydroxy-3-(4- Asinex 361.4 
nitrophenoxy)propan-1-aminium 
1-methyl-2-(piperidin-1-ylmethyl) 
ICLGA19 CXCR4 -N-(pyridin-2-ylmethyl)-1 H-benzo[d] ChemDiv 335.5 
imidazol-5-amine 
2-(benzo[d][1,3]dioxol-5-yl) 
ICLGA20 CXCR4 -9-( 4-methylbenzyl)-9H-benzo[d] I BScreen 381.4 
imidazo[1,2-a]imidazole 
N-(1-(2,3-dihydrobenzo[b][1,4] 
ICLGA21 CXCR4 dioxin-2-yl)ethyl)-2-hydroxy-3-(4- IBScreen 375.4 
nitrophenoxy)propan-1-aminium 
N-((1-benzyl-1 H-benzo[d] 
ICLGA22 Gai imidazol-2-yl)methyl)-1,2-dimethyl- IBScreen 381.5 
1 H-benzo[d]imidazol-5-amine 
2-(([1,1'-biphenyl]-4-yloxy)methyl) 
ICLGA23 CXCR4 -5-( (2-morpholinoethyl)amino) IBScreen 404.5 
oxazole-4-carbonitrile 
N-(3,4-dimethylisoxazol-5-yl)-4-((3-
ICLGA24 CXCR4 (phenylsulfonamido )quinoxalin-2- Enamine 550.6 
yl)amino )benzenesulfonamide 
N-(3-(( 4-( dimethylamino )phenyl) 
ICLGA25 CXCR4 amino )quinoxalin-2-yl)- Enamine 464.5 
4-nitrobenzenesulfonamide 
1-( 1-( 4-fluorophenyl)-2,5-dimethyl 
ICLGA26 Gai -1 H-pyrrol-3-yl)-2-(furan-2- Enamine 326.4 
yl( methyl)amino )ethanone 
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Table 14, continued: Virtual screening identifies thirty-seven commercially 
'1 bl d f th' t rf f CXCR4 d G . avala e compoun s targe mg eme ace 0 an al. 
Target NAME Supplier MW 
ethyl 2-(2-(benzo[d]thiazol-2-ylthio) 
ICLGA27 CXCR4 -2-phenylacetamido )-6-methyl- Enamine 522.7 4,5,6,7-tetrahydrobenzo[b] 
thiophene-3-carboxylate 
(E)-4-( ((2-(3,4-d imethylphenyl) 








ICLGA30 CXCR4 dimethoxyphenethyl)amino) Enamine 373.44 
-2-hydroxypropoxy) 
phenyl)ethanone 
N-(3,4-dimethylphenyl)-2- Enamine-ICLGA31 CXCR4 ((5-((4-methoxyphenyl)amino)- REAL 400.52 1 ,3,4-thiadiazol-2-yl)thio )acetamide 
2-( 4-( ethoxycarbonyl)-3,5-
ICLGA32 CXCR4 dimethyl-1 H-pyrrol-2-yl)-2-oxoethyl Enamine- 410.42 5-methyl-3-phenylisoxazole REAL 
-4-carboxylate 
2-(2-chlorophenyl)-N'-( 4-
ICLGA33 CXCR4 methylcyclohex-1-en-1-yl) Enamine 391.89 
quinoline-4-carbohydrazide 
1-(naphthalen-1-ylamino )-1- Enamine-ICLGA34 CXCR4 oxopropan-2-yl 2-(3,5-dimethyl-4- REAL 396.4 
nitro-1 H-pyrazol-1-yl)acetate 
1-( 4-( methoxycarbonyl)phenyl) 
ICLGA35 CXCR4 -2-( methylamino )-2-oxoethyl Enamine 408.4 5-methyl-3-phenylisoxazole-4-
carboxylate 
N-(3-( (9-ethyl-9H-carbazol-3-
ICLGA36 CXCR4 yl)amino )quinoxalin-2-yl)-4- Otava 507.61 
methylbenzenesulfonamide 
2-( (3,4-dimethylphenyl)amino) 
ICLGA37 Gai -N-( 5-( 3-( trifluo romethyl )benzyl) Otava 419.46 
thiazol-2-yl)acetamide 
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Figure 54: ICLGA Compounds. Structures of thirty-seven compounds identified 
in virtual screens targeting the interface between the intracellular surface of 
CXCR4 and Gai are illustrated below. 
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Figure 54: ICLGA Compounds 
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Compounds targeting the CXCR4:Gai interface specifically inhibit 
chemotaxis 
Our goal was to target the CXCR4:G-protein interface to discover novel small 
molecules which could selectively inhibit receptor function and be used as 
scaffolds for development of clinically active anti-metastatic compounds. We 
sought to evaluate the compounds by chemotaxis assays which quantitatively 
examined the capability of cells to migrate towards a ligand gradient. Initial 
screening of the thirty-seven ICL compounds at 50 IJM identified twenty-four 
compounds which significantly inhibited chemotaxis as depicted in Figure 55. 
Dose response analysis was used to determine the concentration of the active 
compounds where chemotaxis was inhibited by 50% in reference to the CXCL 12 
alone control (IC50). Ten of the twenty-four active compounds had chemotaxis 
IC50 values of 10 IJM or less (Figure 56), for an exceptionally high initial hit rate 
of 27%. Compounds ICLGa28 and ICLGa36 were two of the most promising 
compounds identified , with effective inhibition of chemotaxis at 1 IJM. Other 
notable compounds included ICLGa 8 with effective inhibition at 3 IJM and ICLGa 
compounds 5, and 37 with effective inhibition at 5 IJM. 
It is important to note that the hit rate of our virtual screening studies is 
significantly higher than what is seen in similar published studies. Our initial hit 
rate of 64.9% at 50 IlM for the initial screening of our thirty seven ICL compounds 
represents a great increase over contemporary studies. For comparison, recent 
investigations using virtual screening of glycogen synthase kinase-313 (GSK-313) 
had an initial hit rate of 12.5% for 162 compounds [314]. A recent investigation of 
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Figure 55: ICLGa compounds inhibit CXCR4 mediated Chemotaxis. 
Chemotaxis assays performed with ICLGa compounds at a concentration of 50 
IJM. Vertical axis is presented in terms of chemotaxis index wherein sample 
chemotaxis is normalized to chemotaxis of the CXCL 12 alone control. Successful 
inhibition of chemotaxis reduced chemotaxis of samples compared to CXCL 12 
alone. 24 of 37 tested compounds significantly inhibited chemotaxis at the initial 
screening concentration of 50 IJM. 
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Figure 56: IC50 of ICLGa compound mediated chemotaxis inhibition. 
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone 
signaling (IC50) were determined for active ICLGa compounds. Vertical axis is 
presented in terms of IC50 of chemotaxis in I-lM. 10 of the 26 active compounds 
exhibited significant inhibition of chemotaxis at 10 I-lM or less. 
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integrin av~3 using virtual screening of a large compound library had an initial hit 
rate of 14% for 50 compounds, with IC50 values ranging from 30 to 200 J.!M 
[315]. Another study targeting bacterial NAD synthetase had an initial hit rate of 
20% at 300 J.!M, but only 2 of the 40 (5%) active compounds had IC50s less than 
50 J.!M [316]. 
We then sought to determine the specificity of the ICLGa compounds for 
CXCL 12-induced chemotaxis. Chemotaxis assays were carried out using 300.19 
cells expressing the class A GPCR BL T1 mediating chemotaxis in response to 
L TB4. Initial screening of the twenty-four active ICLGa compounds revealed that 
fifteen of the compounds also inhibited L TB4-mediated chemotaxis at 50 J.!M. 
However, as can be seen in Figure 57, dose response analysis of the ICLGa 
compounds with anti-BL T1 activity revealed that only four of the compounds 
(ICLGa6, ICLGa12, ICLGa14 and ICLGa16) had IC50 values that were lower for 
BL T1 than for CXCR4. There was an average difference of 18.5 IJM in the IC50 
values of the compounds in reference to CXCR4 versus BL T1. It is important to 
note that of the ten ICLGa compounds which inhibited CXCR4-mediated 
chemotaxis at 10 IJM or less, only five exhibited any anti-BL T1 activity, and none 
of these possessed an anti-BL T1 IC50 of less than 25 IJM. This suggests that the 
inhibitory effects produced by these compounds are specific for CXCR4. 
Division of ICLGa compounds into calcium and non-calcium inhibitors of 
CXCR4 
Intracellular calcium mobilization is a common method for assessing 
GPCR receptor activation and signaling. CXCL 12-induced calcium mobilization is 
245 
Figure 57: ICLGa compounds selectively inhibit CXCR4 Mediated 
Chemotaxis. Specificity screening of active ICLGa compounds in BL T1 
expressing cells revealed that 15 compounds inhibited chemotaxis in both 
systems. Only 3 of the 15 compounds with BL T1 activity inhibited BL T1 
chemotaxis to a greater degree than CXCR4 mediated chemotaxis. Only 5 of the 
ICLGa compounds with anti-CXCR4 activity at 10 !-1M or less exhibited anti-BL T1 
activity, and none had anti-BL T1 IC50 values of less than 25 !-1M. 
246 








>< CU 25 
-0 E 
(1) 








a pertussis toxin sensitive [317] process, suggesting that this process is 
dependent on Ga signaling. Thus, we investigated the impact of ICLGa 
compounds on CXCL 12-induced calcium mobilization. CXCL 12-induced 
signaling was assessed by the change in amplitude of the calcium signal and 
results were normalized to the CXCL 12-alone control. Initial screening of the 
ICLGa targeted compounds at 50 !-1M identified twelve compounds which 
significantly reduced calcium release , seen in Figure 58. Dose response analysis 
determined that six of the twelve active compounds, ICL9 (1 !-1M) , ICL 12 (5 !-1M) , 
ICL 13 (5 !-1M) , ICLGA25 (1 !-1M) , ICL28 (10 !-1M) and ICL36 (6 !-1M) had calcium 
mobilization IC50 values of 10 !-1M or less as seen in Figure 59. 
We then sought to determine the specificity of the ICLGa compounds for 
CXCL 12-induced intracellular calcium mobilization. Calcium mobilization assays 
were carried out using 300.19 cells expressing BL T1 and signaling was assessed 
in response to L TB4. Initial screening of the twelve active ICLGa compounds 
revealed that nine of the twelve significantly inhibited L TB4-induced intracellular 
calcium mobilization. Subsequent dose response analysis, depicted in Figure 60, 
revealed that six of the nine ICLGa compounds with anti-BL T1 activity had IC50 
values that were lower for BL T1 than for CXCR4. Differences in calcium 
mobilization were relatively small for ICLGa2 (45 !-1M vs. 40 !-1M) , ICLGa4 (35 !-1M 
vs . 27.5 !-1M) , ICLGa12 (5 !-1M vs. 2.5 !-1M) , ICLGa13 (5 !-1M vs. 2.5 !-1M) , and 
ICLGa16 (35 !-1M vs. 30 !-1M) , suggesting that inhibition of calcium signaling by 
these five compounds is not selective. In contrast the IC50 of calcium 
mobilization was significantly greater for CXCR4 than BL T1 for ICLGa9 (1 !-1M vs. 
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Figure 58: ICLGa compounds inhibit CXCR4 mediated Intracellular Calcium 
Mobilization. Calcium Mobilization assays performed with ICLGa compounds at 
a concentration of 50 !-1M. Vertical axis is presented in terms of normalized 
calcium signal, wherein the amplitude of the calcium response to the CXCL 12-
alone control corresponds to 1. Decreased signal amplitude correlates with 
inhibition of calcium mobilization. Eleven of thirty seven tested ICLGa 
compounds significantly inhibited calcium mobilization. 
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Figure 59: IC50 of ICLGa compound mediated inhibition of calcium 
mobilization. Concentrations which inhibited 50% of calcium mobilization in 
relation to CXCL 12 alone signaling (IC50) were determined for active ICLGa 
compounds. Vertical axis is presented in terms of IC50 of calcium mobilization in 
IJM. Six of the twelve active compounds exhibited significant inhibition of calcium 
mobilization at 10 IJM or less. 
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Figure 60: ICLGa compounds selectively inhibit CXCR4 Mediated Calcium 
Mobilization. The twelve ICLGa compounds which inhibited CXCL 12-induced 
calcium mobilization were tested for specificity in BL T1 expressing cells, 
revealing that nine compounds inhibited calcium mobilization is in both systems 
at a 50 IJM screening concentration . Five of the nine compounds produced BL T1 
mediated calcium mobilization equivalent to CXCR4 mediated calcium 
mobilization. Three of the compounds were selective for CXCR4 mediated 
calcium mobilization with IC50 values less that 10 IJM. 
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20 IJM), ICLGa25 (1 IJM vs. 40 IJM), and ICLGa28 (10 IJM vs. 22.5 IJM) 
suggesting that anti-calcium mobilization activity in these compounds is selective 
for CXCR4. 
The thirteen ICLGa anti-CXCR4 compounds with activity at 10 IJM or less 
are depicted in Table 15. Seven compounds exhibit CXCR4-specific and 
exclusive anti-chemotaxis activity. Three compounds exhibit CXCR4-specific 
anti-chemotaxis and anti-calcium mobilization activity. Two compounds exhibit 
non-specific exclusive anti-calcium mobilization activity. The remaining 
compound exhibits CXCR4-specific and exclusive anti-calcium mobilization 
activity. Given that CXCL 12-induced calcium modulation is dependent on Ga 
signaling, one would expect that compounds targeting Gai would preferentially 
inhibit intracellular calcium mobilization; however that was not the case for our 
compounds. Of the nine compounds targeting the Gai side of the interface, only 
three of these (ICLGa2, ICLGa4, and ICLGa5) significantly inhibited calcium 
mobilization, and the IC50 values of these compounds were much greater than 
for many of the CXCR4 targeted compounds which inhibited this signaling. One 
explanation for this discrepancy lies in the signaling pathway. CXCL 12-induced 
calcium mobilization is a pertussis toxin sensitive process [317], but also requires 
activation of phospholipase C~ [318]. Gai, the Ga subunit which interacts with 
CXCR4, is incapable of activating phospholipase C~ , and the only Ga subunit 
which activates phospholipase C~, Gaq, is insensitive to pertussis toxin [319, 
320]. The G~y subunit is also capable of activating phosphol ipase C~ [321]. 
Thus, CXCL 12-induced calcium mobilization could be dependent on interactions 
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Table 15: Classification of compounds with anti-CXCR4 activity at 10 IJM or 
less. ICLGa compounds with anti-CXCR4 activity with IC5a values of less than 
1 a IJM in either chemotaxis or calcium mobilization are listed in the table below. 
Three of the compounds ICLGa25, ICLGa28 and ICLGa36 produced inhibition of 
CXCR4 below 1 a IJM for both activities. 
256 
Table 15: Classification of compounds with anti-CXCR4 activity at 10 IJM or 
less. 
Compound Chemotaxis Calcium IC50 Activity Target IC50 (IJM) (IJM) 
ICLGa4 10 35 Chemotaxis Gai 
ICLGa5 5 45 Chemotaxis Gai 
ICLGa8 3 -- Chemotaxis CXCR4 
ICLGa9 45 1 Calcium CXCR4 
ICLGa12 12.5 5 Calcium CXCR4 
ICLGa13 12.5 5 Calcium CXCR4 
ICLGa17 10 -- Chemotaxis CXCR4 
ICLGa22 10 -- Chemotaxis Gai 
ICLGa25 10 1 Dual CXCR4 
ICLGa28 1 10 Dual CXCR4 
ICLGa29 10 -- Chemotaxis CXCR4 
ICLGa36 1 6 Dual CXCR4 
ICLGa37 5 -- Chemotaxis Gai 
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between Gai and either Gaq or G~V. In the case of the ICLGa compounds, some 
compounds could interfere with the interaction between CXCR4 and Gai, 
completely preventing signal transmission through the receptor inhibiting both 
chemotaxis and calcium mobilization as is the case with ICLGa25, ICLGa28 and 
ICLGa36. 
Compounds targeting the CXCR4:Gai interface have relatively little non-
specific cytotoxicity, but three active ICLGa compounds selectively inhibit 
tumor cell proliferation. 
Inhibition of chemotaxis and calcium mobilization by ICLGa compounds 
could be due to nonspecific toxic side effects, the active ICLGa compounds were 
screened for cytotoxicity. Mimicking the conditions in the chemotaxis assay, 
300.19 cells were cultured in the presence of ICLGa compounds at the initial 
screening concentration of 50 IJM and cytotoxicity was assessed using propidium 
iodide (PI) based flow cytometry. PI is unable to penetrate the cell membrane in 
viable cells, so cells staining positive for PI do not have intact membranes. 
Cytotoxicity values are presented as percentage of cells staining positive for PI in 
Figure 61. Of the twenty-six ICLGa compounds producing significant inhibition of 
chemotaxis and calcium mobilization, only seven produced displayed elevated 
cytotoxicity when compared to untreated cells or cells treated with DMSO only 
control. To further investigate the cytotoxicity of these compounds, dose 
response assays were conducted at concentrations of 10, 5, and 1 ~M, seen in 
Figure 62. Compounds ICLGa9, ICLGa25, and ICLGa36 displayed no 
cytotoxicity beyond the initial 50 ~M screening concentration. Compounds 
258 
Figure 61: ICLGa compounds produce relatively little non-specific 
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI, 
a marker for membrane disruption and non-viable cells. Only seven of the 
twenty-six ICLGa compounds with anti-CXCR4 activity compounds exhibited 
significant cytotoxicity. Only five of the compounds produced greater than 50% 
cytotoxicity at 50 IJM. Two additional compounds, ICLGa25 and ICLGa36, 
displayed elevated cytotoxicity compared to untreated and DMSO-alone controls, 
but to a lesser extent than 50% cytotoxicity. 
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Figure 62: Toxic concentrations of ICLGa compounds. Only one of the 7 
ICLGa compounds exhibiting cytotoxicity at 50 ~M exhibited cytotoxicity at 5 ~M 
or less. The three compounds with significant anti-CXCR4 activity below 1 a ~M 
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ICLGa2, ICLGa7 and ICLGa16 all retained significant cytotoxicity at 10 )lM. Only 
compound ICLGa4 maintained significant cytotoxicity at 5 )lM. There were no 
structural similarities between the compounds with cytotoxicity beyond 10 )lM. 
ICLGa9, ICLGa25 and ICLGa36 all selectively inhibited CXCR4 activity at 
1 )lM in either chemotaxis or calcium mobilization. All three of these compounds 
also displayed significant cytotoxicity at 50 )lM, but no cytotoxic effects at lower 
concentrations. As BIM-46174 had been demonstrated to inhibit tumor 
proliferation and induce apoptosis [301] we sought to investigate the impact of 
ICLGa on tumor cell proliferation. To determine the potential for the ICLGa 
compounds to impact the proliferation of tumor cells, we assessed cell growth 
capacity using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay. We investigated the effect of these compounds on four cell lines: 
HS27, a "normal" fibroblast cell line; MCF7, an estrogen-dependant non-
metastatic breast cancer cell line; MDA-MB-231, an estrogen-independent 
metastatic breast cancer cell line; and A549, a lung cancer cell line. Cells were 
left untreated, treated with 12.5 mM DMSO, or treated with varying 
concentrations of three ICLGa compounds, ICLGa9, ICLGa25 and ICLGa36, 
then incubated for four days before analysis. In our analysis, the absorbance 
values were normalized to untreated samples. 
The three ICLGa compounds showed particularly interesting effects on 
cell proliferation. In the normal cell line HS27 cells as depicted in Figure 63a, 
both ICLGa25 and ICLGa36 displayed marginal proliferation inhibition at higher 
concentrations, but these effects abated as concentration dropped below 20 !-1M. 
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Figure 63: Inhibition of cell proliferation by ICLGa compounds. Cell 
proliferation was assessed by MTT assay. Vertical axis represents MTT signal 
detected in each sample normalized to the untreated control. Horizontal axis 
represents concentration of ICLGa sample. 
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ICLGa9 consistently inhibited cell proliferation even at concentrations nearing 1 
!-1M. (Fig . 1119) 
In MCF7 cells as depicted in Figure 63b, ICLGa9 inhibited cell proliferation 
with an ICSO value of S !-1M. ICLGa36 also significantly inhibited cell proliferation 
with an ICSO value of 12.S !-1M. ICLGa2S only marginally inhibited cell 
proliferation of MCF7 cells at high concentrations. 
In MDA-MB-231 cells as depicted in Figure 63c, ICLGa9 inhibited cell 
proliferation with an ICSO value of S !-1M. ICLGa2S significantly inhibited 
proliferation of MDA-MB-231 cells; with an ICSO value of 10 !-1M. ICLGa36 
significantly inhibited cell proliferation of MDA-MB-231 cells, with an ICSO value 
of 30 !-1M. 
Finally, in AS49 cells as depicted in Figure 63d , ICLGa9 inhibited cell 
proliferation with an ICSO value of 7.S !-1M. ICLGa2S significantly inhibited cell 
proliferation of AS49 cells, with an ICSO value of 10 !-1M. ICLGa36 significantly 
inhibited cell proliferation of AS49 cells, with an ICSO value of 22.S !-1M. 
The three compounds illustrate three avenues of proliferation inhibition. 
ICLGa9 is generally inhibitory, affecting both normal and cancer cells at levels 
lower than the cytotoxicity levels seen in Figure 62. ICL2S inhibited the growth of 
metastatic cancer cell lines AS49 and MDA-MB-231, but not HS27 cells or non-
metastatic MCF7 cells. Finally, ICL36 inhibited the growth of non-metastatic 
MCF7 cells, metastatic cancer cell lines to a lesser extent, and did not inhibit 
proliferation of HS27 cells. These results are intriguing as a CXCR4 inhibitor 
need not be cytotoxic to function as a metastasis inhibitor. 
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Analysis of anti-CXCR4 compound mechanism through molecular 
dynamics simulations 
As demonstrated by Holland et aI, heterotrimeric G-protein interaction with 
CXCR4 occurs in metastatic breast cancer cell lines but not non-metastatic lines 
[137]. We have postulated that this behavior is due to differential activation of 
CXCR4 in the metastatic cell lines producing altered CXCR4 conformation, a 
hypothesis that is supported by the find ings of Dr. Napier that in silico the 
constitutively active N 1198 conformation of CXCR4 is capable of interacting with 
the G-protein heterotrimer while the native protein conformation is not. 
The initial native CXCR4 and N1198 mutant structures were developed by 
Dr. Kelby Napier via homology modeling utilizing the high resolution rhodopsin 
crystal structure [288]. When this work was conducted, the x-ray crystal structure 
for CXCR4 had not yet been released, so th is structure was not a viable option 
for these studies. 
Molecular modeling of CXCR4 and ICLGa complexes 
We hypothesize that the binding of ICLGa complexes with anti-CXCR4 
activity induces a conformational change in the receptor, impeding signaling. 
Complexes of active ICLGa compounds and CXCR4 were investigated by 
molecular dynamics. The highest scoring conformations of the ICLGa 
compounds were utilized as a guide to initial placement of the inhibitor. 8urflex-
Dock [234, 244] was used to dock 12 ICLGa compounds with anti-CXCR4 
activity at 10 IJM or less and without excessive cytotoxicity into the defined 
intracellular surface of the native structure of CXCR4. All twelve compounds 
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were successfully docked into the structure regardless of their initial status as 
CXCR4-targeted or Gai targeted compounds. Fully solvated lipid bilayer 
molecular dynamics simulations of native CXCR4 bound with active ICLGa 
compounds were performed using the AMBER suite of programs using the 
parm99 force field [284]. 
Some ICLGa compounds do not bind to the Native conformation of CXCR4 
in molecular dynamics simulations. 
The final averaged structures of native CXCR4 in complex with each of 
the anti-CXCR4 compounds from the 5 ns molecular dynamics simulation are 
shown in Figures 64. Of the twelve docked compounds, stable CXCR4: 
compound complexes were generated for compounds ICLGa8, ICLGa12, 
ICLGa25, ICLGa28, ICLGa29 and ICLGa37. ICLGa5, ICLGa9, ICLGa13, 
ICLGa17, ICLGa22, and ICLGa36 did not form stable complexes with the native 
conformation of CXCR4. 
Inverse agonist, antagonist and weak partial agonist inhibitors all 
potentially can bind to different structures of CXCR4. Weak partial agonists 
should prefer to interact with inactive conformations of the receptor, where their 
partial agonistic activity is more capable of inducing a partially active 
conformation. Conversely, inverse agonists interact with constitutively active 
receptors and receptors with basal activity suggesting that these inhibitors should 
preferentially interact with an inactive conformation of the receptor, in order to 
shift the conformation to an inactive state. The fact that these 6 active ICLGa 
compounds do not bind to the native conformation of the receptor suggests that 
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Figure 64: Final averaged structure of Native CXCR4 dynamically bound to 
ICLGa Compounds. Average structure of CXCR4 presented in ribbon. ICLGa 
compounds are in their dynamically determined binding position in red . 
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Figure 64: Final averaged structure of Native CXCR4 dynamically bound to 
ICLGa Compounds. 
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these active anti-CXCR4 compounds may act as inverse agonists, and may be 
unable to interact with the inactive conformation of the receptor. 
The ICLGa compounds which did form stable complexes with native 
CXCR4 were energetically stable throughout the production run as can be seen 
in Figures 65. Conformational stability of the bound CXCR4-compound 
complexes was investigated using RMSD analysis, seen in Figures 66. RMSD 
values remained stable for the majority of the production runs, with the final 
average structure representative of the trajectory after approximately 1.5 ns. The 
helices were stable through the production run and the majority of the variation 
was seen in the loops. The conformation assumed by ICLGa29 was the closest 
to that of uncomplexed native CXCR4. The RMSD of the ICLGa29 complex was 
3.1, compared to RMSD values of 3.2 for ICLGa28, 3.3 for ICLGa8, 3.4 for 
ICLGa37, 4.0 for ICLGa25 and 4.5 for ICLGa12. 
The dynamic binding site of ICLGa8, shown in Figure 67, consists of ICL 1 
superior to the compound , ICL2 to the right, and the C-terminal tail to the left and 
posterior to the compound . The ethoxybenzene component of ICLGa8 is 
stabilized by hydrophobic interactions with the aliphatic portions of the Lys149 
and Ser71 side chains. The central imidazole component is stabil ized by 
interactions with the Lys 68 side chain, as well as the backbones of Thr342 and 
Glu343. The anisole group is interposed between folds of the C-terminal tail, 
interacting with a hydrophobic network composed of the side chain of Va1340, the 
backbone of Ser338, and the aliphatic portion of the side chains of Glu345, Ser 
346 and Ser348. 
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Figure 65: Energy plot of ICLGa compounds bound to native CXCR4. 
Energy values across the trajectory fo r total energy (blue), kinetic energy (red) 
and potential energy (green) are presented. CXCR4 was found to be 
energetically stable and maintained equilibrium across the production run . A) 
ICLGa8, 8) ICLGa12, C) ICLGa25 D) ICLGa28 E) ICLGa29 F) ICLGa37 
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Figure 65: Energy plot of ICLGa compounds bound to native CXCR4. A) 
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Figure 66: RMSD values of CXCR4 bound to ICLGa Compounds across 5 ns 
of the production trajectory. Total RMSD calculated at the Co position 
presented in green. Helical domains are presented in blue, and loop regions are 
presented in red. The CXCR4 structure was noted to be stable, and the average 
structure was noted to represent the conformation present in the trajectory after 
0.5 ns of simulation time. A) ICLGa8, 8) ICLGa12, C) ICLGa25 D) ICLGa28 E) 
ICLGa29 F) ICLGa37 
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Figure 66: RMSD values of CXCR4 bound to ICLGa Compounds across 5 ns 
of the production trajectory. A) ICLGa8, B) ICLGa12, C) ICLGa25 D) 
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Figure 67: Dynamic binding site of ICLGa8 to native CXCR4. Critical residues 
for ICLGa8 binding to CXCR4 are highlighted. ICLGa is depicted in red ball-stick 
representation, while CXCR4 residues within 3 angstroms of the compound are 
presented in stick representation and superstructure of CXCR4 is presented as 
teal ribbon. ICLGa8 interacts with the ICL 1, ICL2, and C-terminal regions of the 
intracellular surface. 
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The dynamic binding site of ICLGa12, shown in Figure 68 consists of ICL 1 
superior to the compound, ICL2 to the right, and the C-terminal tail to the left and 
posterior to the compound. The anisole and quinolone components of ICLGa12 
are oriented in a planar conformation. The quinolone portion lies between folds of 
the C-terminal tail and ICL 1, in a conformation stabilized by interactions with the 
aliphatic portion of the Lys68 and thr342 side chains and the backbone of Ser344 
above and the backbones of Ser 348,351 and 352 below. The aromatic region of 
the anisole component is stabilized by interactions with the aliphatic portion of 
the Lys149 side chain and Pro147. 
The dynamic binding site of ICLGa25, shown in Figure 69 consists of ICL 1 
superior to the compound, ICL2 to the right, and the C-terminal tail to the left and 
posterior to the compound. The nitrobenzene and dimethylaniline components of 
ICLGa25 are in a stacked conformation. The nitrobenzene component is 
stabilized by hydrogen bonding to the side chain of Arg334 which is further 
stabilized by intramolecular hydrogen bonding between Arg334 and Glu345. The 
dimethylaniline is further stabilized by hydrophobic interaction with Phe349. The 
central quinoxaline component of ICLGa25 is projected between ICL 1 and ICL3 
and is stabilized by hydrogen bonding to Lys68, as well as a hydrophobic 
network composed of the backbone of Ser 71, the side chain of Leu150, and the 
aliphatic portion of the Lys149 side chain. 
The dynamic binding site of ICLGa28, shown in Figure 70 consists of ICL 1 
superior to the compound, ICL2 to the right, the C-terminus anterior to the 
compound , the ICL3 posterior to the compound. The phenol group of ICLGa28 is 
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Figure 68: Dynamic binding site of ICLGa12 to native CXCR4. Critical 
residues for ICLGa12 binding to CXCR4 are highlighted . ICLGa12 is depicted in 
red ball-stick representation , while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as magenta ribbon. ICLGa12 interacts with the ICL 1, ICL2, and C-
terminal regions of the intracellular surface. 
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Figure 68: Dynamic binding site of ICLGa12 to native CXCR4 
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Figure 69: Dynamic binding site of ICLGa25 to native CXCR4. Critical 
residues for ICLGa25 binding to CXCR4 are highlighted . ICLGa25 is depicted in 
red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as orange ribbon. ICLGa25 interacts with the ICL 1, ICL2, and C-
terminal regions of the intracellular surface. 
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Figure 69: Dynamic binding site of ICLGa25 to native CXCR4. 
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Figure 70: Dynamic binding site of ICLGa28 to native CXCR4. Critical 
residues for ICLGa28 binding to CXCR4 are highlighted. ICLGa28 is depicted in 
red ball-stick representation, while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as white ribbon. ICLGa28 interacts with the ICL 1, ICL2, ICL3 and C-
terminal regions of the intracellular surface. 
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Figure 70: Dynamic binding site of ICLGa28 to native CXCR4. 
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interposed between the C-terminus and ICL3 stabilized by interactions with 
Lys236 of ICL3, and Lys308 and His337 of the C-terminus. The isoquinolone 
structure extends towards ICL 1, and is stabi lized by a hydrophobic network 
composed of the aliphatic portions of the Lys68 and Ser71 side chains, as well 
as the backbone of Arg70 and the side chain of Leu150. The dimethyl benzene 
component is stabilized by a separate hydrophobic network composed of the 
aliphatic portion of the Lys149 side chain , Pro147 and the backbone of Arg148. 
The dynamic binding site of ICLGa29, shown in Figure 71 consists of ICL 1 
superior to the compound , ICL2 to the right, and the C-terminal tail to the left and 
posterior to the compound. The orientation of the compound in the binding site is 
unique among the ICLGa compounds in that the compound is oriented vertically 
in the binding site whereas the other compounds were oriented horizontally in the 
site. The compound is stabilized by hydrogen bonding between linker chain 
carboxyl groups and the side chain amines of Lys68 and Lys149. The 2,4 
dimethyl-3-nitro-pyrazole projects towards ICL 1, and is stabilized by a 
hydrophobic network composed of the aliphatic portion of the Lys68, Lys149 side 
chains as well as the backbone of Arg70, Ser71 and the side chain of Leu150. 
The dynamic binding site of ICLGa37, shown in Figure 72 consists of ICL 1 
superior to the compound, and ICL2 and the C-terminus posterior to the 
compound. The 3,4 dimethyl-benzene group is stabilized by hydrophobic 
interactions with the aliphatic portions of the side chains of CXCR4 residues Lys 
68, Ser71 , Leu150 and Ser348. The benzyl portion of the meta-trifluoromethyl 
benzene component of the compound is stabilized by hydrophobic interactions 
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Figure 71: Dynamic binding site of ICLGa29 to native CXCR4. Critical 
residues for ICLGa29 binding to CXCR4 are highlighted. ICLGa29 is depicted in 
red ball-stick representation , while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as yellow ribbon. ICLGa29 interacts with the ICL 1, ICL2 and C-
terminal regions of the intracellular surface. 
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Figure 71: Dynamic binding site of ICLGa29 to native CXCR4. 
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Figure 72: Dynamic binding site of ICLGa37 to native CXCR4. Critical 
residues for ICLGa37 binding to CXCR4 are highlighted. ICLGa37 is depicted in 
red ball-stick representation , while CXCR4 residues within 3 angstroms of the 
compound are presented in stick representation and superstructure of CXCR4 is 
presented as blue ribbon . ICLGa37 interacts with the ICL 1, ICL2 and C-terminal 
regions of the intracellular surface. 
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Figure 72: Dynamic binding site of ICLGa37 to native CXCR4. 
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with the aliphatic portion of the side chain of Lys149 and Leu150. In the center of 
the compound, hydrogen bonds form between Lys149 and the thiazole of the 
compound. 
These structures shed light on the potential mechanism of the activity of 
the bound ICLGa compounds. All of the compounds interacted with the aliphatic 
components of the side chains and backbones of ICL 1 and ICL2, suggesting that 
the compounds could act as bridging elements between these two regions, 
stabilizing their position and preventing signal transduction or producing a more 
closed intracellular surface potentially incapable of binding Gai. Interaction by the 
compounds with the C-terminal region could potentially stabilize TM?, or interfere 
with the interface between the C-terminus and Gai. This could be especially true 
in the case of ICLGa28, where interposition of the compound between the C-
terminus and ICL3 could restrict the movement of both regions and directly 
impede the cleft which would be occupied by bound Gai. 
ICLGa compound binding alters the conformation of the extracellular and 
intracellular surfaces of CXCR4. 
Given the interactions of the ICLGa compounds with the intracellular 
surface of CXCR4, we sought to investigate what effect inhibitor binding could 
have on overall receptor conformation. To do this, we sought to compare the 
structure of the ICLGa complexed conformations of CXCR4 to the inactive native 
conformation and the constitutively active N119S conformations of the protein. 
The extracellular surface of CXCR4 is highly conserved between ICLGa8 and 
native CXCR4. Although the structure of the loops is conserved between the 
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three conformations, there are several differences in positioning. In the N-
terminal region, the anti-parallel ~-sheet is more compact and the distance 
between ECL 1 and the N-terminal region is decreased, mimicking the N119S 
conformation, while the entire region is displaced away from the extracellular 
surface of the TM regions. ECL2 retains the native conformation and positioning, 
while ECL3 is outwardly displaced from the center of the receptor. At the 
intracellular surface of CXCR4, the ICLGa conformation retains the native 
conformation and position of ICL 1, ICL2 and the C-terminus. A loss of one turn of 
helical structure at the cytoplasmic surface of TM5 produces a displacement of 
ICL3 towards the C-terminal tail in the ICLGaB complexed structure. 
Several significant structural changes characterize the extracellular 
surface the ICLGa12 complex conformation. In the N-terminal region, the three-
strand ~ sheet of the native conformation is converted into a two-strand sheet by 
extension at ThrB rather than flexion. The proximal portion of the N-terminus also 
takes on an additional turn of a-helical structure. ECL 1 and ECL2 adopt the 
native conformation of the loops, while the apex of the ECL3 loop is displaced 
towards the base of the N-terminal strand as in the constitutively active N119S 
conformation. At the intracellular surface of the receptor, ICL 1 adopts the native 
conformation, while the plane of the ICL2 loop is inclined towards the center of 
the receptor, rather than away from the center as in the native conformation. 
ICL3 adopts the unkinked structure of the native conformation, and is displaced 
away from the center of the receptor as in the N119S conformation of CXCR4. 
Helix B structure and positioning is conserved between ICLGa12 and native, 
292 
while a section of the C-terminal tail between Ser319 and Ser330 takes on a 
more helical conformation and is inclined towards the center of the receptor when 
compared to the native conformation. 
The extracellular surface of CXCR4 is highly conserved between ICLGa25 
and native CXCR4. The structures of the N-terminal region and the three ECL 
structures are nearly identical to that of the native conformation. However at the 
ICL surface, while ICL 1 structure is conserved between the ICLGa25 and native 
conformations of the receptors, significant differences are apparent for the other 
intracellular structures. The apex of ICL2 is located at the midpoint of the loop as 
in the native conformation, while the angle of inclination of ICL2 is closer towards 
the center of the receptor as in the N 119S conformation. The distance between 
the apex of ICL3 and Helix 8 is also significantly decreased when compared to 
the native structure. Finally, the tail of the C-terminal region is in a more vertical 
orientation than in the native or N119S conformations. 
Several significant structural changes characterize the extracellular 
surface the ICLGa28 complex conformation. The N-terminal j3-sheet is more 
compactly packed in the ICLGa28 complexed conformation as in the N119S 
structure. The proximal portion of the N-terminal tail is displaced towards ECL3. 
ECI1, ECL2 and ECL3 strongly conserve the native conformation. At the 
intracellular surface of the receptor, ICL 1 maintains the native conformation, 
while the apexes of ICL2 and ICL3 are displaced towards the center of the 
receptor, and Helix 8 is outwardly displaced from the cytoplasmic terminal of 
TM1. 
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The extracellular surface of CXCR4 is highly conserved between ICLGa29 
and native CXCR4. The structures and positioning of the N-terminal region, 
ECL2 and ECL3 maintain the native conformation of the receptor. There is also a 
slight displacement of ECL 1 towards the N-terminal region. At the intracellular 
surface of the receptor, ICL 1 conformation and positioning maintains the native 
conformation, while the angle of inclination for ICL2 is decreased, displacing the 
apex of this loop towards the center of the receptor. ICL3 adopts the linear 
conformation of the native receptor, while the apex of ICL3 is displaced towards 
the apex of ICL2. Finally, although the structure of the C-terminal tail is largely 
preserved between the ICLGa29 complexed conformation and the native 
structure, the distal portion of the tail is brought into close contact with the 
apexes of ICL2 and ICL3. 
The extracellular surface of CXCR4 is highly conserved between ICLGa37 
and native CXCR4. The distal N-terminal I)-sheet adopts the compact 
conformation of the N119S structure, and the proximal region adopts the 
displacement towards ICL 1 as in the N119S conformation. ECL2 is maintained in 
the native conformation, while ECL3 is outwardly displaced from the center of the 
receptor. At the intracellular surface of the receptor, ICL 1 and C-terminal region 
conformation and positioning largely maintains the native structure. The angle of 
inclination for ICL2 is decreased, displacing the apex of this loop towards the 
center of the receptor and the apex of ICL3 is displaced away from the center of 
the receptor. 
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The overall implication from these ICLGa complex conformations is that 
the receptor adopts either the inactive native conformation (ICLGa25, ICLGa29) 
or an intermediary structure between the inactive and active conformations 
(ICLGa8, ICLGa12, ICL28, ICLGa37). 
ICLGa compound binding alters the conformation of the transmembrane 
helixes of CXCR4. 
Given the interactions of the ICLGa compounds with the intracellular 
surface of CXCR4 and the altered conformations of the intracellular and 
extracellular surfaces, we investigated the effect of inhibitor binding on the 
structure of the helixes. To do this, we compared the reduced representations of 
the transmembrane helices for each of the ICLGa complexed conformations of 
CXCR4 to the inactive native conformation and the constitutively active N119S 
conformation of the protein. Comparison of multiple receptor conformations to the 
native CXCR4 structure and the constitutively active N119S variant was 
facilitated by the helixanal program developed by Dr. Trent. 
In investigating the reduced representations of the transmembrane region 
of the complexes produced by ICLGa8, ICLGa12, ICLGa25, ICLGa29, and 
ICLGa37, we found that they were similar in conformation to native CXCR4 as 
depicted in Figure 73. The N-terminal portion of the TM region is highly 
conserved compared to the native structure, and as a consequence, there are 
multiple deviations by the complexed structures from the structure of the 
constitutively active N119S mutant. The bulge of TM5 produced by loss of helical 
character between residues Val206 and lIe215 present in the native conformation 
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Figure 73: Transmembrane regions of ICLGa compound-CXCR4 complexes 
adopt a similar conformation to native CXCR4. Reduced representations of 
receptor transmembrane helices are presented: native CXCR4 in green, N119S 
in red, and the ICLGa8 conformation in teal, ICLGa12 conformation in magenta, 
ICLGa25 conformation in orange, ICLGa28 conformation in yellow, ICLGa29 
conformation in white, ICLGa37 conformation in purple. The ICLGa8, ICLGa12, 
ICLGa25, ICLGa29, and ICLGa37 conformations adopt the transmembrane 
structure of the native receptor. The ICLGa28 conformation adopts an 
intermediate conformation between the active and inactive conformations of the 
receptor. 
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Figure 73: Transmembrane regions of ICLGa compound-CXCR4 complexes 
adopt a similar conformation to native CXCR4. 
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was present in the complexed structures. Conversely, the kink of TM1 at Va154, 
the more linear conformation of TM2, the outward flexion of TM3, the greater 
angle of inclination of TM4, the axial rotation of TM6, and the outward shift of 
TM7 present in the N119S conformation were not present in the complexed 
structures. This suggests that ICLGa8, ICLGa12, ICLGa25, ICLGa29 and 
ICLGa37 stabi lize the TM structures in the inactive native conformation of the 
receptor potentially acting as inverse agonists. 
The transmembrane region of the complex produced by ICLGa28 seems 
to be an intermediate form of the receptor between the native and N119S 
conformations as depicted in Figure 73. TM1 is more linear in the complexed 
conformation and lacks a kink at Ser46 present in the native conformation. TM2 
and TM3 structure and positioning is conserved between the complexed 
conformation and the native form. The complexed TM4 and TM6 structures are 
more closely aligned with the structure of the N119S active conformation. The 
TM5 bulge present in the native structure is present in the complexed structure, 
but the helix seems to be rotated towards TM3. Finally, the cytoplasmic portion of 
TM7 is rotated outward from the center of the receptor. In total, ICLGa28 drives 
CXCR4 into an intermediate conformation with elements of the inactive native 
structure and the active N119S configuration, suggesting that this compound 
may act as a weak partial agonist. 
Further examination of the transmembrane helixes involved assessment 
of the distances between the intracellular and extracellular termini of the 
interhelical segments. At the extracellular surface, as seen in Table 16, variation 
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Table 16: ICLGa induced conformations adopt native interhelical distances 
at the extracellular surface of CXCR4. Interhelical distances measured at 
extracellular termini of transmembrane domains of native CXCR4, constitutively 
active N119s, and compound docked structures. Distances measured at the 
extracellular termini of reduced representations of the averaged structures. 
Illustrated interhelical distances demonstrate 1.5 angstrom or greater deviation 
from N119S structure, demonstrating that at the extracellular surface, the bound 
ICLGa structures maintain or induce the native conformation of CXCR4. 
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Table 16: IClGa induced conformations adopt native interhelical distances 
at the extracellular surface of CXCR4. 
TMA TMB Native N119S ICl8 ICl12 ICl25 ICl28 ICl29 ICl37 
5 6 11.2 13.1 11.4 11.9 11.3 11.3 11.7 11.6 
4 7 14.3 17.5 14.4 14.9 14.3 14.2 14.6 13.8 
1 7 15.8 14.6 15.9 15.9 15.5 16.0 16.3 16.6 
3 7 18.8 21.3 18.6 18.7 18.8 18.3 19.3 18.5 
5 7 21.4 24.7 20.9 21.3 21.4 21.0 21.3 21.3 
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from N119S interhelical distance between TM7 and helices one, three, four and 
five was a consistent finding in all of the active CXCR4 inhibitors investigated. 
There was a similarly uniform decrease in the TM5-6 interhelical distance 
when compared to N119S. All of these interhelical distances were compatible 
with the expected distances for the native receptor. IClGa37 did produce a 
unique 1.8 angstrom increase in the interhelical distance between TM1-2, which 
is an unusual finding in that this is the shortest interhelical distance on the 
receptor and is highly conserved across conformations. In this case it could 
represent a shift between the native conformation of the N-terminal and ECl1 
conformations and the N119S conformation. There was an additional decrease in 
the interhelical distance in TM2-7 in the conformation of IClGa12. This decrease 
could be the source of the altered conformation of ECl3. 
At the intracellular surface, as seen in Table 17, several key similarities 
are noted between the complexed conformations and the native structure of 
CXCR4. The TM3-6 interhelical distance is uniformly decreased in all of the 
active receptor structures. Interhelical distance between transmembrane regions 
TM1-5, TM2-3, TM2-5, TM2-6, TM3-4, TM3-5, and TM4-6 is decreased 
compared to the conformation of N119S, and reflects the expected difference 
between the native conformation of the receptor and the N119S conformation. 
This relationship is also reflected in the distance between TM1-7 in the 
conformations produced by compounds IClGa8, IClGa12, IClGa25 and 
IClGa37. These compounds all also exhibit an increased interhelical distance 
between TM4-7 when compared to the native structure. 
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Table 17: ICLGa induced conformations adopt native interhelical distances 
at the intracellular surface of CXCR4. Interhelical distances measured at 
cytoplasmic termini of transmembrane domains of native CXCR4, constitutively 
active N119s, and compound docked structures. Distances measured at the 
intracellular termini of reduced representations of the averaged structures. 
Illustrated interhelical distances demonstrate 1.5 A or greater deviation from 
either the Native or N119S structure. 
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Table 17: IClGa induced conformations adopt native interhelical distances 
at the intrace"ular surface of CXCR4. 
TMA TMB Native N119S ICl8 ICl12 ICl25 ICl28 ICl29 ICl37 
2 6 10.7 12.9 11.1 10.9 10.8 10.3 10.7 10.7 
3 5 11.5 16.5 11.6 11.9 12.0 11.6 11.8 11.2 
3 6 12.0 13.4 11.3 11.1 11.2 11.1 11.4 11.8 
1 7 12.2 13.6 12.1 12.3 12.6 13.7 13.4 12.1 
2 3 15.6 17.9 15.4 15.3 15.2 15.9 15.8 15.6 
3 4 16.0 12.6 16.2 15.9 16.0 15.1 15.5 15.6 
4 6 19.5 17.6 20.1 19.2 19.3 17.9 18.7 19.2 
4 7 22.3 21.0 22.5 23.1 23.1 24.2 25.2 21.9 
2 5 22.5 25.3 23.3 22.6 22.7 22.8 22.9 22.7 
1 5 32.2 33.9 31.5 32.1 31.5 32.4 32.4 31.8 
303 
In addition to these alterations, compounds ICLGa28 and ICLGa29 also 
produce additional alterations in the interhelical distances between TM7 and the 
other helices as seen in Table 18. The interhelical distance between TM7 and 
TM2, TM3, TM5 and TM6 was significantly increased compared to both native 
and N 119S conformations. The TM4-7 was also increased to a greater extent 
than seen in the other compounds, while the TM1-7 interhelical distance in the 
conformation produced by these two compounds closely reflects that of the 
N119S conformation. 
This data reflects that the majority of compound complex conformations 
reflect the native conformation. In add ition , each of the compounds produced a 
decrease in the interhelical distance between TM3-6 suggesting increased 
stability of the inactive conformation. The complexed structures produced by 
ICLGa28 and ICLGa29, produced significant variation in the position of TM7 
reflecting significant structural variation from the native structure and N119S, 
suggesting an intermediate conformation of the receptor. 
Interhelical hydrogen bonding characterizes differences between ICLGa 
compound binding. 
To continue to investigate the differences in interhelical movements 
produced by compound binding , receptor hydrogen bond ing was analyzed. As 
the N119 residue was located on TM3, and we previously demonstrated 
significant variation in the interhelical distances of TM7, our efforts were focused 
on the hydrogen bonds formed by TM3 and TM7. Hydrogen bonding in each of 
the compound-CXCR4 complex molecular dynamics trajectories at equilibrium 
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Table 18: ICLGa28 and ICLGa29 alter the position of TM7 at the intracellular 
surface of CXCR4. Interhelical distances measured at cytoplasmic termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and 
compound docked structures. Distances measured at the intracellular termini of 
reduced representations of the averaged structures. Illustrated interhelical 
distances demonstrate 1.5 angstrom or greater increase from the Native and 
N119S structures, indicating significant alterations of the structure of TM7 by 
compounds ICLGa28 and ICLGa29. 
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Table 18: ICLGa induced conformations adopt native interhelical distances 
at the intracellular surface of CXCR4. 
TMA TMB Native N1195 ICL28 ICL29 
2 7 11.7 12.3 13.8 14.5 
6 7 12.3 11.8 15.8 16.3 
3 7 21.5 22.2 24.7 25.3 
5 7 24.8 23.7 27.8 28.6 
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was determined using a PTRAJ program to process and analyze sets of 3-D 
coordinates and trajectory files. Occupancy is defined as the prevalence of a 
hydrogen bond across the 5 ns trajectory, as is used to quantify the influence of a 
hydrogen bond on receptor structure. 
The hydrogen bonding by TM7 residues in each of the compound-CXCR4 
complexes was analyzed. Bonds between TM7 and TMs 2, 3, 6, and ECL2 were 
identified for each of the conformations residues as illustrated in Table 19. 
Hydrogen bonding between Asn298-Tyr76, Asp187-Ser285, and Asp187-Thr287 
was consistent between all of the compound-CXCR4 complexes. Compounds 
ICLGa12, ICLGa25, ICLGa28 and ICLGa29 each formed stable hydrogen bonds 
between Asp84-Asn298 and Asn119-His294, but the hydrogen bond occupancy 
of Asp84-Asn298 for ICLGa28 was significantly reduced as was the hydrogen 
bond occupancy of Asn119-His294 for ICLGa25. In addition, the hydrogen bond 
occupancy between Thr240 and Tyr302 was 70.2% for the ICLGa25 complex 
while this value was significantly reduced for ICLGa28 and ICLGa29, and there 
was no bond at all in the ICLGa12 complex. Hydrogen bonding between Asn288 
and Lys282 also significantly varied between compound complexes, with 
ICLGa 12 and ICLGa28 producing almost full occupancy of this hydrogen bond 
across the trajectory, whi le ICLGa25 and ICLGa29 produced significant 
reductions in the occupancy of this hydrogen bond. ICLGa12, ICLGa25, ICLGa28 
and ICLGa29 each exhibit hydrogen bonding between His294 and Trp252, 
although this hydrogen bond is much more prevalent in the ICLGa28 
conformation. 
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Table 19: Hydrogen bonds formed by the side chains of TM7 in anti-CXCR4 
compound bond molecular dynamics simulations. Hydrogen bonds mediated 
by TM7 residues were found to be conserved in each of the derived 
conformations. % indicates percent occupancy of the hydrogen bond. 
308 
Table 19: Hydrogen bonds formed by the side chains of TM7 in anti-CXCR4 
compound bond molecular dynamics simulations. 
ICLGa12 ICLGa25 
Donor Acceptor % Donor Acceptor % 
84001 298 N02 89.6 84001 298 N02 89.76 
119001 294 NE2 73.12 119001 294 NE2 48.44 
187002 2850G 99.6 187002 2850G 99.64 
187002 2870G1 82.52 187002 2870G1 92.24 
2880E2 282 NZ 53.56 2400G1 3020H 70.24 
2880E2 282 NZ 35.2 2880E2 282 NZ 52.12 
2880E2 282 NZ 8.44 2880E1 282 NZ 8.16 
294 N01 252 NE1 28.4 294 N01 252 NE1 22.24 
298001 760H 86.84 298001 760H 82.52 
ICLGa28 ICLGa29 
Donor Acceptor % Donor Acceptor % 
84001 298 N02 60.04 84001 298 N02 89.6 
119001 294 NE2 80.6 119001 294 NE2 68.28 
187002 2850G 99.88 187002 2850G 99.8 
187002 2870G1 82.2 187002 2870G1 81.2 
2400G1 3020H 17.4 2400G1 3020H 24.76 
2880E2 282 NZ 41.08 2880E1 282 NZ 32 
2880E2 282 NZ 32.24 2880E2 282 NZ 17.72 
2880E2 282 NZ 17.84 294 N01 252 NE1 29.64 
294 N01 252 NE1 57.56 298001 760H 81.76 
298001 760H 89.16 
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The hydrogen bonding by TM1 residues in each of the compound-CXCR4 
complexes was also analyzed in Table 20. Only one hydrogen bond involving 
TM1 was present in all four complexed structures, the bond between TM1 
residue Tyr65 and the C-terminus residue Ser319. Although present over 30-
40% of the trajectory for compounds ICLGa28 and ICLGa29, this bond was 
nearly non-existent for residues ICLGa12 and ICLGa25. 
Significant differences in TM3 mediated interhelical hydrogen bonding in 
each of the compound-CXCR4 complexes is illustrated in Table 21 . Hydrogen 
bonding between Asp171-His113 and Asp187-Tyr116 was consistent for all of 
the residue complexes. 
However hydrogen bond occupancy was reduced for the bonds between 
Tyr116-Tyr255 and Asn119-His294 for compounds ICLGa25 and ICLGa29. 
Occupancy of the Thr117 -Arg188 bond was increased for the ICLGa12 complex 
and decreased for the ICLGa29 complex. Occupancy of the Tyr121-Ala188 bond 
was increas~d by compounds ICLGa28 and ICLGa29. Finally, the occupancy 
between Asp84-Asn119 was decreased by ICLGa12 and increased by ICLGa28. 
Significant differences in TM4 mediated interhelical hydrogen bonding in 
each of the compound-CXCR4 complexes is illustrated in Table 22. All of the 
complexes consistently formed hydrogen bonds between Glu153-Tyr157. 
However, ICLGa28 produced a significantly greater occupancy of the hydrogen 
bond between Tyr157-Lys75, a bond which was barely present in the other 
conformations. Also, hydrogen bonds between Asp171-His113 and Asp171-
Lys110 were occupied in the conformations produced by ICLGa12, 
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Table 20: Hydrogen bonds formed by the side chains of TM1 in anti-CXCR4 
compound bond molecular dynamics simulations. Hydrogen bonds mediated 
by TM1 residues were found to be conserved in each of the derived 
conformations. % indicates percent occupancy of the hydrogen bond. 
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Table 20: Hydrogen bonds formed by the side chains of TM1 in anti-CXCR4 
compound bond molecular dynamics simulations. 
Donor Acceptor % 
ICL 12 3190G 650H 0.04 
ICL25 3190G 650H 0.08 
ICL28 3190G 650H 41.72 
ICL29 3190G 650H 30.44 
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Table 21: Hydrogen bonds formed by the side chains of TM3 in anti-CXCR4 
compound bond molecular dynamics simulations. Hydrogen bonds mediated 
by TM3 residues were found to be conserved in each of the derived 
conformations. % indicates percent occupancy of the hydrogen bond. 
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Table 21: Hydrogen bonds formed by the side chains of TM3 in anti-CXCR4 
compound bond molecular dynamics simulations. 
ICLGa12 ICLGa25 
Donor Acceptor % Donor Acceptor % 
84002 119 N02 49.72 84002 119 N02 34.24 
84001 119 N02 14.64 84001 119 N02 26.24 
84002 119 N02 3.76 84002 119 N02 13.88 
1160H 2550H 77.52 1160H 2550H 51.4 
1170G1 188 NE 48.28 1170G1 188 NH2 20.4 
1170G1 188 NH2 3.16 1170G1 188 NE 3.52 
119001 294 NE2 73.12 119001 294 NE2 48.44 
1210H 188 NH2 2.36 1210H 188 NH2 2.52 
1210H 188 NH1 1.64 1210H 188 NH2 1.04 
171 002 113 NE2 15.52 171 002 113 NE2 16.8 
187001 1160H 99.04 187001 1160H 99.32 
ICLGa28 ICLGa29 
Donor Acceptor % Donor Acceptor % 
84002 119 N02 92.76 84002 119 N02 57.6 
84001 119 N02 1 84001 119 N02 11.24 
84002 119 N02 0.44 84002 119 N02 5.2 
1160H 2550H 69.72 1160H 2550H 59.72 
1170G1 188 NE 20.16 1170G1 188 NE 0.28 
119001 294 NE2 80.6 119001 294 NE2 68.28 
1210H 188 NH2 21.32 1210H 188 NH1 42.16 
1210H 188 NH2 2.04 1210H 188 NH2 2.36 
171 002 113 NE2 21.16 171 002 113 NE2 17.24 
187001 1160H 98.76 187001 1160H 95.32 
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Table 22: Hydrogen bonds formed by the side chains of TM4 in anti-CXCR4 
compound bond molecular dynamics simulations. Hydrogen bonds mediated 
by TM4 residues were found to be conserved in each of the derived 
conformations. % indicates percent occupancy of the hydrogen bond. 
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Table 22: Hydrogen bonds formed by the side chains of TM4 in anti-CXCR4 
compound bond molecular dynamics simulations. 
ICLGa12 ICLGa25 
Donor Acceptor % Donor Acceptor % 
1530E1 1570H 46.72 1530E1 1570H 31.24 
1530E2 1570H 52.8 1530E2 1570H 68.16 
1570H 75 NZ 0.04 1570H 75 NZ 0.16 
171 002 113 NE2 15.52 1570H 75 NZ 0.04 
171 002 110 NZ 12.12 1570H 75 NZ 0.04 
171 002 110 NZ 11.28 171 002 113 NE2 16.8 
171 001 110 NZ 11.16 171 002 110 NZ 27.92 
171 001 110 NZ 8.48 171 002 110 NZ 21 
171 001 110 NZ 7.24 171 002 110 NZ 19.12 
171 002 110 NZ 10.84 171 001 110 NZ 4 
171 001 110 NZ 2.88 
171 001 110 NZ 2.56 
ICLGa28 ICLGa29 
Donor Acceptor % Donor Acceptor % 
1530E1 1570H 96.12 1530E1 1570H 41.56 
1530E2 1570H 0.56 1530E2 1570H 56.72 
1570H 75 NZ 9.08 1570H 75 NZ 0.16 
1570H 75 NZ 9 1570H 75 NZ 0.04 
1570H 75 NZ 8.6 1570H 75 NZ 0.04 
171 002 113 NE2 21.16 
171 002 110 NZ 26.08 
171 002 110 NZ 19.92 
171 002 110 NZ 16.76 
171 001 110 NZ 2.12 
171 001 110 NZ 1.72 
171 001 110 NZ 1.64 
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ICLGa25 and ICLGa28 but completely absent in the conformation formed by 
ICLGa29. 
This hydrogen bonding data suggests that movements of TM7 induced by 
ICLGa28 and ICLGa29 produce an alteration of the hydrogen bonding network, 
which is distinct from ICLGa12 and ICLGa25. The ICLGa28 and ICLGa29 
hydrogen bonding networks may produce a CXCR4 conformation with less 
internal stabi lity due to decreased hydrogen bonding by TM3, TM4 and TM7. 
Discussion 
Our goal was to target the CXCR4:G-protein interface to discover novel 
small molecules which could selectively inhibit receptor function and be used as 
scaffolds for development of clinically active anti-metastatic compounds. Initial 
screening of the thirty-seven ICLGa compounds at 50 IJM identified twenty-four 
compounds which inhibited chemotaxis (Figure 55). This hit rate of 64.9 % at 50 
flM for initial screening of our thirty-seven ICLGA compounds represents a 
significant increase over contemporary studies [314-316]. Ten of the twenty-four 
active compounds had chemotaxis IC50 values of 10 IJM or less (Figure 56), for 
an exceptional hit rate of 27%. Of the ten ICLGa compounds inhibiting CXCR4-
mediated chemotaxis at 10 IJM or less, only five exhibited any anti-BL T1 activity, 
and none of these possessed an anti-BL T1 IC50 of less than 25 IJM, suggesting 
that the most active compounds are highly specific. 
Subsequent investigations of the impact of the ICLGa compounds on 
signal transduction by CXCR4 revealed that twelve ICLGa compounds produced 
significant reductions in calcium release (Figure 58), and six of the twelve active 
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compounds had calcium mobilization IC50 values of 10 IJM or less (Figure 59). 
Selectivity screening of the ICLGa compounds with anti-calcium release activity 
revealed that six of the nine ICLGa compounds with anti-BL T1 activity had IC50 
values that were lower for BL T1 than for CXCR4, suggesting that the anti-
calcium release activity produced by these compounds was not specific for 
CXCR4. However, three of the most active compounds had significantly greater 
anti-CXCR4 activity than anti-BL T1 activity, suggesting that anti-calcium 
mobilization activity in these compounds is selective for CXCR4. 
The effects of the twenty-six active anti-CXCR4 compounds were 
produced in the absence of significant cytotoxicity, as only seven of the 
compounds produced elevated cytotoxicity at 50 IJM, and only four of these 
compounds produced any cytotoxicity at less than 10 IJM. 
Sorting of the thirteen ICLGa compounds with anti-CXCR4 activity at 10 
IJM or less in chemotaxis and calcium mobil ization allows the compounds to be 
divided into four categories (Table 23). Seven compounds exhibit CXCR4-
specific and exclusive anti-chemotaxis activity. Three compounds exhibit 
CXCR4-specific anti-chemotaxis and anti-calcium mobilization activity. Two 
compounds exhibit non-specific exclusive anti-calcium mobilization activity. The 
remaining compound exhibits CXCR4-specific and exclusive anti-calcium 
mobilization activity. The ICLGa compounds could be interfering with the 
interaction between CXCR4 and Gai, completely preventing signal transmission 
through the receptor inhibiting both chemotaxis and calcium mobil ization as is the 
case with ICLGa25, ICLGa28 and ICLGa36. 
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Table 23: Classification of ICLGa Compounds with anti-CXCR4 activity of 
10 IJM or less. ICLGa compounds with anti-CXCR4 activity can be classified by 
their primary mode of inhibition; either chemotaxis or calcium mobilization. 
Additional subclassification based on molecular dynamics studies suggest that 
compounds which do not successfully interact with the native structure can be 
classified as potential inverse agonists, while dynamically bound compounds can 
be classified as potential antagonists or weak partial agonists. 
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Table 23: Classification of compounds with anti-CXCR4 activity at 10 JJM or 
less. 
Chemotaxis Calcium Activity Target Mode IC50 (JJM) IC50 (JJM) 
ICLGa4 10 35 Chemotaxis Goi 
ICLGa5 5 45 Chemotaxis Goi Inverse Agonist 
ICLGa8 3 Chemotaxis CXCR4 Weak Partial -- Agonists 
ICLGa9 45 1 Calcium CXCR4 Inverse Agonist 
ICLGa12 12.5 5 Calcium CXCR4 Weak Partial Agonists 
ICLGa13 12.5 5 Calcium CXCR4 Inverse Agonist 
ICLGa17 10 Chemotaxis CXCR4 Inverse -- Agonist 
ICLGa22 10 Chemotaxis Goi Inverse -- Agonist 
ICLGa25 10 1 Dual CXCR4 Antagonists 
ICLGa28 1 10 Dual CXCR4 Weak Partial Agonists 
ICLGa29 10 -- Chemotaxis CXCR4 Antagonists 
ICLGa36 1 6 Dual CXCR4 Inverse Agonist 
ICLGa37 5 Chemotaxis Goi Weak Partial -- Agonists 
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Assessment of inhibition of tumor proliferation by three of the most active 
ICLGa compounds by MTT screening revealed that the three compounds 
produce three different avenues of proliferation inhibition. ICLGa9 is generally 
inhibitory, affecting both normal and cancer cells at levels lower than the 
cytotoxicity levels seen in Figure 62 . ICL25 inhibited the growth of metastatic 
cancer cell lines A549 and MDA-MB-231, but not normal cells or non-metastatic 
MCF7 cells. Finally, ICL36 inhibited the growth of non-metastatic MCF7 cells, 
metastatic cancer cell lines to a lesser extent, and did not inhibit proliferation of 
H827 cells. These results are intriguing as a CXCR4 inhibitor need not be 
cytotoxic to function, for instance ICL36 inhibits chemotaxis but does not affect 
metastatic cell proliferation. 
Of the twelve docked compounds, stable CXCR4: compound complexes 
were generated for compounds ICLGa8, ICLGa12, ICLGa25, ICLGa28, ICLGa29 
and ICLGa37. ICLGa5, ICLGa9, ICLGa13, ICLGa17, ICLGa22, and ICLGa36 did 
not form stable complexes with the native conformation of CXCR4. As these 
compounds were initially designed to target the constitutively active N 1198 
conformation of CXCR4, it may be that ICLGa5, ICLGa9, ICLGa13, ICLGa17, 
ICLGa22, and ICLGa36 are only capable of interacting with the receptor in active 
conformation , suggesting that these compounds could be acting as inverse 
agonists. 
The bound ICLGa compounds were able to demonstrate several 
significant differences in CXCR4 structure. All of the compounds interacted with 
the aliphatic components of the side chains and backbones of ICL 1 and ICL2, 
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suggesting that the compounds could act as bridging elements between these 
two regions, stabilizing their position and preventing signal transduction or 
producing a more closed intracellular surface potentially incapable of binding Gai. 
Interaction by the compounds with the C-terminal region could potentially 
stabilize TM?, or interfere with the interface between the C-terminus and Gai. 
This could be especially true in the case of ICLGa28, where interposition of the 
compound between the C-terminus and ICL3 could restrict the movement of both 
regions and directly impede the cleft which would be occupied by bound Gai. 
Comparisons of the intracellular and extracellular surfaces of CXCR4 
produced by the ICLGa compounds revealed that the receptor adopts either the 
native conformation (ICLGa25, ICLGa29) or an intermediary structure between 
the inactive native conformation and the constitutively active conformation 
(ICLGa8, ICLGa12, ICL28, ICLGa3?), suggesting that the receptor is being 
stabilized in an inactive state by the ICLGa compounds, either by an inverse 
agonist or by a weak partial agonist. This stabilization is further suggested by the 
uniformly decreased interhelical distance TM3-6 in the compound conformations. 
In prior lipid bilayer molecular dynamiCS simulations, a decrease in TM3-6 
distance has been associated with T140 acting as an inverse agonist, while 
AMD3100 acting as a weak partial agonist did not produce this effect [200]. This 
suggests that these compounds are acting as inverse agonists, and producing 
similar alterations to the inverse agonist T140. 
Thus, we have developed a series of compounds with anti-CXCR4 activity 
by targeting the intracellular CXCR4:Gai interface. This study represents the first 
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successful attempt to generate potential pharmaceuticals by targeting this 
interface that has produced phenotypical changes in the GPCR, rather than just 
conformational changes of the receptor. Molecular dynamics demonstrated that 
several of these compounds produced changes in CXCR4 consistent with 
inverse agonist activity. As CXCR4 represents one of the central mechanisms in 
cancer metastasis, these novel compounds could represent lead templates for 
the possible treatment of metastatic disease. 
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CHAPTER IV 
VALIDATION OF INHIBITOR COMPOUNDS IDENTIFIED BY 
VIRTUAL SCREENING 
The process of structure based drug design 
Although high-throughput screening methodologies have provided the 
traditional pipeline for lead compounds for pharmaceutical development [322, 
323], SBDD has produced some notable successes. Some of the most notable 
successes have involved the development of the inhibitors targeting HIV 
protease [324, 325] and the neuraminidase inhibitors for treating influenza [326]. 
SBDD is an iterative process, illustrated in Figure 74. The process begins 
with identification of a structural basis for a pathological phenomenon. 
Compounds are screened targeting this process, through high-throughput or 
virtual screening to identify lead compounds which modulate a phenotype. Active 
compounds are then tested for toxicity and specificity. Compound and receptor 
interactions are then modeled. The basic structure of the compound is then 
investigated through the development of derivatives based on the initial model of 
compound:receptor interaction. Quantitative structure activity relationship 
analysis (QSAR) can then be developed to characterize compound activity based 
on modifications to select structural regions. In addition, mutational analysis can 
be used to determine particular regions of the target essential to compound 
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Figure 74: Progression in the SBDD protocol for developing inhibitors of 
CXCR4. Surflex-Dock was used to virtually re-dock ECLVS and ICLGa compounds 
into their respective surfaces of CXCR4 to identify potential interaction residues between 
the receptors and compounds. Molecular dynamics based on in silico mutants were 
used to determine if structural modifications of the target sites would induce an altered 
conformation of CXCR4. Site directed mutagenesis would also be used to develop 
mutants to identify the in vitro effects of modification of the active site residues. Finally, 
the most active anti-CXCR4 compounds wi ll be tested in in vivo assays to determine if 
they can inhibit metastasis. 
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Figure 74: Progression in the SBOO protocol for developing inhibitors of 
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function or to further characterize the structure of the target. Additional 
derivatives can be generated based on the regions described in QSAR analysis 
to test a new hypothesis of interaction in an effort to uncover the mechanism of 
action for the lead compounds. Well-characterized and strongly active 
compounds can then be submitted for animal testing in an effort to translate 
findings from the laboratory to the clinical setting. 
In the case of our work, the identification of metastatic cells expressing 
elevated concentrations of cell surface CXCR4, combined with migration by 
these cells in relation to a CXCL 12 gradient by Muller [9], highlighted CXCR4 as 
a potential target for inhibiting metastasis. We utilized virtual screening targeted 
at separate regions or targets of CXCR4 to identify two series of active inhibitors 
of the receptor, using CXCR4-mediated chemotaxis as a model for metastasis. 
Our compounds are highly specific in their anti-CXCR4 activity, and lack non-
specific cytotoxicity, as discussed in Chapters II and III. Thus, continuing 
development of our identified compounds will involve reflecting back on our 
mechanistic model, as well as looking forward to testing of the compounds in vivo 
in animal models of pathology. 
In silico methods can be high-throughput methodologies for SBDD. 
Virtual screening of compounds through molecular docking methods such 
as Surflex[234], Autodock[227], and DOCK[226] is based on the theory that the 
suggested compound placement produced by the docking program corresponds 
to the compound conformation adopted in the cellular milieu. Several studies 
have confirmed that virtual docking studies can reproduce the active site 
327 
placement of the compounds seen in the crystal structure [327-329] with 
particular success in carbohydrate ligands [330], factor Xa inhibitors [331], 
acetylcholinesterase [332] and cytochrome P450 [333]. 
Evaluation of successful compound placement is largely based on 
evaluation of electrostatic and hydrophobic interactions between the compound 
and the receptor, as well as steric factors such as clash scores which quantify 
penetration by the placement of the compound in the surface of the target 
protein. The scores used to evaluate the docked conformations can either be 
proprietary to the programs as in Surflex[234], DOCK[226] or Autodock[227] or 
ligand conformations can be output by the docking program and a separate 
scoring program such as FlexX[240], SCORE[226], and Ligandfit[241] can be 
used to evaluate the compounds. 
Surflex-Dock [234, 244] screening begins with the development of a 
protomol, a series of pseudo-atoms used to define the target for the docking 
sequence. Ligand based protomols based on ligands, inhibitors or partner protein 
substructures allow specific interaction residues to be highlighted by the docking 
process. The same is true for residue based protomols, which can be generated 
based on series of defined residues to target specific regions of an active site. 
Proper placement and focus of a target site for a virtual screening program can 
make the difference between a screen that identifies active inhibitors and one 
that returns nothing but false positives [334]. 
The results of a Surflex-Dock virtual screen are not simply a list of single 
compounds with an associated score. The program generates multiple initial 
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fragmentations of the compounds in its flexible docking protocol. These initial 
fragments are scored and used as a starting position for construction of the full 
virtual compound. Greater results variety and exploration of the space of the 
active site can be achieved by randomizing the initial conformation of the 
compound and varying the site for initial placement of the compound fragments. 
Randomization of the compound starting conformation causes the docking 
program to consider different fragmentation schemes, and thus attempts build 
the flexible ligand in the active site in different fashions between different 
conformations. Varying the initial starting position of the compound fragments 
causes different chemical elements of the active site to come into play in building 
the rest of the compound depending on where the process is begun. As a result 
of this, hundreds of unique compound conformations can be produced for a 
single compound, and by expanding the sampling pool the highest scoring 
compound conformations from a true sampling of the entire space of the active 
site can be identified. 
Mutagenesis assays can be used to characterize receptor structure and 
function. 
SBDD can also be approached from the perspective of the receptor and 
not just the compound, in order to gain greater understanding of receptor 
structure. Mutagenesis studies have been extensively used to characterize 
GPCR functional mechanisms. There are three primary mechanisms by which 
mutation can alter receptor function: 1, the mutation can directly interfere with 
ligand binding; 2, the mutation can result in a conformational shift altering the 
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ligand binding pocket; and 3, the mutation can modulate allosteric movement 
altering signal transduction. 
One of the best examples of mutational studies directly interfering with 
ligand binding corresponds to studies concerning the mechanism of ligand 
binding for CCR5. CCR5 is the GPCR co-receptor used for plasma membrane 
fusion in M-tropic strains of HIV-1 [335]. Scanning alanine site directed 
mutagenesis has been used to identify acidic residues (Asp2, Asp11 and Glu18) 
which are essential to chemokine and gp120 binding, and by extension, HIV 
entry [336]. Further study of this region by this technique added the aromatic 
residues Tyr3 and Tyr10 to the residues which are essential to chemokine and 
gp120 binding [337, 338]. Further analysis of the extracellular surface of CCR5 
including the extracellular loops identified Lys171 and Lys191 as essential 
elements in the binding of ligands MIP-1a and RANTES [339]. 
In GPCRs, mutations modulating allosteric sites and preventing signal 
transduction usually correspond to mutations of the TMs. Basu et al in the Trent 
and Bodduluri laboratories utilized a series of mutants targeting the TM region of 
the Leukotriene B4 receptor BL T1 to characterize the allosteric effects of that 
mutations to this region had on receptor function. Mutations of the TM1 residue 
Asn36, TM3 residue Asp64, and the TM7 residues Ser277, Ser278, Ser279 and 
Asn281 produced a significant reduction in L TB4 mediated chemotaxis and 
calcium mobilization. Specifically, mutation of these residues prevented 
interactions between Asp64 and Asn281 as well as Asp64 and Asn36, which 
were required for transition of the molecule to its active state [151]. Similar 
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studies involving the thyrotropin receptor [340] and histamine H1 receptor [341] 
revealed that mutation of TM regions could prevent transition of the receptors to 
the active state. 
Mutational analysis has helped to characterize the structure and function 
of CXCR4. Chimeras replacing the extracellular domains of CXCR4 with 
comparable domains of CXCR2 were used in some of the earliest studies of 
CXCR4 structure to characterize interactions between the extracellular surface of 
the receptor at the distal N-terminus and ECL3 and CXCL 12. [342] These studies 
also demonstrated that the serine and threonine residues of the carboxyl 
terminus were essential to CXCL 12-induced signaling, through a series of 
truncation mutants, which reduced the length of the C-terminus. Mutational 
analysis has also been used to characterize the antagonist binding site of anti-
CXCR4 compounds T140 and AMD3100 [200]. Alanine scanning mutations 
identified Asp171 , Arg188, Tyr190 and Asp262 as essential to binding of T140 to 
the extracellular surface of the CXCR4 at ECL2. Additional alanine scanning 
mutations identified Phe189, Tyr190, Asp262 and Glu288 as essential to the 
binding of AMD31 00 to the base of ECL3. 
Biophysical studies can be used to characterize GPCR structure, but 
analysis of transmembrane proteins remains difficult. 
Biophysical analysis is another method which can be used to define and 
develop characteristics of protein structure, although these methods are not 
without their difficulties when applied to transmembrane proteins. Crystallography 
remains the gold standard of biophysical and structural characterization of 
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proteins. However, growth of well-ordered three dimensional crystals remains the 
major constraint of generating high-resolution structural data. Novel 
crystallization techniques have allowed the crystal structures of the ~2-adrenergic 
receptor [108], a2A-adrenergic receptor [111] and recently, CXCR4 [257] to be 
characterized. These techniques have essentially been designed to minimize the 
mobility and flexibility of the protein including removal of the N-terminal and C-
terminal subunits as well as substitution of ICL3 with T 4L [109, 110] which 
exchanges a mobile and flexible unit for a solid and immobile element which is a 
desirable characteristic in the development of well-ordered three dimensional 
crystals. In spite of the good resolution of these novel crystallization studies, one 
has to question the impact of removing essential elements of protein structure, 
and what impact this would have on the derived crystals of the remaining 
structure. 
Spin labeling is another method which can be used to monitoring the 
structure and dynamics of soluble and membrane bound proteins. In this method, 
sulfhydryl groups are modified by a nitroxide reagent to produce a nitroxide probe 
on substructures of a larger group. This nitroxide probe possesses unique 
paramagnetic properties which can be used in conjunction with electron 
paramagnetic resonance spectroscopy to define the solvent accessibility, 
mobility, polarity index of the adjacent environment, and the distance between 
the probe and the paramagnetic center of the protein, all vital information for the 
biophysical characterization of biomolecules [343]. Some of the earliest 
characterizations of GPCR structure were derived from experimentation based 
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on incorporation of rhodopsin into lipid bilayers with motion of TM segments 
assessed by the spin-labeled phosphatidylcholine which made up the bilayers 
[344]. Subsequent development of site-directed mutagenesis allowed 
development of a site-directed spin labeling technique for assessing biophysical 
properties of proteins [345]. In this method, site directed mutagenesis is used to 
replace protein residues with cysteine, which can be subsequently used to react 
with the nitroxide probe of the spin-labeling reaction allowing characterization of 
specific protein subunits. The developer of this method, Dr. Wayne L Hubbell, 
has utilized the method primarily to detect structural changes between the active 
and inactive conformations of rhodopsin. Site directed spin labeling has been 
used to characterize the mobility of the C-terminus region, describing the 
structure as a disordered and dynamic unit tethered at one end of the protein, 
with no additional stability provided by palmitoylation of the protein at residues 
322 or 323 [346]. Spin-labeling of N-terminal and C-terminal elements allowed 
the active state of the receptor to be characterized by movement of TM7 away 
from TM1 when compared to the inactive state of the receptor [347]. This method 
is not without its problems in assessing biophysical characteristics of 
transmembrane proteins. As the paramagnetic signal is highly sensitive to its 
surrounding environment, the protein should be placed in purified micelles rather 
than the cell membrane to directly assess the influence of the protein on the 
paramagnetic signal rather than the surrounding elements of the cellular milieu. It 
is difficult to purify sufficient volumes of TM protein to perform these assays, as 
well as place the proteins in micelles while maintaining some semblance of 
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structural elements of an active receptor. In addition, as GPCR structure is highly 
dependent on several conserved cysteine linkages, addition of other cysteine 
elements could produce abnormal structural conformations by incorrect linkages 
with substituted cysteine residues. The bulky nitroxide labels provide another 
potential source of error in the form of disrupted native structure, and 
conformational flexibility of the labels themselves leading to poor resolution [348]. 
In vivo analysis of inhibition of metastasis in animal models 
Given the myriad factors and conditions involved in successful metastasis 
of neoplastic cells, accurate in vivo models of metastasis are exceptionally 
difficult to develop. In xenograft models, neoplastic cells are directly injected into 
proposed sites of metastasis, such as long bones like the femur in an orthotopic 
model [349] or into the mammary fat pad [350], and tumor growth in the novel 
microenvironment is assessed. Non-small cell lung cancer (NSCLC) cells can 
also be used in the assessment of metastasis. One such method injected A549 
cells (a NSCLC cell line) directly into SCID mouse lung tissue and assessed 
distant organ and contralateral lung metastasis development. Philips et al used 
this method to identify increased cell surface expression of CXCR4 in A549 cells 
with increased metastasis to distant organs and the contralateral lung, a process 
which could be inhibited by knockdown of CXCL 12 expression [32]. Another 
common model of metastasis used in conjunction with pharmaceutical 
development is the tail vein injection method. In this method, severe combined 
immune deficient mice are injected in their large diameter tail veins with cells 
from tumor cell lines such as MDA-MB-231 [9,351]. This method was utilized in 
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the MOiler paper to identify favorable microenvironments and homing locations 
for metastatic cells expressing cell surface CXCR4. This method has also been 
utilized to demonstrate the anti-metastatic properties of T140 derivative TN 14003 
[351]. Other models of metastasis focus on the development of bone metastasis. 
In this model, tumor cell lines such as MDA-231-BSC12 are directly injected into 
the left ventricle of athymic mice and cells preferentially metastasize to sites in 
the bone marrow [350]. This model has been successfully used to demonstrate 
the anti-metastatic properties of anti-CXCR4 peptide CTCE-990B [350]. 
Tail vein injection remains one of the most popular methods for assessing 
in vivo metastasis, primarily because of its ease of use and draw backs of the 
other methods. Direct injection of cells into the lung parenchyma runs the risk of 
producing pneumonia in the injected lung, and carries an increased risk of 
bleeding and pneumothorax. Direct injection of cells into the left ventricle carries 
its own difficulties, with an experienced and steady hand required to successfully 
place the needle in the required location, and an increased risk of mortality in the 
injected animals due to arrhythmia or cardiac tamponade due to disruption of the 
ventricular chamber. Tail vein injections are not without their own drawbacks, as 
they suffer from a significant first pass effect, as the cells must pass through the 
portal and pulmonary circulation, increasing the risk of entrapment of tumor cells 
in the attendant capillary beds of these systems. One of the main benefits of the 
bone metastasis model is that it avoids this first pass effect by directly injecting 
the cells into the systemic circulation, and thus provides at least one full pass of 
the cells through the systemic circulation. 
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In this chapter, we will seek to continue the SSOO process for our anti-
CXCR4 compounds targeting the extracellular and intracellular surfaces of the 
receptor. We will use virtual screening in a novel manner, taking advantage of 
the additional structural information gained from the virtual screening process, to 
identify the sites of our targets on the extracellular and intracellular surfaces of 
the receptor where our compounds most frequently interacted in virtual screens. 
In this manner, we will identify the residues where interaction with the anti-
CXCR4 compounds produced an altered phenotype of the receptor. We will then 
utilize molecular dynamics to demonstrate that alteration of these ECL2, ECL3, 
ICL3 and C-terminal residues modulate the TM regions of the receptors, and 
affect the conformation of CXCR4. We will then use mutatagenesis analysis to 
determine the effects of these mutations on CXCR4 mediated signaling and 
migration. We will also advance further in the SSOO process and test the anti-




Surflex-Dock [234, 244] was used to generate high-accuracy docked 
conformations of the ICLGa compounds, as well as the ECLVS and EVS14 
compounds. Compound structures were generated in Sybyl (Tripos) and 
subjected to 2500 iterations of steepest descent minimization. Compound 
conformation was randomized using the Surflex-Dock "random" command to 
generate ten random conformations of each compound . The ligand-based 
protomol targeting the intracellular surface of the constitutively active N119S 
CXCR4 described in the virtual screening protocol in Chapter III was reused for 
this procedure for ICLGa compounds. A novel protomol targeting the residues 
listed in Table 24 was designed to dock the compounds targeting the 
extracellular surface of CXCR4. Surflex-Dock [234, 244] was used to dock the 
ten random conformations of each compound using 5 randomized starting 
positions. The top 200 scored poses produced by the Surflex-Dock [234, 244] 
protocol were collected for each compound . The top 5 for each compound were 
then subjected to distance analysis on either the extracellular or intracellular 
surface and used to identify CXCR4 residues within 3 A of the compounds. 
Transfection and generation of 300.19 stable cell lines expressing 
mutations of hCXCR4-GFP 
Site-specific mutations of CXCR4 and their effects on inhibitor function 
and cell phenotype were investigated using 300.19 cell lines overexpressing 
stably transfected hCXCR4-GFP mutants. Residues identified in the virtual re-
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Table 24: Extracellular Residues of CXCR4 used in protomol development 
in Surflex. Residues on CXCR4 within 15 A of a centroid placed on the 
extracellular surface of CXCR4 were used to develop a residue based protomol 
targeting the extracellular surface of the receptor. 
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Table 24: Extracellular Residues of CXCR4 used in protomol development 
in Surflex. 
Residue Amino Residue Amino Residue Amino Acid Acid Acid 
1 Met 171 Asp 194 Leu 
2 Glu 172 Phe 195 Trp 
3 Gly 173 lie 196 Val 
4 lie 174 Phe 197 Val 
5 Ser 175 Ala 198 Val 
21 Tyr 176 Asn 199 Phe 
22 Asp 177 Val 200 Gin 
23 Ser 178 Ser 203 His 
24 Met 179 Glu 263 Ser 
25 Lys 180 Ala 266 Leu 
26 Glu 181 Asp 267 Leu 
27 Pro 182 Asp 270 lie 
28 Cys 183 Arg 271 Lys 
29 Phe 184 Tyr 276 Phe 
31 Glu 185 lie 277 Glu 
102 Trp 186 Cys 280 Val 
104 Phe 187 Asp 281 His 
105 Gly 188 Arg 282 Lys 
106 Asn 189 Phe 283 Trp 
107 Phe 190 Tyr 284 lie 
109 Cys 191 Pro 285 Ser 
110 Lys 192 Asn 286 lie 
113 His 193 Asp 288 Glu 
116 Tyr 
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screening protocol for site directed mutagenesis are listed in Table 25. Additional 
mutants were developed based on distance calculations between the intracellular 
surface of CXCR4 and the comparable interface surface of Gai , which are also 
listed in Table 25. PCR-based site- directed mutagenesis was utilized to 
generate sequence confirmed plasm ids using primers listed in Tables 26 and 27. 
PCR-based site-directed mutagenesis was carried out using the followed 
parameters for each sample: 5 IJI 10X Thermo Pol Buffer, 1 IJI 100 mM MgS04, 
2.5 mM dNTPs, 1 IJI Deep Vent Polymerase, 2 IJI 50 ng/IJI Template DNA, 1 IJI 
each of Sense and Anti-sense primer and 31 IJI Millipore H20. PCR was run 
using the following specifications: an initial denaturing step of 4 min at 95 °C, 
followed by 20 repetitions of 45 s 95 °C, 1 min 54 °c , 6 min 72 °C, and a final 
annealing step of 15 min at 72 °C. 300.19 cells were maintained as suspension 
cultures in RPMI supplemented with 10% FBS, 100 U/ml penicillin and 100 Ilg/ml 
streptomycin, and 55 IlM of 2-mercaptoethanol. Transfections were performed by 
electroporation. The stable cell lines are maintained in the presence of 1 mg/ml 
of G418. Cells are cultured in complete medium for 24 hrs after transfection and 
used for microscopy. The cell surface expression of hCXCR4 is also determined 
by incubating receptor or parental cells with 12G5 Ab followed by PE labeled 
secondary Ab as well as detection of protein GFP tag and expression was 
analyzed by FACS (BD Biosciences). 
Chemotaxis analysis 
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4-
GFP mutants were performed as previously described in chapter 2. 
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Table 25: Residues identified for SOM. Residues identified in the virtual 
redocking protocol which established close contacts with the ECl VS compounds 
are listed in the first column. Close contact residues interacting with the IClVS 
compounds are listed in the second column. Residues which were identified as 
within 2 A of the Gai G-protein subunit in the N 119S-G-protein hetero trimer 
homology model are listed in the third column. 
341 
Table 25: Residues identified for SOM. 
ECl ICl Gai 
Val177 Lys239 Lys234 
Ser178 Thr240 Arg322 
Glu179 Ala307 Lys327 
Phe189 Lys308 Lys333 
Asn192 Phe309 Ser341 




Table 26: CXCR4 ECl SOM plasmids. Plasmids utilized in PCR based site 
directed mutagenesis SOM of CXCR4 to mutate residues of the extracellular 
region of CXCR4 identified by virtual redocking. Listed with mutant and sense 
and anti-sense plasmids for development of SOM for each residue. 
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Table 26: CXCR4 ECLSDM plasm ids. 
Mutant Direction Plasmid 
Sense 5'-CTTIGCCAACGCCAGTGAGGCAGA-3' 
V177A 
Anti-sense 5'-TCT GCC TCA CTG GCG TTG GCA AAG-3' 
Sense 5'-TIC TAC CCC GCT GAC TIG TGG GTG G-3' 
N192A 
Anti-sense 5'-CCA CCC ACA AGT CAG CGG GGT AGA A-3' 
Sense 5'-GGT GTG AGG CTG AGA ACA CTG TGC A-3' 
F276A 
Anti-sense 5'-TGC ACA GTG TTC TCA GCC TCA CAC C-3' 
Sense 5'-GAA CAC TGT GGC CAA GTG GAT TIC CA-3' 
H281A 
Anti-sense 5'-TGG AM TCC ACT TGG CCA CAG TGT TC-3' 
S178A- Sense 5'-TTG CCA ACG TCG CTG CGG CAG ATG-3' 
E179A Anti-sense 5'-CAT CTG CCG CAG CGA CGT TGG CAA-3' 
F189A- Sense 5'-GAC CGC GCC TAC CCC AA T GAC GCG TGG GTG-3' 
L194A Anti-sense 5'-CAC CCA CGC GTC ATT GGG GTA GGC GCG GTC-3' 
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Table 27: CXCR4 ICL 80M plasmids. Plasmids utilized in PCR based site 
directed mutagenesis SDM of CXCR4 to mutate residues of the intracellular 
region of CXCR4 identified by virtual redocking. Listed with mutant and sense 
and anti-sense plasm ids for development of SDM for each residue. 
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Table 27: CXCR4 ICL 80M plasmids. 
Mutant Direction Plasmid 
K234A 
Sense 5'-GGC CAC CAG GCG CGC MG GCC CT-3' 
Anti-sense 5'-CCG GTG GTC CGC GCG TTC CGG GA-3' 
K239A 
Sense 5'-MG GCC CTC GCG ACC ACA ATC-3' 
Anti-sense 5'-TTC CGG GAG CGC TGG TGT TAG-3' 
K239A- Sense 5'-GCG TTC CGG GAG CGC CGG TGT TAG TAG GGG TA-3' 
T240A Anti-sense 5'-CGC MG GCC CTC GCG GCC ACA ATC ATC CCC AT-3' 
T240A 
Sense 5'-MG GCC CTC MG GCC ACA ATC ATC C-3' 
Anti-sense 5'-TTC CGG GAG TTC CGG TGT TAG TAG G-3' 
A307E 
Sense 5'-GCT TTC CTT GGA GAG AM TTT AM-3' 
Anti-sense 5'-CGA MG GM CCT CTC TTT AM TTT -3' 
K308A 
Sense 5'-TTC CTT GGA GCC GCA TTT AM ACC-3' 
Anti-sense 5'-MG GM CCT CGG CGT AM TTT TGG-3' 
F309A 
Sense 5'-TTG GAG CTA AGG CTA AM CCT CTC C-3' 
Anti-sense 5'-MC CTC GGC TTC GAT ATT GGA GAT G-3' 
A307E- Sense 5'-TTT CCT TGG AGA GGC ATT TM MC CTC TGC CG-3' 
K308A Anti-sense 5'-AM GGA ACC TCT CCG T MATT TTG GAG ACG GG-3' 
K308A- Sense 5'-TTT CCT TGG AGC CGC AGC TM MC CTC TGC CC-3' 
F309A Anti-sense 5'-AM GCA ACC TCG GCG TCG ATT TTG GAG ACG GG-3' 
A307E- Sense 5'-TTT CCT TGG AGA GGC AGC TM MC CTC TGC CC-3' 
K308A-
Anti-sense 5'-AM GGA ACC TCT CCG TCG ATT TTG GAG ACG GG-3' F309A 
R322A 
Sense 5'-GTG AGC GCA GGG TCC AGG CT-3' 
Anti-sense 5'-CAC TCG CGT CCC AGG TCG GA-3' 
K327A 
Sense 5'-GGG TCC AGC CTC GCG ATC CTC TCC AM-3' 
Anti-sense 5'-CCC AGG TCG GAG CGC TAG GAG AGG TTT-3' 
K333A 
Sense 5'-CCC AGG TCG GAG CGC TAG GAG AGG TTT-3' 
Anti-sense 5'-TAG GAG AGC --- CCT TTC GCT G-- -3' 
S338A 
Sense 5'-GGT GGA CAT GCA TCT GTT TCC ACT -3' 
Anti-sense 5'-CCA CCT GTA CGT AGA CM AGG TGA-3' 
S341A Sense 5'-TCA TCT GTT GCC ACT GAG TCT G-3' 
Anti-sense 5'-AGT AGA CM CGG TGA CTC AGA C-3' 
S351A Sense 5'-AGT TTT CAC GCC AGC CTA CG-3' 
Anti-sense 5'-TCA AM CTG CGG TCG GAT GT-3' 
S352A Sense 5'-TTT CAC TCC GCC CTA CAT CAT -3' 
Anti-sense 5'-AM GTG AGG CGG GAT GTA GTA-3' 
S351A- Sense 5'-CM GTT TTC ACG CCG CCC TAC ATC ATC AT -3' 
S352A Anti-sense 5'-GTT CM MG TGC GGC GGG ATG TAG TAG TA-3' 
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Cell signaling analysis 
Cell signaling by CXCR4 was investigated by assessment of intracellular 
calcium mobilization as seen in chapter 2. 
Molecular dynamics 
Fully solvated lipid bilayer molecular dynamics simulations of mutated 
CXCR4 structures were performed using the AMBER suite of programs using the 
parm99 force field [284]. As previously described in chapter 2. Calculations were 
performed on servers from the Cardinal Research Cluster. 
Development of animal model for CXCR4 dependent cancer metastasis in 
lungs. 
Lewis lung carcinoma, B16F10 melanoma and TC-1 cervical cancer 
carcinoma, mouse cell lines known to metastasize to lungs in mice models, were 
screened for CXCR4 cell surface expression using flow cytometry based surface 
receptor staining using a flurochrome labeled antibody to mouse CXCR4 
receptor. TC-1 cervical cancer carcinoma cell lines were selected for tail vein 
injection studies. 
Toxicity of lead compounds was assessed by intraperitoneal injection of 
compounds at an initial dose of 5 mg kg-1 body weight, followed by a second 
dose two days later of either 20 mg kg-1 body weight or 40 mg kg-1 body weight. 
Toxicity was assessed by loss of body weight and development of signs of 
physical distress including lethargy and signs of illness over a period of 3 weeks. 
Antimetastatic compound activity was assessed using a mouse pulmonary 
metastatic cancer model. In this model, 21 days of daily intra-peritoneal injection 
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of AMD3100, ECLVS14, ICLGa28 or ICLGa36 (5 mg kg-1 body weight) were 
followed by injection of 5 x 105 TC-1 cells intravenously into tail veins of C57BI/6 
mice. On day 21 post tumor challenge, mice were sacrificed and lungs were 
perfused and stored in formalin for 16 hours prior to transfer to 70% ethanol. 
Tumors were counted by magnifying glass, microscopy and size was measured 
by digital caliper. The total number of tumors counted in all the five lung lobes of 
an individual mouse was presented as tumor incidence and addition of the mean 
tumor sizes were done to calculate cumulative tumor size which was presented 
as tumor burden for each mouse. 
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Results 
Virtual Re-docking analysis identifies potential critical residues on the 
extracellular and intracellular surfaces of CXCR4. 
Virtual screening can produce more information than just the placement of 
a single compound in a binding site. The results of a virtual screen are frequently 
presented by the program as a list of the top scored conformations of the 
individual compounds, but the number of compounds returned in a given screen 
is a variable that can be set by the user. As can be seen in Figure 75, there is 
significant diversity in the poses produced by docking a single compound into a 
receptor. Our hypothesis is that by docking multiple conformations of active 
compounds into the active site of the receptors, we will be able to identify specific 
sites which are essential to receptor activity. In essence we will be virtually 
screening the residues of the active sites to identify potential targets for site 
directed mutagenesis analysis under the assumption that because the natural 
function of these residues is interrupted by the anti-CXCR4 compounds, their 
interruption by site directed mutagenesis could produce similar results. 
To this end, we employed a high-intensity docking protocol using Surflex-
Dock [234, 244] to identify CXCR4 amino acid residues within two A of the top 
five scored conformations of each compound. The high-intensity docking protocol 
incorporated ten randomized starting conformations for each compound and five 
unique starting positions for the initial fragment placement in the flexible docking 
protocol of Surflex-Dock. The extracellular-targeted compounds most frequently 
interacted with nine residues illustrated in Figure 76. Compounds primarily 
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Figure 75: Virtual screening can be used to assess the interaction of 
multiple conformations of a single compound within an active site. By 
inspecting the position of multiple compounds in an active site, additional 
information about the receptor can obtained, identifying specific interaction 
residues which can affect phenotypical changes through many different 
compounds. A) The top 10 scored conformations of ECLVS14 produced by 
Surflex-Dock, placed in the extracellular surface of the receptor. B) The top 10 
scored conformations of ICLGa36 produced by Surflex-Dock, placed in the 
extracellular surface of the receptor. 
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Figure 75: Virtual screening can be used to assess the interaction of 
multiple conformations of a single compound within an active site. 
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Figure 76: Virtual rescreening of extracellular loop targeted compounds 
identifies specific contact residues. Scores are presented as percentage of 
compound poses within two A of the residue for the entire set of compounds (in 
blue), those with anti-chemotaxis activity (in red) and those with anti-calcium 
mobilization activity (in green). Compounds primarily interacted with nine specific 
residues of ECL2 and ECL3. 
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Figure 76: Virtual rescreening of extracellular loop targeted compounds 
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contacted the second and third extracellular loops along with the N-terminal 
methionine. The most frequently interacting residues were Va1177, Ser178, 
Glu179 on the N-terminal side of the second extracellular loop and Phe189, 
Pro191, Asn192 and Leu 194 on the C-terminal side of the loop. Phe276 and 
His281 on the third extracellular loop also frequently interacted with the 
compounds. It is important to note that there was relatively little overlap between 
the compounds with anti-chemotaxis activity and those with anti-calcium 
signaling activity. 
The intracellular-targeted compounds primarily interacted with six residues 
illustrated in Figure 77. The six most common contact points were located on 3 
regions of the intracellular surface. Lys239 and Thr240 were located on the 
intracellular surface of TM6. Ala307, Lys308 and Phe309 are located on the 
intracellular surface of TM7. Ser338 was located on the C-terminal tail of CXCR4. 
As these compounds represent a structurally diverse initial virtual screen, the 
contact frequencies seen in the virtual re-docking were substantially decreased 
when compared to screening results of the structurally similar extracellular-
targeting compounds. There is a wider diversity in contact residues between 
compounds with anti-chemotaxis activity and anti-calcium signaling, with anti-
calcium signaling compounds coming into more frequent contact with Lys239, 
Ala307 and Phe309. In contrast, contact with residues Lys308 and Ser338 
seems to favor anti-chemotaxis activity. It is also important to note that the 
docked position of these compounds is in direct conflict with the docked position 
of a key projection of G-protein Gai into the intracellular surface of CXCR4. 
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Figure 77: Virtual rescreening of intracellular loop targeted compounds 
identifies specific contact residues. Scores are presented as percentage of 
compound poses within two A of the residue for the entire set of compounds (in 
Blue), those with anti-chemotaxis activity (in Red) and those with anti-calcium 
mobilization activity (in Green). Compounds primarily interacted with six residues 
on the intracellular surface of TM6 and TM7 and the C-terminal tail of the protein. 
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Figure 77: Virtual rescreening of intracellular loop targeted compounds 
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We also sought to investigate the interaction between CXCR4 and Gai. 
Using the model developed for th is interaction, we sought to identify close 
contact residues of CXCR4 important to the interaction of the two proteins. 
Seven CXCR4 residues were identified that were within 2 A of Gai: ICL3 residue 
Lys 234, and C-terminus residues Arg322, Lys327, Lys333, Ser 341, Ser 351 , 
and Ser 352. 
Analysis of CXCR4 mutants through molecular dynamics simulations 
The virtual redocking protocol identified several amino acid residues which 
were consistent interaction points for our anti-CXCR4 compounds. Modulation of 
CXCR4 through interaction with these residues produced significant alterations in 
the phenotype of the receptor. Thus, in line with our SSOO method, we sought to 
further investigate and characterize the structure of our receptor by in silico 
mutagenesis of the native structure of CXCR4, to investigate whether mutations 
of these residues would similarly alter its conformation. As mentioned in 
Chapters II and III , the native CXCR4 and N 119S structures were developed by 
Dr. Napier via homology modeling based upon the high resolution crystal 
structure of rhodopsin [288]. 
Molecular Dynamics simulations of intracellular CXCR4 mutants 
We hypothesize that disruption of residues which are purported to interact 
with compounds targeting the intracellular and extracellular surfaces of the 
receptor as well as the residues identified as being within binding distance of the 
Gai G-protein subunit will produce significant alteration of the structure of 
CXCR4. To investigate this hypothesis, mutations of the native CXCR4 structure 
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were investigated by molecular dynamics as described in Chapters II and III. 
However, rather than the ten 500 ps production runs conducted in the compound 
docking dynamics studies in the previous Chapters, twenty production runs of 
500 ps were conducted for a 10 ns total production run for each mutant to assess 
structural conformation. 
Molecular dynamics simulations of CXCR4 intracellular and extracellular 
surface residue mutations form stable conformations of the receptor. 
The final averaged structures of the mutated CXCR4 conformations from 
the 10 ns molecular dynamics simulations are shown in Figure 78 along with the 
location of the mutated residues. The mutated CXCR4 conformations were 
energetically stable throughout the production run (data not shown), indicating 
that the simulation was well-equilibrated prior to production analysis. 
Conformational stability of the mutated CXCR4 structures were investigated 
using root mean square deviation (RMSD) analysis, (data not shown). RMSD 
values as measured at the Ca position remained stable for the majority of the 
production runs, with the final average structure representative of the trajectory 
after approximately 1.5 ns. The helical domains were stable through the 
production run , and the majority of structural variation was in the loop regions. 
Conformation of the mutant receptors will be presented in reference to the 
inactive native structure and the constitutively active N119S conformations. As 
discussed in Chapters II and III , significant differences exist between these 
structures. Briefly, the N-terminall3-sheet is more compact for N119S than 
native. The proximal portion the N-terminus is displaced towards ECl1 for 
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Figure 78: Final averaged structures of molecular dynamics of mutated 
CXCR4. Average structure of CXCR4 presented in cyan ribbon . Mutant residues 
are highlighted in ball-stick rendering. A) V177A S) S178A C) E179A D) F189A 
E) N192A F) L 194A G) K234A H) K239A I) T240A J) F276A K) H281A L) A307E 
M) K308A N) R322A 0) K327A P) K333A Q) S338A R) S341A S) S351A T) 
S352A U) V177 A-F189A-L 194A V) V177 A-F189A-L 194A-F276A W) V177 A-
F276A X) S 178A-E 179A Y) S 178A-E 179A-H281 A Z) S 178A-E 179A-N 192A AA) 
S178A-E179A-N192A-H281A AS) F189A-L 194A AC) F189A-L 194A-F276A AD) 
N192A-H281A AE) K239A-T240A AF) A307E-K308A AG) A307E-F309A AH) 
A307E-K308A-F309A AI) K308A-F309A AJ) S351A-S352A 
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Figure 78: Final averaged structure of molecular dynamics of mutated 
CXCR4. A) V177A B) S178A C) E179A D) F189A E) N192A F) L 194A G) 
K234A H) K239A I) T240A J) F276A K) H281A L) A307E M) K308A N) R322A 
0) K327A P) K333A Q) S338A R) S341A S) S351A T) S352A U) V177A-
F189A-L 194A V) V177 A-F189A-L 194A-F276A W) V177 A-F276A X) S178A-
E179A Y) S178A-E179A-H281A Z) S178A-E179A-N192A AA) S178A-E179A-
N192A-H281A AB) F189A-L 194A AC) F189A-L 194A-F276A AD) N192A-
H281A AE) K239A-T240A AF) A307E-K308A AG) A307E-F309A AH) A307E-











N119S. ECl1 is conserved as a short bridging loop between TM2 and TM3 and 
ECl2 is conserved as a two-stranded anti-parallel ~-sheet structure. ECl3 is a 
disordered loop between TM6 and TM7. The apex of this loop is in close 
proximity to the distal ~ sheet structure of the N-terminus in the native 
conformation, but is displaced towards the proximal portion of the N-terminus in 
the N11 9S conformation. As a result, constitutively-active N11 9S is more open at 
the extracellular surface, allowing greater access to the acidic residues of the 
extracellular termini of the TM regions. ICl1 forms a short loop joining TM1 and 
TM2, and the apex is displaced towards the cytoplasmic terminus of TM3 for 
N119S. ICl2 is a more extended loop that joins TM3 and TM4, with an apex that 
occurs towards the midpoint of the loop in the native conformation and more 
proximally in the N11 9S conformation. The apex of the loop is oriented towards 
ICl1 in the native conformation, but is displaced away from the center of the 
receptor in the N119S conformation. Kinks in the structure of ICl3 in the N119S 
conformation produce increased angles at residues lys 230 and Ala 237, 
causing the apex of ICl3 to be displaced upward and away from the center of the 
receptor. The C-terminal region produces an eighth helix aligned perpendicular to 
the rest of the helices and parallel with the lipid surface. In the N11 9S 
conformation torsion at Ser313 causes this eighth helix to lose a-helix 
conformation, and the distal C-terminal is brought into much closer contact with 
the cytoplasmic termini of TM1 and TM4. 
Mutation of the distal end of ICl3 alters CXCR4 structure. 
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Significant variations characterized the four mutants targeting ICL3: 
K234A, K239A, T240A and K239A-T240A. Although the majority of the structure 
mirrored the native conformation of the receptor, the mutants exhibited 
differences in the structure and positioning of the N-terminus, ICL 1, ICL2, ICL3 
and ECL3. The N-terminus of the K234A mutant adopted the more compact 
structure and orientation. This region in the K239 mutant was more distended 
than the native structure converting the three strand anti-parallel terminal portion 
of the structure to adopt a two strand anti-parallel conformation. The T240 mutant 
N-terminus was displaced towards ECL3 as in the N119S conformation, but the 
p-sheet adopted the native conformation. The mutants primarily maintained the 
conserved ICL 1 loop, although the K239A-T240A mutant shifted the apex of this 
loop towards the center of the receptor. K234A and K239A-T240A mutants 
maintained the native conformation of ICL2, but the apex of the loop was shifted 
towards ICL 1 by K239A and T240A. The T240A mutant shifted the apex of ICL3 
towards the C-terminus and the center of the receptor, while the K234A, K239A, 
and K239A-T240 mutants shifted the apex of this loop away from the C-terminal 
region and towards ICL2. Finally, the K239A-T240A mutant shifted the apex of 
ECL3 towards the N-terminal region, while T240A caused an opposite effect, 
shifting the Apex of the loop away from the N-terminus of the receptor. 
These surface changes of the receptor suggest that the mutations are 
causing CXCR4 to adopt different conformations. There were relatively few 
modifications of receptor structure caused by the K234A mutation, but those 
changes resulted in a more compact N-terminus producing a more exposed 
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CXCL 12 binding site and a more open Gai binding site at the intracellular 
surface. The K239A mutation seemed to primarily affect the N-terminal region of 
the receptor, resulting in a more open intracellular surface, but primarily 
maintaining the native conformation. The T240A mutation seems to drive CXCR4 
more towards a more inactive form, shifting the N-terminus and ECL3 to produce 
a distortion of the extracellular surface, but producing greater shifting of the 
intracellular loops toward ICL 1 and the center of the receptor than in the native 
receptor, producing obstructions to G-protein binding. K239A-T240A mutation 
produces greater interaction between the N-terminus and ECL3, producing 
greater exposure of the CXCL 12 ligand binding surface, but greater interaction 
between ICL2 and ICL3, suggesting that while the extracellular surface is more 
receptive to ligand binding, the intracellular surface would be less receptive to 
signal transduction. 
Conformational differences were noted with respect to the 
intermembranous segments of the mutant CXCR4 structures as well. Although 
the conformations primarily conformed to the native structure of the receptor, 
several key differences were apparent. As depicted in Figure 79a, the K234A 
mutant produced no gross deviations from native CXCR4 TM structure. The 
same was true for the K239A mutant shown in Figure 79b, which aside from a 
more linear TM4 conformation produced little variation from the native structure. 
The T240A and K239A-T240A mutants produced more significant variations in 
Figure 79c-79d. The T240A mutant produced a shift at the apex of TM4 though 
additional angularity of the helix at Thr168. An additional kink in TM5 was 
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Figure 79: Transmembrane regions of the ICL3 mutants adopt a similar 
conformation to native CXCR4. Reduced representations of receptor 
transmembrane helices are presented: native CXCR4 in green, N119S in red, the 
K234A conformation in teal, K239A conformation in white, T240A conformation in 
magenta, and the K239A-T240A conformation in blue. A) K234A, 8) K239A, C) 
T240A, D) K239A-T240A 
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Figure 79: Transmembrane regions of the ICL3 mutants adopt a similar 
conformation to native CXCR4. A) K234A B) K239A C) T240A D) K239A-
T240A 
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produced at Pro211 while in the K239A-T240A mutant this helix was tiled 
towards TM4. The basal termini of TM6 and TM7 in both mutants were shifted 
towards the intracellular surface of the membrane. 
The TM regions of the receptors were further characterized by 
measurement of interhelical distances as depicted in Table 28. At the 
extracellular surface, K234A mutation primarily altered TM1 and TM5 positioning, 
modulating distances based on these TM regions and reproducing the N119S 
interhelical distance for TM1-2, TM1-3, and TM1-4. K239A mutation seemed to 
have widespread effects, modulating interhelical distances corresponding to 
TM1 , TM4 and TM6, reproducing the N119S interhelical distance for TM1-2, 
TM1 -4, TM1-5, TM2-4, and TM5-6. T240A and K239A-T240A did not produce as 
much change at the extracellular surface of the receptor, primarily modulating 
TM6 position. 
Interhelical distances at the intracellular surface of the receptor are 
illustrated in Table 29. K234A mutation had relatively few effects on intracellular 
interhelical distances, decreasing the TM4-7 distance compared to native and 
causing TM1-6 to approach the N119S interhelical distance. K239A produced 
similar light effects at the intracellular surface, causing a mild increase in TM6-7 
distance, and a decrease in the TM5-6 distance. A more substantial difference 
was noted in the T240A mutant, where mutation produced increased interhelical 
distances forTM1-7, TM2-7, and TM6-7, and decreases in the TM5-6 distance. 
Very substantial modifications were noted with the K239A-T240A mutant, as this 
mutant produced significant alteration in the positioning of TM7, leading to an 
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Table 28: Interhelical distances at the extracellular surface for the ICL3 
mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and ICL3 
mutant structures measured in averaged conformations of dynamically 
determined structures. At the extracellular surface, the K234A and K239A 
mutants alter the position of TM1. 
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Table 28: Interhelical distances at the extracellular surface for the lel3 
mutants. 
Native N119S K234A K239A T240A K239A-T240A 
TM1-2 6.5 7.6 7.7 7.4 7.1 6.9 
TM 1-3 20.9 22.2 22.4 21.5 21.4 21.7 
TM 1-4 21.9 23.3 23.1 23.6 22.7 22.3 
TM 1-5 33.6 34.8 33.6 34.5 33.5 34.6 
TM 1-6 26.0 25.4 26.7 26.3 26.4 27.6 
TM 1-7 15.8 14.6 17.1 17.2 15.3 16.2 
TM 2-6 28.7 28.0 28.6 29.3 29.3 29.9 
TM 4-6 15.9 15.4 16.7 17.1 17.0 16.3 
TM 5-6 11.2 13.1 11.4 12.8 12.3 11.3 
TM 6-7 12.1 13.1 11.4 11.1 12.3 12.8 
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Table 29: Interhelical distances at the intracellular surface for the lel3 
mutants. Interhelical distances measured at intracellular termini of 
transmembrane domains of native CXCR4, constitutively active N11 9s, and ICL3 
mutant structures of averaged structures dynamically determined structures. 
Mutations of residues 239 and 240 altered the position of TM6 and TM? 
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Table 29: Interhelical distances at the extracellular surface for the lel3 
mutants. 
Native N119S K234A K239 T240A K239A-T240A 
TM 1-5 32.2 33.9 32.7 30.8 31.9 33.6 
TM 1-6 20.5 21.3 21.2 20.3 20.7 21.3 
TM 1-7 12.2 13.6 11.5 11.9 13.1 13.1 
TM 2-5 22.5 25.3 23.0 22.4 23.1 23.8 
TM 2-7 11.7 12.3 10.4 11.9 12.7 14.3 
TM 3-4 16.0 12.6 15.7 16.2 15.8 14.8 
TM 3-6 12.0 13.4 11.6 11.4 11.2 10.7 
TM 3-7 21.5 22.2 20.6 21.8 24.3 26.0 
TM 4-7 22.3 21.0 20.4 22.3 23.7 24.6 
TM 5-6 13.3 12.7 13.3 12.7 12.8 13.1 
TM 5-7 24.8 23.7 24.8 24.6 27.3 29.6 
TM 6-7 12.3 11.8 12.6 13.4 15.1 17.5 
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average increase of 3.4 A for the interhelical distances involving this helix when 
compared to the native conformation. This effect seems to correlate across the 
mutants, as the interhelical distance between TM6-7 for the K239A mutant 
exhibited a mild increase, which was greater in the T240A mutant and greater 
still in the double mutant. This suggests that the base of TM6 where K239 and 
T240 are located is essential to the maintenance of TM7 position and that these 
modifications do substantially affect CXCR4 structure. 
Mutations proximal to Helix eight alter TM7 position. 
Mutations of the proximal portion of the C-terminal region corresponding to 
the beginning of helix eight primarily adopt the native conformation of the 
receptor, including maintenance of helical structure in helix 8 in all mutants. 
There were a few notable exceptions to conservation of native conformation. At 
the N-terminus the A307E mutant adopted a more extended conformation of the 
~ sheet, while the A307E-F309A mutant adopts a more compact conformation. 
Several of the mutants also altered the conformation of ECl1 , with the A307E 
mutant producing a shift of the apex of the loop towards the N-terminus and the 
center of the receptor. The K308A mutant adopted a similar conformation, 
although the apex of the loop was directed more towards the base of the N-
terminus rather than the center of the receptor. Finally, the A307E-K308A mutant 
shifted ECl1 opposite the other two mutants and outward from the center of the 
receptor. ECl3 was altered in the A307E, A307E-F309A, K308A, and K308A-
F309A mutants to adopt a conformation more in line with the N11 9S mutant but 
shifted away from the n-terminus and outward from the center of the receptor. 
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Thus, while the majority of the structures of the extracellular terminus are 
maintained in their native conformation in many of the mutants, the A307E-
F309A, K30BA, and K30BA-F309A produce a mild distortion of the CXCL 12 
binding site by altering the position of ECL3. The A307E mutant also seems to 
adopt a more inactive conformation, with distortions of the l3-sheet structure of 
the N-terminus in addition to the distortion of ECL3 conformation. 
On the intracellular surface of the receptor, mutants K30BA, A307E-
F309A, A307E-K30BA and K30BA-F309A all shifted the apex of ICL2 opposite of 
the N119S conformation and towards ICL 1 rather than ICL3 and the C-terminus. 
The A307E-K30BA, K30BA-F309A and A307E-K30BA-F309A mutants shifted the 
apex of ICL3 away from the C-terminus and towards ICL2, while the K30BA 
mutant shifted the apex of the ICL3 loop towards the C-terminus and the center 
of the receptor. The structure of the intracellular surface of the mutant 
conformations once again primarily maintained the native conformation of the 
receptor with a few key differences. The A307E-K30BA and K30BA-F309A 
mutants shifted both ICL2 and ICL3 away from the C-terminal region, suggesting 
that the G-protein binding site would be more open. K30BA shifted ICL2 away 
from the C-terminus but ICL3 towards the C-terminus, distorting the G-protein 
binding site. 
Structural modifications were seen on the TM regions of CXCR4 in several 
of the Helix B mutants illustrated in Figure BO. In TM1 of the K30BA-F309A 
conformation, the base of the helix is displaced by an additional kink at Asn56. 
The TM4 of the A307E-K30BA mutant adopted an intermediate conformation 
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Figure 80: Transmembrane regions of the proximal C-terminal mutants 
adopt a similar conformation to native CXCR4. Reduced representations of 
receptor transmembrane helices are presented: native CXCR4 in green, N119S 
in red, the A307E conformation in white, K30BA conformation in blue, A307E-
K30BA conformation in orange, A307E-F309A conformation in magenta, K30BA-
F309A conformation in yellow, and the A307E-K30BA-F309A conformation in tan. 
The A307E conformation adopts alterations of TM5 and TM6. The K30BA 
conformation adopts alterations of TM1. The A307E-K30BA conformation adopts 
alterations of TM4 and TM5. The A307E-F309A conformation adopts alterations 
of TM5 and TM6. The K30BA-F309A conformation adopts alterations of TM4 and 
TM6. The A307E-K30BA-F309A conformation adopts the transmembrane 
structure of the native receptor. A) A307E 8) K30BA C) A307E-K30BA D) A307E-
F309A E) K30BA-F309A F) A307E-K30BA-F309A 
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Figure so: Transmembrane regions of the proximal C-terminal mutants 
adopt a similar conformation to native CXCR4. A} A307E B) K30SA C) 
A307E-K30SA D) A307E-F309A E) K30SA-F309A F) A307E-K30SA-F309A 
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between that of the native and N 119S conformations of the receptor, while an 
additional kink displaced the base of the helix in the K30BA-F309A mutant. The 
characteristic bulge of TMS was rotated in the A307E, A307E-F309A and A307E-
K30BA mutants, suggesting rotation of the helix as a whole. TM6 in the A307E 
and A307E-F309A mutants was in a more linear conformation than the native 
TM6, while the apex of the helix was shifted towards TMS in the K30BA-F309A 
mutant. Given their proximity to the base of TM7, it was interesting that none of 
these mutants produced any gross deviation of this helix. 
The interhelical distances of the proximal C-terminal mutants measured at 
the extracellular surface are depicted in Table 30. The A307E mutation produced 
the most significant variation from the native conformation, primarily altering 
increasing interhelical distances or shifting them to coincide with the expected 
value for the N119S conformation by altering positioning of TM1 and TM2. Less 
substantial alterations were seen for the K30BA mutation which only increased 
the interhelical distances between TM4-6 and decreased the TM4-S distance to 
coincide with the N119S conformation. The A307E-K30BA mutant primarily 
modulated the TM6 position, increasing the interhelical distance for TM4-6, TM1-
6, and TM2-6. The A307E-F309A mutation shifted the interhelical distances of 
TM1-2 and TMS-6 to coincide with the N119S conformation. The K30BA-F309A 
mutation acted primarily by modulating the position of TM1, resulting in increased 
interhelical distances between TM1-2, TM1-7 and TM1-6. A307E-K30BA-F309A 
produced only minor variations of the extracellular surfaces of the TM regions, 
increasing TM4-6 and decreasing TMS-7 and TM6-7. 
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Table 30: Interhelical distances at the extracellular surface for the helix 8 
mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and helix 
B mutant structures measured in averaged conformations of dynamically 
determined structures. At the extracellular surface, A307E altered TM1 and TM2, 
A307E-K30BA altered TM6, K30BA-F309A altered TM1 and A307E-K30BA-
F309A altered TM6. 
385 
Table 30: Interhelical distances at the extracellular surface for the lel3 
mutants. 
A307E- A307E- K308A- A307E-TM Native N119S A307E K308A K308A F309A F309A K308A-F309A 
1-2 6.5 7.6 7.6 6.7 6.8 7.6 7.3 6.7 
5-6 11.2 13.1 12.2 11.2 11.3 13.0 11.4 12.1 
6-7 12.1 13.1 12.0 12.2 12.8 11.7 12.7 11.2 
1-7 15.8 14.6 17.0 15.7 17.8 15.5 16.7 16.2 
4-6 15.9 15.4 15.4 16.6 16.9 15.3 15.9 17.1 
4-5 16.8 15.6 15.7 15.7 17.3 16.8 16.4 16.3 
2-4 20.6 21.6 22.3 21.0 22.1 20.9 21.3 20.9 
1-3 20.9 22.2 22.7 21.3 21.0 20.3 20.8 21.8 
5-7 21.4 24.7 21.8 20.7 21.8 22.9 21.8 20.3 
1-6 26.0 25.4 27.8 26.6 27.7 24.4 27.1 25.8 
2-6 28.7 28.0 30.5 29.6 30.3 28.2 30.1 28.6 
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The interhelical distances of the proximal C-terminal mutants measured at 
the intracellular surface are depicted in Table 31 . The A307E mutation had 
relatively few effects on interhelical distances, increasing TM6-7 and decreasing 
TM1-4 to coincide with the N119S conformation. The K30BA mutant primarily 
altered TM7 position, increasing TM3-7, TM4-7, TM5-7, and TM6-7 interhelical 
distances. The A307E-K30BA mutation mildly altered TM1 position, resulting in 
decreases of the TM1-4 and TM1-5 interhelical distances. The A307E-F309A 
mutant primarily altered TM7 position, increasing TM3-7, TM5-7 and TM6-7 
interhelical distances, and decreasing the TM1-7 distance. K30Ba-F309A 
mutation primarily altered TM6 position, increasing interhelical distance of TM1-6, 
TM2-6, TM4-6 and TM6-7. The A307E-K30BA-F309A mutant produced 
significant variation of TM6 and TM7 position, increasing the distances of TM1-7, 
TM2-7, TM3-7, and TM4-7 and decreasing the distance of TM2-6 andTM4-6. 
Helix B mutations primarily maintained the inactive conformation of the 
receptor, although several of the mutations possessed alterations of TM 
structures. At the extracellular surface, A307E altered TM1 and TM2, A307E-
K30BA altered TM6, K30BA-F309A altered TM1 and A307E-K30BA-F309A 
altered TM6. At the intracellular surface, K30BA, A307E-F309A altered TM7, 
A307E-K30BA altered TM1 , K30BA-F309A altered TM6 and A307E-K30BA-
F309A altered TM6 and TM7.This suggests that the conformations adopted by 
the mutant structures could be more inactivated than the native structure due to 
altered interhelical distances, especially in mutants A307E-F309A and A307E-
K30BA-F309A where disruption of TM7 could alter signal transduction. 
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Table 31: Interhelical distances at the intracellular surface for the helix 8 
mutants. Interhelical distances measured at intracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and helix 
B mutant structures of averaged structures dynamically determined structures. At 
the intracellular surface, K30BA, A307E-F309A altered TM7, A307E-K30BA 
altered TM1, K30BA-F309A altered TM6 and A307E-K30BA-F309A altered TM6 
and TM7. 
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Table 31: Interhelical distances at the intracellular surface for the helix 8 
mutants. 
A307E- A307E- K308A- A307E-TM Native N119S A307E K308A K308A-K308A F309A F309A F309A 
2-6 10.7 12.9 10.5 10.9 10.7 11.3 13.4 8.9 
2-7 11.7 12.3 12.0 15.4 11.6 11.8 13.0 12.9 
3-6 12.0 13.4 11.4 11.3 11.2 11.3 11.4 13.2 
1-7 12.2 13.6 12.3 12.5 11.6 11.2 12.7 13.2 
6-7 12.3 11.8 13.3 17.6 12.8 15.1 14.0 12.7 
1-4 18.2 17.7 17.3 17.4 17.5 17.4 18.2 16.8 
4-6 19.5 17.6 18.3 18.6 18.9 19.0 21.3 17.9 
1-6 20.5 21.3 20.7 19.9 20.5 21.1 21.7 18.5 
3-7 21.5 22.2 21.5 26.7 20.4 23.2 22.6 24.4 
4-7 22.3 21.0 22.0 25.4 21.5 22.1 23.5 23.8 
5-7 24.8 23.7 24.4 28.6 24.4 26.9 25.2 24.7 
1-5 32.2 33.9 31.9 30.7 30.9 32.6 31.6 30.3 
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Mutations of the distal C-terminus alter the structure of CXCR4 at TM7. 
Mutations of the distal tail of the C-terminus primarily preserved the 
structure of the native receptor. However, several of the mutants produced 
variations of the native conformation at the extracellular and intracellular surfaces 
of the receptor. The N-terminus of the receptor was predominantly preserved 
amongst the distal C-terminal mutants, except for the R322A mutant who altered 
the N-terminal ~-sheet to a more compact structure, much like the N119S 
conformation. ECl1 was also altered by several of the mutants, with the apex of 
the loop being repositioned towards the apex of TM1 in the S338A mutant. The 
S341A and S351A mutants both shifted the apex of the loop towards the N-
terminus, while the S351A-S352A mutant shifted the apex of this loop away from 
the N-terminus. In addition, K327A, S351A, S352A, and S351A-S352A mutants 
all caused ECl3 to adopt a conformation reminiscent of the N119S conformation, 
but shifted away from the N-terminus. Thus, K327 A and S352A feature disruption 
of the CXCl12 binding pocket by distortion of ECl3, while S351A and S351A-
S352A also disrupt this structure while also modulating ECl1 structure, 
producing a more open, but potentially more unstable extracellular surface. 
At the intracellular surface of the receptor, K333A shifts the apex of ICl1 
downwards while S351A-S352A displaces the apex of the loop towards the C-
terminus. ICl2 adopts a variety of conformations in the different mutants. R322A 
and S341 A shift the apex of ICl2 into a conformation opposite that of the N119S 
structure, and away from ICl3. K327 A, K333A and S352A all feature a more 
compact conformation of the loop, which is displaced downwards from the native 
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position. There is a similar variety of positions for ICL3, with K327 A, R322A, and 
K333A shifting the apex of the loop towards the C-terminus and the center of the 
receptor, while S338A, S351A, and S352A each shift the apex of the loop away 
from the C-terminus and towards ICL2. Finally, mutants R322A, S341A, S351A, 
and S351A-S352A produce an increased angle in Helix 8, shifting the distal end 
of the helix away from the cell membrane, and displacing the loop outwards from 
the native conformation. 
Modifications of CXCR4 structure were also seen in the TM regions of the 
distal C-terminal mutations depicted in Figure 81. In the TM1 of the R322A 
mutant, the apex of the helix was displaced by a kink at Asn56, while the S352A 
mutant TM1 was displaced towards TM2. TM2 is also modulated by several of 
the mutants. In the conformation of the S338A mutant, the apex of the helix is 
shifted outwards away from the center of the receptor. In the S352A mutant 
conformation, the helix is more bowed in the direction ofTM4. In the S351A and 
S351A-S352A mutant conformations, the base of the helix aligns with the native 
conformation, but the apex of the helix is aligned with the N119S conformation. In 
the conformation of TM4 in the R322A mutant, a kink displaces the base of the 
helix, while an increased angle of TM4 at Leu165 results in an outward 
displacement of the helix in the S338A and S341A mutants. The position ofTM7 
is shifted towards TM1 in the S338A mutant. 
The interhelical distances of the native, N119S and distal C-terminal 
mutants at the extracellular surface are listed in Table 32 . The R322A mutant 
had almost no position on the interhelical distances, essentially maintaining the 
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Figure 81: Transmembrane regions of the C-terminal mutants adopt a 
similar conformation to native CXCR4. Reduced representations of receptor 
transmembrane helices are presented: native CXCR4 in green, N119S in red, the 
R322A conformation in teal, K327 A conformation in magenta, K333A 
conformation in white, S338A conformation in yellow, S341 A conformation in 
orange, S351A conformation in blue, S352A conformation in tan, and the S351A-
S352A conformation in violet. The R322A, K327 A, K333A, S338A, S341 A, 
S351A, S352A, and S351A-S352A mutant conformations adopt the 
transmembrane structure of the native receptor. A) R322A 8) K327 A C) K333A 
D) S338A E) S341A F) S351A G) S352A H) S351A-S352A 
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Figure 81: Transmembrane regions of the C-terminal mutants adopt a 
similar conformation to native CXCR4. A) R322A B) K327 A C) K333A D) 
5338A E) 5341A F) 5351A G) 5352A H) 5351A-5352A 
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Table 32: Interhelical distances at the extracellular surface for the distal C 
terminus mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and 
distal C terminus mutant structures measured in averaged conformations of 
dynamically determined structures. At the extracellular surface, K237 A altered 
TM1 and TM2, K333A alter TM1, S338A alters TM1 and TM2, S341 A alters TM3, 
S351A alters TM1 and TM2, S351A-S352A alters TM1 and TM2. 
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Table 32: Interhelical distances at the extracellular surface for the distal C 
terminus mutants. 
TM Native N1195 R322A K327A K333A 5338A 5341A 5351A 5352A 5351 A-5352A 
1-2 6.5 7.6 6.7 8.0 6.9 7.3 7.1 10.8 7.0 8.6 
1-7 15.8 14.6 16.6 16.5 17.0 19.4 16.4 16.6 16.1 18.2 
2-3 18.3 18.6 18.4 18.8 18.0 20.0 19.1 18.1 18.4 18.1 
2-7 19.1 19.3 19.8 20.5 19.7 22.6 19.9 21.8 19.7 22.2 
2-4 20.6 21.6 21.1 20.8 21.1 23.6 21.4 20.9 20.9 21.0 
1-3 20.9 22.2 21.0 22.3 21.5 22.6 21.8 22.5 21.5 22.1 
1-4 21.9 23.3 22.3 22.4 23.0 24.8 22.7 22.8 22.4 22.8 
1-6 26.0 25.4 26.7 26.7 26.4 28.6 26.5 27.6 27.2 27.1 
2-6 28.7 28.0 29.2 29.8 28.7 31.3 29.3 31.6 29.8 30.0 
1-5 33.6 34.8 34.3 34.8 33.2 36.0 34.4 35.0 33.8 34.2 
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native conformation of the receptor. More substantial alterations were seen in the 
K237A mutant, where TM1 and TM2 were displaced to produce increased 
distances in TM1-2, TM1-3, TM1-5, TM2-6, and TM2-7. K333A mutation altered 
TM1 position, increasing the TM1-4 and TM1-7 distance. S338A significantly 
altered the extracellular termini of TM1 and TM2, producing an average 
increased interhelical distance of 2.5 A for each of the helices involving TM1 and 
TM2. S341 A mutation altered the position of TM3, increasing the distance of 
TM1-3 and TM2-3. S351A mutation altered the positions of TM1 and TM2, 
increasing the distance ofTM1-2, TM1-3, TM1-5, TM1-6, TM2-6 and TM2-7. 
S352A mutation had only minor effects on the extracellular surface of the 
receptor, increasing the distance only for TM1-6. S351A-S352A mutation altered 
the positions of TM 1 and TM2 in a manner similar to the S351 A mutant, 
increasing the distance of TM1-2, TM1-3, TM1 -6, TM1-7, TM2-6 and TM2-7. 
The interhelical distances of the native, N119S and distal C-terminal 
mutants at the intracellular surface are listed in Table 33. Two of the mutants 
produced relatively little alteration of interhelical distance at the intracellular 
surface. The K327 A mutant primarily altered the position of TM6, producing 
increased interhelical distances for TM3-6, TM5-6 and TM3-7, while the K333 
mutant increased the interhelical distance of TM1-6, while decreasing the 
interhelical distance of TM4-7. The rest of the distal C-terminal mutants altered 
the position of TM7, producing significant interhelical distance variation between 
TM7 and each of the other helices. 
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Table 33: Interhelical distances at the intracellular surface for the distal C 
terminus mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and distal 
C terminus mutant structures measured in averaged conformations of 
dynamically determined structures. At the intracellular surface, R322A, S338A, 
S341A, S351A, S352A and S351A-S352A alter TM7. 
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Table 33: Interhelical distances at the intracellular surface for the distal C 
terminus mutants 
TM Native N1195 R322A K327A K333A 5338A 5341A 5351A 5352A 5351A-5352A 
1-4 18.2 17.7 17.0 17.5 17.9 18.3 17.5 17.9 18.2 19.2 
1-6 20.5 21.3 21.2 19.5 21.3 21.9 21.1 21.2 21.3 21.0 
2-7 11.7 12.3 12.4 12.1 10.9 14.1 12.5 13.7 13.2 13.1 
3-6 12.0 13.4 11.1 13.2 11.4 11.2 11.4 11.5 11.4 11.4 
3-7 21.5 22.2 22.5 22.4 19.7 25.6 22.4 25.1 25.2 22.1 
4-7 22.3 21.0 22.0 22.3 21.0 24.4 22.7 23.9 24.0 23.9 
5-6 13.3 12.7 12.6 14.3 12.9 13.3 13.1 12.6 12.6 12.8 
5-7 24.8 23.7 25.5 25.5 23.5 29.7 26.5 28.2 27.6 25.5 
6-7 12.3 11.8 14.4 12.2 12.2 17.2 14.6 16.6 16.2 13.9 
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While the distal C-terminal mutants maintain the native conformation of 
the receptor, the increased distance between TM7 and the other helices 
suggests that the receptor may have difficulty successfully transducing signals 
from the extracellular surface to the intracellular surface due to displacement of 
the TM7. 
Mutations of polar extracellular mutants alter the intracellular position of 
TM7 and the extracellular position of TM1 and TM2 
Mutations of the polar and charged groups of the extracellular surface of 
CXCR4 produced significant alteration of several facets of the extracellular 
surface. Mutation of E179A and S178A produced a more compact N-terminal 
conformation matching the N119S conformation the receptor. In contrast, S 178A-
E179A mutation produced a less compact conformation than the native receptor. 
The N192A-H281A mutation produced a compact N-terminal region matching the 
N119S conformation, as well as displacing the N-terminus of the receptor 
towards the extracellular surface of the TM region as in the N119S conformation. 
The E 179A, H281 A, N 192A-H281 A, S 178A and S 178A-E 179A-N 192A-H281 A 
mutations shifted the apex of ECL3 away from the N-terminus and outward from 
the center of the receptor. 
Several mutations of the polar and charged extracellular residues were 
demonstrated to produce a shift of the first intracellular loop towards the C-
terminus of the receptor, including mutations involving S178A and E179A, and 
the N 192A-H281 A mutations. E 179A, H281 A, N 192A-H281 A, S 178A-E 179A, 
S178A-E179A-N192A and S178A-E179A-N192A-H281A mutations shifted the 
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apex of the ICL2 away from the C-terminus and towards TM1, in a conformation 
that seems to be opposite of the N119S conformation. Two different 
conformations of ICL3 were also seen in the mutations of the polar and charged 
residues. The E 179A, H281 A and S 178A-E 179A-N 192A-H281 A mutations each 
shifted ICL3 towards the C-terminus and the center of the receptor. In contrast, 
the N 192A, N 192A-H281 A, S 178A, S 178A-E 179A, S 178A-E 179A-N 192A and 
S 178A-E 179A-H281 A mutations caused ICL3 to be shifted away from the C-
terminus and downward away from the cytoplasmic membrane. Finally, mutants 
H281A, N192A-H281A and S178A produce an increased angle in Helix 8, 
shifting the distal end of the helix away from the cell membrane, and displacing 
the loop outwards from the native conformation. 
Alterations of the conformation of the TM regions are also seen in the 
mutants of the charged and polar extracellular residues, as seen in Figure 82. 
Mutation of E179A alters TM1 such that there is increased angularity at residues 
Tyr45 and Gly55 producing angularity of the base and apex of the helix. The 
S178A mutation produces a more extended conformation of TM1. The H281A 
and N192A mutations cause the apex of TM2 to be displaced towards TM2, while 
the N 192A-H281 A and E 179A mutants possess decreased angularity at Asp84, 
producing a displacement of the apical portion of the helix. Decreased angularity 
at Leu120 displaces the base of TM3 in the E179A mutant, while the Apex of the 
mutant is displace towards TM4 in the S 178A-E 179A-N 192A mutant. The 
N 192A, H281 A, S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutations each 
produce an outward tilt of TM4. Multiple conformations of tTM5 are adopted by 
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Figure 82: Transmembrane regions of the polar/charged ECl mutants 
adopt a similar conformation to native CXCR4. Reduced representations of 
receptor transmembrane helices are presented: native CXCR4 in green, N119S 
in red, S178A conformation in yellow, E179A conformation in teal, N192A 
conformation in white, H281A conformation in blue, S178A-E179A conformation 
in tan, S178A-E179A-N192A conformation in teal, S178A-E179A-H281A 
conformation in yellow, S 178A-E 179A-N 192A-H281 A conformation in teal, and 
the N 192A-H281 A conformation in white. The S 178A, E 179A, N 192A, H281 A, 
S178A-E179A,S178A-E179A-N192A,S178A-E179A-H281A,S178A-E179A-
N192A-H281A, and N192A-H281A conformations adopt the transmembrane 
structure of the native receptor. A) S178A 8) E179A C) N192A D) H281A E) 
S178A-E179A F) S178A-E179A-N192A G) S178A-E179A-H281A H) S178A-
E 179A-N 192A-H281 A I) N 192A-H281 A 
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Figure 82: Transmembrane regions of the polar/charged ECl mutants 
adopt a similar conformation to native CXCR4. A) 5178A B) E179A C) 
N192A D) H281A E) 5178A-E179A F) 5178A-E179A-N192A G) 5178A-E179A-
H281A H) 5178A-E179A-N192A-H281A I) N192A-H281A 
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the polar extracellular mutants. An additional kink at Pro211 displaces the apex 
of TM5 outwards in the S 178A-E 179A-H281 A mutant, while the entire helix is 
displaced towards TM4 in the S178A-E179A mutant. The H281A and S178A-
E179A-N192A-H281A mutations each cause the TM5 bulge to reproduce the 
more extended structure of the N119S conformation. In contrast, the N192A and 
S178A mutants cause the TM5 bulge to adopt a tighter conformation than the 
native structure, producing outward displacement of the apical and basal termini 
of the helix. Modulation of TM6 structure is also affected by the mutants. S178A, 
N 192A, H281 A, S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutations are 
characterized by an additional kink at the base of the helix, shifting the terminus 
towards TM5. The S178A-E179A and N192A-H281A mutations each produced 
an additional angularity at Tyr255, shifting the apex of the helix towards TM5 and 
producing a more complex apical loop. S178A, E179A, S178A-E179A, N192A, 
S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutants each featured and 
additional angularity of the base of TM7 producing an outward displacement of 
the terminus. 
Several of the mutations of polar extracellular residues produced relatively 
little impact on the intrahelical distances at the extracellular termini of the TM 
regions as seen in Table 34. S178A produced increases of the TM1-2 and TM1-3 
distances, and a decrease of the TM3-5 distance, causing these distances to 
coincide with the expected interhelical distance of N119S. S178A-E179A-H281A 
and S 178A-E 179A-N 192A-H281 A had simi lar sparse influence on the 
extracellular termini of the helices, in the case of S 178A-E 179A-H281 A 
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Table 34: Interhelical distances at the extracellular surface for the polar 
extracellular mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and polar 
extracellular mutant structures measured in averaged conformations of 
dynamically determined structures. At the extracellular surface, K237 A altered 
TM1 and TM2, K333A alter TM1, S338A alters TM1 and TM2, S341A alters TM3, 
S351A alters TM1 and TM2, S351A-S352A alters TM1 and TM2. 
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Table 34: Interhelical distances at the extracellular surface for the polar 
extracellular mutants. 
S178A- N192A- S178A TM Native N119S S178A E179A N192A H281A E179A H281A E179A N192A 
1-2 6.5 7.6 7.8 8.8 7.9 6.9 8.2 11.9 7.5 
1-3 20.9 22.2 22.2 22.3 21.5 21.6 20.7 22.0 22.0 
1-4 21.9 23.3 22.6 22.4 22.3 22.7 22.4 23.5 23.3 
1-5 33.6 34.8 34.1 34.8 34.3 35.6 34.2 34.1 32.5 
1-6 26.0 25.4 27.0 27.7 25.3 27.6 26.8 27.7 25.6 
1-7 15.8 14.6 15.6 17.0 16.2 15.2 17.9 17.7 15.9 
2-3 18.3 18.6 18.6 19.8 20.9 18.7 17.9 18.1 18.8 
2-4 20.6 21.6 20.8 22.1 23.9 21.5 21.3 21.2 21.4 
2-5 34.5 34.9 34.2 36.2 37.6 36.4 35.5 34.9 33.0 
2-6 28.7 28.0 29.4 31.7 30.8 30.3 30.2 32.3 28.5 
2-7 19.1 19.3 19.2 22.3 22.2 19.0 21.7 23.1 19.5 
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increasing TM2-7, but decreasing TM3-5, while S178A-E179A-N192A-H281A 
decreased TM2-5 and increased TM4-6 to coincide with the N119S distances. 
In contrast several other mutations significantly altered these interhelical 
distances. E179A mutation significantly altered the position of TM1 and TM2, 
producing an average deviation of the interhelical distances involving these to 
helices by 1.6 and 2.2 A respectively. Similar effects were seen in N192A, where 
alteration of TM2 position increased the interhelical distances involving this helix 
by an average of 2.6 A. H281 altered the TM5 and TM6, increasing TM1-5 and 
TM2-5 by an average of 2 A, and TM1-6, TM2-6, and TM6-7 by an average of 
1.5 A. S178A-E179A mutation caused TM1-2, TM1-7, TM2-6 and TM2-7 to 
increase by an average of 2 A. The N192A-H281A mutation significantly altered 
TM1 at the extracellular surface, increasing interhelical distances involving this 
helix by an average of 2.3 A. S178A-E179A-N192A seemed to have a different 
effect from the rest of the mutations, in that it modulated TM5 position, producing 
and average decrease in interhelical distance of this helix by 1.8 A. 
Alterations of the interhelical distances at the intracellular surface are 
listed in Table 35. S178A, N192A, S178A-S179A, S178A-E179A-N192A, S178A-
E179A-H281 and S178A-E179A-N192A-H281A alter the position of the base of 
TM7, altering the average interhelical distance involving this helix by 2.9 A, 4.5 
A, 2.9 A, -1.4 A, 3.1 A and 2.6 A, respectively. 
This suggests that mutations of the extracellular polar residues alter the 
conformation of CXCR4, primarily by displacing TM7 at the intracellular surface, 
and displacement of TM1 and TM2 at the extracellular surface. 
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Table 35: Interhelical distances at the intracellular surface for the polar 
extracellular mutants. Interhelical distances measured at intracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and polar 
extracellular mutant structures measured in averaged conformations of 
dynamically determined structures. At the intracellular surface, N192A altered 
TM6 and TM7, H281A altered TM3 and TM6, N192A-H281A altered TM1, 
S178A,S178A-E179A,S178A-E179A-H281A,S178A-E179A-N192A,and 
S178A-E179A-N192A-H281 altered TM7. 
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Table 35: Interhelical distances at the intracellular surface for the polar 
extracellular mutants. 
S178A S178A S178A 
TM Native N119S S178A E179A N192 H281A S178A N192A E179A E179A E179A E179A H281A N192A H281A N192A H281A 
1-4 18.2 17.7 17.8 18.4 17.2 16.7 18.8 17.1 18.0 18.0 17.6 
1-6 20.5 21.3 21.7 20.7 22.4 20.7 20.5 21.7 21.8 21.0 20.0 
2-7 11.7 12.3 11.3 11.5 12.6 11.2 13.5 11.8 10.5 12.9 13.1 
3-5 11.5 16.5 11.7 11.5 11.9 14.3 12.4 11.5 11.5 12.2 11.7 
3-7 21.5 22.2 23.3 21.2 25.2 20.5 24.3 21.3 19.9 25.5 25.0 
4-6 19.5 17.6 18.7 18.5 19.0 20.1 19.1 19.5 19.1 17.7 18.4 
4-7 22.3 21.0 21.8 21.9 22.7 21.1 24.4 21.5 20.8 23.3 24.4 
5-7 24.8 23.7 28.4 25.8 29.5 25.0 28.2 25.0 24.1 28.1 27.1 
6-7 12.3 11.8 15.6 12.5 17.3 13.1 15.6 13.3 12.3 16.3 16.0 
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Mutations of non-polar extracellular mutants alter the extracellular 
positions of TMs. 
Mutations of the polar and charged groups of the extracellular surface of 
CXCR4 produced significant alteration of several facets of the extracellular and 
intracellular surface. V177 A-F276A, F189A-L 194A, V177 A-F189A-L 194A, 
V177A-F189A-L 194A-F276A mutations produced a more compact distal N-
terminus resembling the N119S conformation. The L 194A, V177 A and F189A-
L 194A mutations each shifted the apex of ECL 1 towards the N-terminus. 
Substantial modifications of ECL3 were noted in conjunction with the V177 A-
F276A, F189A-L 194A, V177 A-F189A-L 194A, V177 A-F189A-L 194A-F276A 
mutations, shifting the apex of the loop away from the N-terminus and outwards 
from the center of the receptor. 
At the intracellular surface of the receptor, mutations altered the 
positioning of several loop regions. V177 A, F189A, L 194A, F189A-L 194A, 
V177 A-F189A-L 194A and V177 A-F276A mutations produced a shift of ICL2 
tangential to the TM helices, but in the opposite direction from the N119S 
mutation. F276A or F189A-L 194A-F276A mutation produces an intermediate 
conformation for this loop between the native and N119S positions, while 
directing the apex of the loop towards ICL3. The F189A, L 194A, F189A-L 194A 
and V177 A-F189A-L 194A mutations each shifted the apex of ICL3 towards the 
C-terminus and the center of the receptor. In contrast, V177 A, F276A, F189A-
L 194A-F276A and V177 A-F189A-L 194A-F276A mutations shifted the apex of 
ICL3 away from the C-terminus and downward away from the cytoplasmic 
410 
membrane. V177 A mutation was associated with a more extended and distended 
C-terminal region. F189A, L 194A, V177 A-F276A and V177 A-F189A-L 194A 
mutations were also associated with and increased angle in Helix 8, shifting the 
distal end of the helix away from the cell membrane, and displacing the loop 
outwards from the native conformation. 
These mutations also significantly altered the conformations of the TM 
regions, as depicted in Figure 83. The F189A and V177 A-F276A mutations 
produced greater displacement of TM1 towards TM2. In the F276A and V177 A-
F189A-L 194A mutations, decreased angularity of Asp84 at the base of the helix 
displaces the apical termini. Several of the mutations, including V177 A, L 194A, 
F276A, F189A-L 194A, F189A-L 194A- F276A, V177 A-F276A and V177 A-F189A-
L 194A-F276A displaced the apex and base of TM4 by producing an increased 
outward tilt of the helix. In the L 194A and F276A mutations, the bulge of TMS 
was in a tighter conformation than the native, producing an outward displacement 
of the basal terminus. In contrast, the F189A-L 194A-F276A mutation produced a 
more extended bulge in the mode of N1 19S. The F276A and F189A-L 194A 
mutations exhibited increased at Tyr2SS, shifting the apex of the helix towards 
TMS. L 194A and V177 A-F276A mutations exhibited an additional angularity of 
Phe249, shifting the base of the helix towards TMS. Finally, V177 A, F189A, 
L 194A, F276A, V177 A-F189A-L 194A and F189A, L 194A, V177 A-F276A 
mutations exhibited an additional angularity at Pro299, shifting the base of the 
helix outwards from the center of the receptor. 
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Figure 83: Transmembrane regions of the non-polar ECl mutants adopt a 
similar conformation to native CXCR4. Reduced representations of receptor 
transmembrane helices are presented: native CXCR4 in green, N119S in red, the 
V177 A conformation in teal, F189A conformation in yellow, L 194A conformation 
in white, F276A conformation in magenta, V177 A-F276A conformation in orange, 
V177 A-F189A-L 194A conformation in teal , V177 A-F189A-L 194A-F276A 
conformation in tan, F189A-L 194A conformation in violet, and the F189A-L 194A-
F276A conformation in aqua. The V177 A, F189A, L 194A, F276A, V177 A-F276A, 
V177 A-F189A-L 194A, V177 A-F189A-L 194A-F276A, F189A-L 194A, and F189A-
L 194A-F276A conformations adopt the transmembrane structure of the native 
receptor. A) V177A 8) F189A C) L 194A D) F276A E) V177A-F276A F) V177A-
F189A-L 194A G) V177A-F189A-L 194A-F276A H) F189A-L 194A I) F189A-
L 194A-F276A 
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Figure 83: Transmembrane regions of the non·polar ECl mutants adopt a 
similar conformation to native CXCR4. A) V177A B) F189A C) l194A D) 
F276A E) V177A·F276A F) V177A·F189A·l194A G) V177A·F189A·l194A· 
F276A H) F189A·l194A I) F189A·l194A·F276A 
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Several of the mutations of non-polar extracellular residues significantly 
altered intra helical distances at the extracellular termini of the TM regions as 
seen in Table 36. Apical TM1 position was altered by the V177 A, L 194A, V177 A-
F276A and V177 A-F189A-L 194A-F276A mutations producing an average 
increase in interhelical distance of 1.5, 1.9, 1.8, and 2.3 A, respectively. The apex 
of TM2 was significantly altered by the F189A-L 194A mutation increasing the 
intrahelical distances by an average of 1.8 A. The F189A and F189A-L 194A-
F276A mutations each altered the apical position of TM5, decreasing interhelical 
distances by 1.3 and 1.2 A, while L 194A mutation increased the interhelical 
distances involving TM5 by an average of 2 A. 
Interhelical distances produced by the non-polar mutants at the 
intracellular surface are depicted in Table 37. Mutation of V177 A produces an 
average decrease of interhelical distances involving TM3 of 1.5 A. The mutation 
of F276A modulates the position of TM5, increasing interhelical distances 
involving this helix by an average of 2.1 A. The F189A mutation displaces TM7 to 
increase its interhelical distances by an average of 3.4 A. In contrast, L 194A and 
V177 A-F189A-L 194A-F276A mutations each decrease the TM7 associated 
interhelical distances by 2.1 and 1.2 A respectively. The remaining mutants 
maintain the native interhelical distances. 
Although the non-polar mutants of the extracellular surface of CXCR4 
mutants primarily maintain the native conformation of the receptor, several key 
differences exist. Although the conformations of the extracellular loops and 
transmembrane helixes are primarily in the native conformation, several of the 
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Table 36: Interhelical distances at the extracellular surface for the non-
polar extracellular mutants. Interhelical distances measured at extracellular 
termini of transmembrane domains of native CXCR4, constitutively active N119s, 
and non-polar extracellular mutant structures measured in averaged 
conformations of dynamically determined structures. A) V177 A, L 194A, F189A-
L 194A, V177 A-F276A, and V177 A-F189A-L 194A-F276A alter TM1 conformation. 
S) F189A, L 194A, F276A, F189A-L 194A, V177A-F276A, F189A-L 194A-F276A, 
V177 A-F189A-L 194A, and V177 A-F189A-L 194A-F276A alter TM5 conformation. 
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Table 36A: Interhelical distances at the extracellular surface for the polar 
extracellular mutants. 
V177A-
TM Native N119S V177A L194A F189A- V177A- F189A-L194A F276A L194A-
F276A 
1-2 13.4 11.9 13.4 13.3 12.3 13.7 13.5 
1-3 24.6 25.7 23.0 24.1 24.2 24.6 24.2 
1-4 18.2 17.7 17.8 18.0 16.9 18.2 16.7 
1-5 32.2 33.9 31.0 31.9 31.4 32.2 31.3 
1-6 20.5 21.3 20.2 21.0 20.6 20.9 20.7 
1-7 12.2 13.6 12.0 12.0 12.2 11.8 12.7 
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Table 36B: Interhelical distances at the extracellular surface for the polar 
extracellular mutants. 
F189A V177A- V177A-
TM Native N119S F189A L194A F276A F189A V177A L194A F189A- F189A-L194A F276A L194A-F276A L194A F276A 
1-5 33.6 34.8 33.1 36.1 33.6 33.5 35.8 32.6 33.9 33.4 
3-5 20.5 19.9 19.1 20.7 19.1 18.5 19.5 19.4 19.2 19.0 
4-5 16.8 15.6 15.6 17.4 15.9 16.0 16.7 16.4 17.4 16.1 
5-7 21.4 24.7 20.7 23.2 22.3 20.1 21.3 20.0 22.2 20.9 
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Table 37: Interhelical distances at the intracellular surface for the non-polar 
extracellular mutants. Interhelical distances measured at extracellular termini of 
transmembrane domains of native CXCR4, constitutively active N119s, and non-
polar extracellular mutant structures measured in averaged conformations of 
dynamically determined structures. A) V177 A, V177 A-F189A-L 194A-F276A, 
F189A, F189A-L 194A, F189A-L 194A-F276A, and F276A each alter the position 
of TM1. 8) V177 A, F189A-L 194A, F189A-L 194A-F276A, F276A, F189A, L 194A, 
and V177 A-F189A-L 194A-F276A each alter the position of TM7. 
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Table 37A: Altered TM1 interhelical distances at the extracellular surface 
for the polar extracellular mutants. 
V177A F189A F189A F189A-TM Native N119S V177A L194A F189A L194A L194A L194A F276A 
F276A F276A 
1-4 18.2 17.7 17.8 16.7 17.2 16.9 18.1 18.0 17.9 
1-5 32.2 33.9 31.0 31.3 30.7 31.4 31.8 31.9 34.6 
1-6 20.5 21.3 20.2 20.7 21.0 20.6 21.6 21.0 22.1 
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Table 378: Altered TM7 interhelical distances at the extracellular surface 
for the polar extracellular mutants. 
F189A V177A 
TM Native N119S V177A F189A L194A F276A F189A L194A F189A L194A F276A L194A F276A 
2-7 11.7 12.3 11.8 12.6 11.5 11.5 14.9 11.0 10.6 
3-7 21.5 22.2 20.1 22.7 20.4 21.8 25.3 19.1 20.4 
4-7 22.3 21.0 22.0 22.4 21.8 21.5 25.0 21.5 20.9 
5-7 24.8 23.7 24.0 25.3 24.5 27.6 27.3 22.9 23.3 
6-7 12.3 11.8 12.3 13.9 12.7 14.0 16.8 12.0 11.6 
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loops are modified the conformations of the extracellular and intracellular loops. 
The cases of the F189A, l1 94A, V177 A-F276A and V177 A-F189A-l 1 94A 
mutations are particularly interesting as these mutations result in a significant 
increase in the angularity of Helix 8, shifting the base of the helix away from the 
intracellular surface of the receptor. These changes are reflected in alterations of 
the interhelical distances of the TM1 and TM5 of the extracellular surface of the 
receptor, and Tm1 and Tm7 on the intracellular surface of the receptor. 
Influence of ECl Mutants on CXCl12-mediated chemotaxis. 
In light of the modifications of native CXCR4 structure produced by the 
mutations of ECl residues, we attempted to generate stable cell lines expressing 
mutated strains of CXCR4 by site directed mutagenesis. Unfortunately, we were 
only able to generate stably transfected cell lines for the N192A, F276A, H281A, 
V177A-F276A, V177A-F189A-l194A, S178A-E179A-H281A, and S178A-E179A-
N192A-H281A mutants. 
We did find that several of these mutants displayed significant reductions 
in chemotaxis as seen in Table 38. Dose response analysis of the mutant 
CXCR4 expressing cell lines to treatment with CXCl12, demonstrated that the 
maximal chemotaxis of the V177 A-F276A, S 178A-E 179A-H281 A, S 178A-E 179A-
N192A-H281A, N192A and H281A each produced significant reductions in 
chemotaxis when compared to wild type CXCR4. Maximal chemotaxis response 
of the N192A mutant was produced by treatment with 10 nM treatment with 
CXCl12, producing a maximal response 37% of the wild type maximal response. 
Maximal chemotaxis response of the V177 A-F276A, S 178A-E 179A-H281 A and 
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Table 38: Mutation of extracellular residues of CXCR4 alters chemotaxis. 
Significant reductions of CXCL 12-induced chemotaxis were produced by V177 A-
F276A, S 178A-E 179A-H281 A, S 178A-E 179A-N 192A-H281 A, and N 192A 
mutations. V177A-F189A-L 194A, F276A, and H281A mutations maintained WT 
amplitude of chemotaxis .. 
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Table 38: Mutation of extracellular residues of CXCR4 alters chemotaxis. 
Strain Maximal Chemotaxis St. Dev. Concentration index 
WT 10 1 0.27 
V177 A-F189A-L 194A 20 1.01 0.19 
V177 A-F276A 20 0.20 0.19 
S178A-E179A-H281A 20 0.44 0.014 
S178A-E179A-N192A-H281A 20 0.10 0.13 
N192A 10 0.37 0.17 
F276A 20 1.47 1.32 
H281A 10 1.29 0.82 
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S178A-E179A-N192A-H281A mutants was achieved with 20 nM of CXCL 12, 
producing a response which was 17%, 44% and 12% of WT. Each of these 
mutations had produced alterations of TM7 interhelical distances at the 
intracellular surface of the receptor suggesting impaired signal transduction 
capabilities in the molecular dynamics studies. 
These poor chemotaxis responses were in contrast to the results seen for 
the V177A-F189A-L 194A, F276A, and H281A mutations. In these cases, 
maximal chemotaxis response at 20 nM produced migrations of 100%, 125%, 
and 150% of wild type. In the case of H281A, this mutant shared many dynamics 
characteristics with the inactive S 178A-E 179A-N 192A-H281 A in that both 
mutants primarily maintained the native conformation of the receptor and shifted 
the apex of ICL3 towards the C-terminus and the center of the receptor. The only 
noted differences were that H281A shifted the apex of the N-terminus outwards 
from the center of the receptor and away from the N-terminus and the angle 
taken at the origin of Helix 8 shifted the base of that helix away from the 
cytoplasmic membrane. The V177 A-F189A-L 194A and F276A mutants did not 
share any common features in the dynamics simulations either. 
Effects of ICL mutants on CXCL 12-mediated chemotaxis. 
We also attempted to generate site directed mutations of ICL residues 
highlighted in the virtual redocking program. However, difficulties in plasmid 
generation, and cell line stability meant that the mutated cell lines available for 
initial CXCL 12 dose response testing were limited to K234A, K239A, K239A-
T240A, A307E-K308A, A307E-K308A-F309A, S341A, S351A and S351A-S352A. 
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Several of these mutants were found to have a significantly reduced 
chemotaxis response to CXCL 12, as seen in Table 39. The K234A, K239A-
T240A, A307E-K30BA, A307E-K30BA-F309A, and S351A mutants each 
expressed significant reduction in chemotaxis response when compared to WT. 
The A307E-K30BA and S351A-S352A mutants produced no significant 
chemotaxis at any of the screened concentrations of CXCL 12. 
The C-terminal serine residues are essential to CXCR4 function through 
truncation mutants [342] and site directed mutagenesis [352] , so it is not 
surprising that loss of these residues would impair chemotaxis. Mutations of helix 
eight have not been demonstrated to adversely affect CXCR4 function, and in 
fact disruption of this helix is one of the characteristics of the constitutively active 
mutants. But perhaps it is because in the constitutively active mutants the center 
of the helix is disrupted, while the mutations of the apex of the helix near the 
base of TM7 continue to maintain helical conformation. 
The K234A, K239A-T240A and A307E-K30BA-F309A mutants each 
migrate in response to CXCL 12 although at a much reduced rate compared to 
the WT strain, with maximal chemotaxis at 20 nM CXCL 12 producing chemotaxis 
which was only 40 % and 5% of WT for the K234A and A307E-K30BA-F309A 
mutants and maximal response at 10 nM for the K239A-T240A of only 20% of 
WT. This suggests that ICL2 residues K234, K239 and T240 playa significant 
role in transduceing the signal from the extracellular surface to the intracellular. 
Effects of CXCR4 mutants on CXCL 12-mediated calcium mobilization. 
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Table 39: Mutation of intracellular residues of CXCR4 alters chemotaxis. 
Significant reductions of CXCL 12-induced chemotaxis were produced by K234A, 
K239A-T240A, A307E-K308A, A307E-K308A-F309A, and S351A mutations. 
K239A mutation maintained the amplitude of the CXCL 12-induced chemotaxis 
response, while S341A and S351A-S352A mutation significantly increased 
CXCL 12 induced Chemotaxis. 
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Table 39: Mutation of extracellular residues of CXCR4 alters chemotaxis. 
Maximal Chemotaxis 
Strain Concentration index St. Dev. 
WT 10 1 0.27 
K234A 20 0.40 0.30 
K239A 20 1.1 0.7B 
K239A-T240A 10 0.20 0.063 
A307E-K30BA 20 0.0053 0.0033 
A307E-K30BA-F309A 10 0.054 0.060 
8341A 10 4.30 0.93 
8351A 1 0.095 0.14 
8351 A-8352A 10 1.53 0.20 
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Several hCXCR4-GFP mutants were generated targeting residues 
identified in the virtual re-docking analysis to see what impact loss of these 
contact residues would have on the activity of active CXCR4 inhibitors. We 
investigated the impact of these mutations on cell signaling via intracellular 
calcium mobilization. We were able to generate cell lines and perform 
intracellular calcium mobilization testing for the following extracellular hCXCR4-
GFP mutants: N192A, F276A, H281A, V177A-F276A, V177A-F189A-L 194A, 
S179A-E179A-H281A, and S179A-E179A-N192A-H281A. We were also able to 
generate cell lines and perform intracellular calcium mobilization testing for the 
following intracellular mutants: K234A, K239A, K239A-T240A, A307E-K308A, 
A307E-K308A-F309A, S341A, S351A and S351A-S352A. The impact of the 
extracellular mutants on CXCL 12 mediated signaling was assessed in terms of 
signal amplitude and maximal CXCL 12 concentration. Table 40 depicts the 
maximal CXCL 12 concentrations and invoked calcium responses for the 
extracellular mutants. Three of these mutants, N 192A, F276A and V177 A-
F189A-L 194A, maintained a maximal CXCL 12 concentration of 10 nM. The 
H281 A, V177 A-F276A, S 179A-E 179A-H281 A and S 179A-E 179A-N 192A-H281 A 
mutations each increased maximal CXCL 12 concentration to 20 nM. Calcium 
response was then assessed, and normalized to the maximal response produced 
by WT CXCR4. Maximal calcium response was reduced by the N192A, F276A, 
V177A-F276A, S179A-E179A-H281A and S179A-E179A-N192A-H281A. The 
H281A and V177A-F189A-L 194A mutants both maintained the calcium 
mobilization of WT CXCR4. 
429 
Table 40: Mutation of extracellular residues of CXCR4 alters CXCL 12-
induced calcium mobilization. Calcium response is presented as maximum 
amplitude of calcium signal normalized to the maximal response of WT CXCR4. 
Calcium response was reduced by N192A, F276A, V177A-F276A, S179A-
E 179A-H281 A and S 179A-E 179A-N 192A-H281 A mutations. H281 A and V177 A-
F189A-L 194A mutants both maintained the calcium mobilization of WT CXCR4. 
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Table 40: Mutation of extracellular residues of CXCR4 alters CXCL 12-
induced calcium mobilization. 
Mutant Maximal Calcium St. Dev. 
concentration Mobilization 
WT 10 0.92 0.22 
N192A 10 0.37 0.17 
F276A 10 0.78 0.46 
H281A 20 1.24 1.15 
V177 A-F276A 10 0.26 0.18 
V177 A-F189A-L 194A 20 1.01 0.19 
S179A-E179A-H281A 20 0.44 0.01 
S179A-E179A-N192A- 20 0.10 0.13 H281A 
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The impact of the intracellular mutants on CXCL 12 mediated signaling 
was assessed in terms of signal amplitude and maximal CXCL 12 concentration. 
Table 41 depicts the maximal CXCL 12 concentrations and invoked calcium 
responses for the extracellular mutants. Three of these mutants, K239A-T240A, 
A307E-K308A-F309A and S351A-S352A maintained a maximal CXCL 12 
concentration of 10 nM. The H K234A, K239A, A307E-K308A, S341A and S351A 
mutations each increased maximal CXCL 12 concentration to 20 nM. Calcium 
response was then assessed , and normalized to the maximal response produced 
by WT CXCR4. Maximal calcium response was reduced by the K234A, K239A, 
K239A-T240A, and A307E-K308A-F309A. The S341A and S351A-S352A 
mutants both enhanced calcium mobilization when compared to WT CXCR4. 
A307E-K308A and S351A mutants did not effectively transmit calcium signaling. 
The impact of hCXCR4-GFP extracellular mutants on the activity of active 
CXCR4 inhibitors of intracellular calcium mobilization was then assessed. 
Compounds were tested using the maximal CXCL 12 concentration for each 
mutant, and results were normalized for each mutant to a DMSO alone control. 
Results were prepared for available mutants; however, due to difficulty in 
successful generation of PCR based site directed mutant plasmid generation and 
difficulties in generation and maintenance of single cell derived cell lines stably 
expressing the plasmid protein, only select mutants were available for study. 
The V177 A-F276A mutation produced an interesting phenotypical 
difference when compared to wild type, as depicted in Figure 84. Mutation of 
these two residues resulted in active inhibition of intracellular calcium 
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Table 41: Mutation of intracellular residues of CXCR4 alters calcium 
mobilization. Significant reductions of CXCL 12-induced chemotaxis were 
produced by K234A, K239A-T240A, A307E-K308A, A307E-K308A-F309A, and 
S351A mutations. K239A mutation maintained the amplitude of the CXCL 12-
induced chemotaxis response, while S341A and S351A-S352A mutation 
significantly increased CXCL 12 induced Chemotaxis. 
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Table 41: Mutation of intracellular residues of CXCR4 alters calcium 
mobilization. 
Mutant Maximal Calcium St. Dev. 
concentration Mobilization 
WT 10 0.92 0.22 
K234A 20 0.40 0.30 
K239A 20 0.65 0.19 
K239A-T240A 10 0.1B O.OB 
A307E-K30BA 20 0.01 0.00 
A307E-K30BA-F309A 10 0.05 0.06 
S341A 20 2.07 0.41 
S351A 20 0.01 0.00 
S351 A-S352A 10 1.53 0.20 
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Figure 84: ECLV514 and EV514·2·AB produce greater calcium inhibition in 
V177 A·F276A mutant CXCR4. V177 A-F276A mutation produces greater 
inhibition of calcium mobilization by ECLVS14 and EVS14-2-AB. EVS-2-AB 
demonstrated a significant reduction in intracellular calcium mobilization, with a 
nearly two-fold decrease in signaling at 50 !-1M. Unpaired samples denoted by * 
have no WT counterpart because lack of screening activity did not warrant dose 
response testing. 
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Figure 84: ECLVS14 and EVS14·2·AB produce greater calcium inhibition in 
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mobilization by EClVS14, a compound with no such activity in wild type cells. In 
V177 A-F276A CXCR4 cells, the IC50 of this activity is roughly 40 I-IM, compared 
to no significant inhibition in Wild type cells, suggesting that interaction with the 
valine and phenylalanine residues in the wild type protein influences the manner 
in which EClVS14 alters downstream signaling. Similarly, while not achieving 
significant inhibition of intracellular calcium mobilization, the V177 A-F276A 
mutation produced a greater than two fold decrease in signal amplitude for 
compound EVS14-2-AB at 50 I-IM. In contrast, EClVS59 and EClVS82 both 
inhibited intracellular calcium mobilization in V177 A-F276A CXCR4 cells, while 
neither EVS14-21 nor EVS14-22 displayed a substantial increase in inhibition. 
The V177 A-F189A-l 194A mutation produced several noteworthy 
phenotypical alterations, as depicted in Figure 85. Unlike the V177 A-F276A 
mutation, this mutation did not produce significant inhibition of intracellular 
calcium mobilization by EClVS14, although signaling was reduced almost two-
fold by V177 A-F189A-l 194A mutation. A similar increase in compound mediated 
inhibition was seen for EVS-2-AB, ·with an almost two fold increase in signaling 
inhibition, but no significant inhibition of intracellular calcium mobilization. 
Conversely, th is mutation caused compound EVS-21 to produce a significant 
increase in intracellular calcium mobilization, with a greater than 2.5 fold 
increase in signaling compared to DMSO alone control. This mutation also 
produced a reduction in activity of compound ECl VS59, which while remaining a 
significant inhibitor of calcium mobilization, saw a decrease in IC50 from 5 I-IM for 
Wild type CXCR4 to 10 I-IM for the V177 A-F189A-l 194A mutant. 
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Figure 85: EVS14-21 produces greater calcium mobilization in V177A-
F189A-L 194A mutant CXCR4. EVS14-21 treatment in cells expressing the 
V177 A-F189A-L 194A mutant produce an almost two and a half fold increase in 
CXCL 12-induced signaling. Inhibitory activity of ECLVS14 and EVS-2-AB is 
increased almost two-fold compared to WT. Unpaired samples denoted by * have 
no WT counterpart because lack of high concentration activity did not warrant 
dose response testing . 
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Figure 85: EVS14-21 produces greater calcium mobilization in V177A-
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N192A mutation produced relatively few phenotypic changes in compound 
function , as depicted in Figure 86. The only two differences involved improved 
but still not significant inhibition of intracellular calcium mobilization by ECl VS 14 
and EVS-2-AB. Mutation of this residue produced a roughly 1.5 fold decrease in 
signaling for EClVS14 and a roughly 2.5 fold decrease in signaling for EVS-2-
AB . 
F276A mutation produced relatively few phenotypic changes in compound 
function , as depicted in Figure 87. Two differences involved improved but still not 
significant inhibition of intracellular calcium mobilization by EClVS14 and EVS-2-
AB. Mutation of this residue produced a roughly 1.5 fold decrease in signaling for 
EClVS14 and a roughly 2 fold decrease in signaling for EVS-2-AB. 
H281A mutation produced relatively few phenotypic changes in compound 
function , as depicted in Figure 88. Two differences involved improved but still not 
significant inhibition of intracellular calcium mobilization by ECl VS 14 and EVS-2-
AB. Mutation of this residue produced a roughly 2 fold decrease in signaling for 
EClVS14 and a roughly 2.5 fold decrease in signaling for EVS-2-AB. 
S178A-E179A-N192A-H281A mutation produced several interesting 
alterations in compound phenotypes, as depicted in Figure 89. While compound 
ECl VS59 activity remained relatively consistent between mutant and wild type, 
inhibition by EClVS14, EVS-21 , EVS-22, and EVS-2-AB was significantly 
enhanced , such that all four compounds produced significant inhibition of 
intracellular calcium mobilization, when compared to DMSO alone control. 
EClVS14 exhibited an IC50 of - 35, and EVS-21 , EVS-22, and EVS-2-AB 
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Figure 86: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium 
mobilization in N192A mutant CXCR4. ECLVS14 and EVS-2-AB achieve an 
over one and a half fold reduction in CXCL 12 induced calcium signaling and a 
nearly three-fold reduction in signaling for EVS-2-AB. Unpaired samples denoted 
by * have no WT counterpart because lack of high concentration activity did not 
warrant dose response testing. 
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Figure 86: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium 
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Figure 87: ECLV514, EV514-21, EV514-22, and EV514-2-AB produce 
greater inhibition of calcium mobilization in 5178A-E179A-N192A-H281A 
mutant CXCR4. EClVS14, EVS-21 , EVS-22, and EVS-2-AB achieve significant 
inhibition of CXCl12-mediated intracellular calcium mobil ization in cells 
expressing S 178A-E 179A-N 192A-H281 A mutant CXCR4. ECl VS 14 was 
improved to an IC5a of 35IJM while EVS-21 , EVS-22 and EVS-2-AB each 
displayed IC5a values of less than 1 a IJM. Unpaired samples denoted by * have 
no WT counterpart because lack of high concentration activity did not warrant 
dose response testing. 
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Figure 87: ECLV514, EV514-21, EV514-22, and EV514-2-AB produce 
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Figure 88: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium 
mobilization in F276A mutant CXCR4. EClVS14 and EVS-2-AB achieve 
significant inhibition of CXCl12-mediated intracellular calcium mobilization in 
cells expressing F276A mutant CXCR4. ECl VS 14 and EVS-2-AB achieve a 
nearly two-fold reduction in signaling for ECl VS 14, and a two-fold reduction in 
signaling for EVS-2-AB. Unpaired samples denoted by * have no WT counterpart 
because lack of high concentration activity did not warrant dose response testing. 
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Figure 88: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium 











Figure 89: EVS14-2-AB produce greater inhibition of calcium mobilization 
in H281A mutant CXCR4. EVS-2-AB achieves an over two and a half fold 
reduction in CXCL 12 signaling. Unpaired samples denoted by * have no WT 
counterpart because lack of high concentration activity did not warrant dose 
response testing 
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Figure 89: EVS14·2·AB produce greater inhibition of calcium mobilization 
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produced IC50 values of 10 !-1M or less. loss of the charged contact residues in 
the S 178A-E 179A-N 192A-H281 A mutation allows ECl VS 14 and its derived 
compounds to inhibit intracellular calcium mobilization to a substantially greater 
degree than seen in wild type CXCR4, suggesting that interaction with these 
residues influences the magnitude of the inhibition by these compounds, as well 
as the specificity of their activity. 
Difficulty in successful generation of site-directed mutant plasmids and 
stably transfected cell lines meant that only one of the six desired intracellular 
mutant cell lines, K239A, was generated for compound testing as depicted in 
Figure 90. There was no significant difference in IClGa9, IClGa13 or IClGa36 
mediated inhibition of intracellular calcium mobilization in K239A or WT cells. 
However, K239A mutation produced a 2.4 fold decrease in IClGa12 activity at 
50 !-1M, and a 2.7 fold decrease in IClGa12 activity at 10 !-1M. From this limited 
data, it suggests that lyseine 239 on the second intracellular loop is important to 
IClGa12-mediated inhibition of intracellular calcium mobilization. 
Due to difficulty in producing stable CXCR4 mutants, there is a limited 
volume of mutations from which to compare the data between the experimental 
protocols exploring the effect of mutation of CXCR4 on chemotaxis and calcium 
mobilization. However, some important conclusions can be drawn, as can be 
seen in Table 42 . The S341A and S351A-S352A mutants each produced 
increased amplitude of response to CXCl12 induced chemotaxis and calcium 
mobilization. Like many of the inactive mutations, these mutants featured a 
displacement of TM7, and helix eight adopted an angle, displacing the distal 
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Figure 90: ICLGa12 produces greater inhibition of calcium mobilization in 
K239A mutant CXCR4. Mutation of this residue significantly increased CXCL 12-
induced signaling for ICL VS 12 at 10 IJM and 50 IJM, increasing the IC50 of this 
compound from 5 IJM in WT CXCR4 to 35 IJM in the K239A strain . 
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Figure 90: ICLGa12 produces greater inhibition of calcium mobilization in 
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Table 42: Comparison of Mutant Molecular Dynamics and Experimental 
data. Comparing the molecular dynamics and experimental data for the CXCR4 
mutants developed by site directed mutagenesis, we find that while the mutants 
primarily maintained the native conformation of CXCR4, each of the mutants 
produced alteration of the dynamically determined structure of CXCR4. Of the 
mutants developed by SDM, only the V177 A-F189A-L 194A and H281 A mutants 
reproduced WT chemotaxis and calcium mobilization activity. Two of the mutants 
were hypersensitive to CXCL 12, two displayed no activity in Chemotaxis or 
Calcium mobilization, and the remaining mutants displayed reduced CXCR4 
activity. 
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Table 42: Comparison of Mutant Molecular Dynamics and Experimental data. 
Molecular Dynamics Experimental 
Mutant 
Primary 
ECl ICl EC IC Chemotaxis Calcium Conformation TM TM Flux 
Vl77A-
N-term, ICl3, Fl89A- Native TM5 none WT WT 
ll94A 
ECl3 C-term 
Vl77A- N-term, ICl2, 
F276A 
Native ECLl, Helix 8 TM 1 TM l decreased decreased 
ECl3 
Sl78A- N-term, ICI2, E179A- Native none TM7 decreased decreased 
H28lA ECLl ICl3 
Sl78A-
ICLl, El79A-
Nl92A- Native none ICl2, none TM7 decreased decreased 
H28lA ICl3 
Nl92A Native ECll ICl3 TM2 TM6, decreased decreased TM7 
ICLl, 
F276A Native none ICl2, TM5 none WT decreased 
ICl3 
ICl2, TM3, TM5, H28lA Native ECl3 ICl3, WT WT 
Helix 8 TM4 TM6 
K234A Native N-term ICl3 TMl, TM5 none decreased decreased 
ICl2, TMl, K239A Native N-term ICl3 none TM4, WT decreased TM6 
K239A- ICLl, TM6, 
T240A Native ECl3 ICl2, TM6 TM7 decreased decreased ICl3 
A307E- Native ECLl ICl2, TM6 TMl Inactive K308A ICl3 Inactive 
A307E-
TM6, K308A- Native None ICl3 TM7 Inactive Inactive 
F309A TM7 
S34lA Native ECLl, Helix 8 TM3 TM7 Increased Increased 
ICl2, TM1, S35lA Native ECLl ICl3, TM7 Inactive Inactive 
Helix 8 TM2 
S35lA-
Native ElC3 ICLl, TM1, TM7 Increased Increased S352A Helix 8 TM2 
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portion of the helix away from the cytoplasmic membrane. However, in contrast 
to many of the other inactive mutants, these two preserved the structure and 
conformation of their intracellular loops with minimal displacement from the 
native conformation. Decreased chemotaxis and calcium mobilization activity. In 
many of the mutants is associated with alteration of the ICL conformations from 
the native. 
In vivo testing of anti-CXCR4 compounds in a metastatic model reveals 
significant anti-metastatic activity. 
Experiments conducted by Dr. Rajesh Sharma sought to establish the 
activity of anti-CXCR4 compounds in a CXCR4 dependant lung tumor metastasis 
model. Initial development of the model centered on identifying CXCR4 cell 
surface expression by a series of metastatic cell lines including Lewis lung 
carcinoma cells, B16F10 melanoma cells, and TC-1 cervical carcinoma cells. Of 
these, TC-1 cells expressed the most cell-surface CXCR4, as illustrated in Figure 
91 a. This result is in line with prior research , demonstrating cidofovir anti-
metastatic activity in TC-1 cells via inhibition of CXCR4 signaling [353]. Lewis 
lung carcinoma cells did not express elevated cell surface concentrations of 
CXCR4, also illustrated in Figure 91 b. 
Three compounds, ECLVS14, ICLGa28, and ICLGa36 were initially 
assessed for in vivo cytotoxicity. These three represented the best of the anti-
CXCR4 compounds targeting the extracellular and intracellular surface of the 
receptor. All three produced almost no cytotoxicity and selectively inhibited 
CXCR4 mediated chemotaxis with chemotaxis IC50 values of 5 IJM for 
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Figure 91: TC-1 cells express increased cell surface CXCR4. TC-1 cells (A) 
express increased cell surface CXCR4 when compared to Lewis Lung carcinoma 
cells (8). Expression of CXCR4 expression of 50 for TC-1 cells compared to 10 
for Lewis Lung carcinoma cells suggests that TC-1 cells would be more 
responsive the CXCR4 targeted inhibitors than Lewis Lung carcinoma cells. 
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Figure 91: TC-1 cells express increased cell surface CXCR4. 
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ECLVS14, 1 IJM for ICLGa28 and 1 IJM for ICLGa36. ICLGa28 and ICLGa36 
also significantly inhibited CXCL 12-induced intracellular calcium mobilization with 
IC50 values of 10 IJM and 6 IJM respectively. In vivo cytotoxicity was initially 
assessed at 5 mg/kg body weight, 20 mg/kg body weight, and 40 mg/kg body 
weight. None of these concentrations produced gross toxicity, as would be 
exhibited by weight loss, physiological distress, overt illness, or lethargy over a 
period of three weeks. 
Further investigation using the Lewis lung carcinoma model revealed that 
in a cell line with reduced surface expression of CXCR4, anti-CXCR4 compounds 
do not inhibit metastasis (Figure 92). Investigation of the anti-CXCR4 compounds 
using the TC-1 metastasis model compared ECLVS14, ICLGa28 and ICLGa36 
mediated inhibition of tumor incidence and lung tumor burden to known inhibitor, 
AMD31 00. As seen in Figure 93, all three compounds significantly reduced tumor 
incidence and tumor burden. ECLVS14 produced a roughly 60% improvement in 
tumor incidence when compared to AMD31 DO, while ICLGa28 and ICLGa36 
produced roughly equivalent reductions in incidence. Average tumor burden in 
ECLVS14 treated mice was reduced by more than 60%, while reduction in tumor 
burden was reduced by nearly 50% for AMD31 DO, ICLGa28 and ICLGa36. This 
data confirms that these compounds are effective inhibitors of metastasis. 
Summary 
In the SBDD process, identification and characterization of active 
compounds, illustrated in Chapters II and III , is followed by rationalization of 
target protein structure and testing of lead compounds in in vivo models to 
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Figure 92: Lewis lung cancer cell metastasis is not altered by anti-CXCR4 
compounds. Usage of Lewis lung cancer cells in an in vivo metastasis model 
reveals that treatment with anti-CXCR4 compound AMD3100 does not alter 
tumor incidence or tumor burden. 
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Figure 92: Lewis lung cancer cell metastasis is not altered by anti-CXCR4 
compounds. 
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Figure 93: Treatment with lead compounds ECLVS14, ICLGa28 and 
ICLGa36 each reduce tumor incidence and tumor burden of TC-1 cells in a 
syngenic mouse model of lung cancer metastasis. ECLVS14 reduced tumor 
burden and incidence to a 60 % greater extent than AMD3100. ICLGa28 and 
ICLGa36 each inhibited tumor incidence and burden to the same extent as 
AMD3100, with each compound reducing tumor incidence and tumor burden by 
50 %. 
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Figure 93: Treatment with lead compounds ECLVS14, ICLGa28 and 
ICLGa36 each reduce tumor incidence and tumor burden of TC·1 cells in a 
syngenic mouse model of lung cancer metastasis. 
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potentially translate the research from the laboratory to the clinic. In this chapter, 
we have used a virtual redocking protocol based on Surflex-Dock to identify 
residues of CXCR4 where interaction with active anti-CXCR4 compounds could 
elicit a modification of phenotype. We sought to mutate these residues, in silico 
through molecular dynamics simulations and in vitro through site directed 
mutagenesis, to investigate whether or not mutations of these residues could 
induce a change in structural conformation or an altered phenotype of CXCR4. 
Virtual redocking identified eight contact residues for the ECl VS compounds, 
and six contact residues for the IClGa compounds. Additional intracellular 
mutants were generated based on contact residues between CXCR4 and Gai 
identified in the dynamically docked structure of the two proteins. Stable 
conformations of thirty-six total mutant structures of CXCR4 were generated to 
investigate whether mutation of the identified residues in and of themselves could 
induce an altered conformation of CXCR4. 
Overall, the dynamically determined structures of the CXCR4 mutants 
primarily adopted the conformation of the inactive native receptor, with no gross 
deviations of transmembrane structure and maintenance of the helical 
conformation of Helix eight. However, several key differences were noted in 
some of the mutant structures. The mutations of ICl3 residues K239 and K240 
altered the conformations of ICl2 and ICl3 as well as the base of TM6 and the 
position of the intrahelical terminus of TM?, suggesting that these residues are 
essential to the maintenance of TM? position and that mutation substantially 
affects CXCR4 structure. 
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Mutations of the initial portion of helix eight were not found to disturb 
helical character of this region; however, several of the mutations produced 
alterations of the conformation of ICl3, as well as the position of TM? Both of 
the mutants developed by SOM targeting this region, A30?E-K308A and A30?E-
K308A-F309A were inactive and failed to produce a significant response to 
CXCl12. This suggests that the apex of helix 8 at the base of the C-terminus is 
essential to CXCR4 function. 
Mutations of the distal C-terminus were found to predominantly maintain 
the native structure of the receptor. However, several of the mutations altered 
TM? position, as well as the angle of helix 8 in relation to the cytoplasmic 
membrane. Interestingly, two of the mutants developed by SOM targeting this 
region displayed hypersensitivity to CXCl12 in the form of increased response in 
chemotaxis and calcium mobilization. One of these hypersensitive mutants, 
S341A, produced a unique series of conformational changes in CXCR4 with 
modulation of ECl1, helix 8, the extracellular terminus of TM3, and the 
intracellular terminus of TM? Further exploration of these mutations would be 
needed to determine the extent of their hypersensitivity. 
Mutations of the extracellular surface of CXCR4 produced a variety of 
alterations in CXCR4 conformation in molecular dynamics screening. In SOM 
analysis, these mutants decreased CXCR4 response to CXCl12 in the form of 
reduced chemotaxis and calcium mobilization. In total, this mutagenesis analysis 
suggests that the altered CXCR4 conformations produced by mutation of target 
site residues, that the target sites are essential to CXCR4 function. 
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Perhaps the most important finding of this chapter though, came in the in 
vivo testing of three of the most active anti-CXCR4 compounds identified in 
Chapters II and III in a mouse model of pulmonary metastasis. In this assay, we 
determined that ICLGa28 and ICLGa36 decreased both tumor incidence and 
tumor burden to the same extent as AMD3100, without any of the associated 
toxicity seen with the bicyclam compounds [160]. ECLVS14 produced even 
greater inhibition of both pulmonary tumor development and tumor proliferation, 
resulting in incidence and burden values of only 40 % of the values elicited by 
AMD3100. By comparison, testing of anti-CXCR4 palindromic peptide CTCE-
9908 in a similar model of pulmonary metastasis produced a 50% reduction in 
tumor incidence and tumor burden [176]. An 4F-Benzoyl derivative of T140, 4F-
Benzoyl-TN140003, was also found to decrease tumor burden by 37% in a 
similar study [30]. Thus, these studies demonstrate that the ICLGa compounds 
ICLGa28 and ICLGa36 each potentially inhibit CXCR4 mediated metastasis to 
the same extent as existing CXCR4 inhibitors. This is the first evidence that 
targeting the intracellular surface of a GPCR in order to inhibit G-protein binding 
can be as effective inhibiting protein function as targeting the extracellular 
surface. In addition, the 60% increase in inhibition of tumor burden and tumor 
incidence marks ECLVS14 as one of the most active inhibitors of CXCR4-
mediated metastasis developed. In a clinical environment where there are 
currently no anti-metastatic compounds in clinical trials, development of a non-
toxic selective inhibitor of metastasis is a significant development. 
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CHAPTER V: SUMMARY 
Tumor metastasis represents a significant portion of the morbidity and 
mortality attributable to neoplasia. Bone metastasis is present in 30-50% of 
patients with highly metastatic visceral cancers such as breast, prostate, and 
non-small cell lung cancer. The diffuse and systemic nature of metastatic disease 
renders many conventional treatment modalities ineffective, presenting a 
particularly perplexing predicament for treatment. Unfortunately there are no 
primary anti-metastatic treatments approved by the FDA or in clinical trials. 
Muller ef a/ proposed a theory of metastasis centered on chemoattraction. 
In this theory, elevated CXCR4 surface expression by neoplastic cells coupled 
with expression of the ligand of CXCR4, CXCL 12, in lung, lymph node, brain, 
bone marrow and liver tissue, leads to directed migration of neoplastic cells to 
these tissues. In these tissues, the neoplastic cells find favorable 
microenvironments from which to spawn new metastatic foci. Elevated CXCR4 
expression has been detected in over twenty three varieties of neoplastic cells 
and is frequently associated with a more aggressive and metastatic phenotype 
leading to greater patient morbidity and mortality. 
CXCR4 is a G-Protein coupled receptor involved in signal transduction 
and cell migration. It is essential in brain and heart development in the embryo, 
and plays a critical role in the immune system, governing stem cell migration and 
sequestration in the bone marrow and the development of lymphocytes and 
465 
leukocytes. CXCR4 is also central to the process of HIV-1 infection, as one of the 
primary coreceptors for HIV-1 entry into T-Iymphocytes. 
One of the goals of SBDD is to identify structural targets which can be 
used as a basis for inhibiting a pathological process. There are five available 
target sites to inhibit a GPCR's signaling. The ligand can be sequestered or 
inactivated or the ligand interaction surface of the receptor can be altered to 
prevent interaction. The transmembrane regions of the receptor responsible for 
signal transduction from the extracellular to the intracellular surface of the cell 
membrane can be disrupted, or held in an inactive position. Finally, the 
intracellular surface of the receptor can be prevented from interacting with the 
coupled G-protein, either by altering or obstructing the intracellular surface of the 
receptor or the complimentary interacting surface of the G-proteins. Inhibitory 
efforts targeting CXCR4 have targeted just the extracellular surface of the 
receptor. The remaining four targets remain largely unexplored. The hypothesis 
of our research is that inhibition of CXCR4 can result in inhibition of metastasis, 
and that this inhibition can be effected by targeting multiple sites of CXCR4, both 
on the intracellular and extracellular surface of the receptor. The goals of this 
research were to utilize SBDD to rationally target specific sites of CXCR4 to 
develop inhibitors of metastasis. In this process, we would gain a greater 
understanding of chemical elements which could induce phenotypical changes 
produced by inhibitors through the use of QSAR analysis. We would also gain 
insight into the structural changes elicited in the receptor by interactions between 
active inhibitors and their targets through the use of molecular dynamics 
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simulations. We would additionally gain insight into the receptor targets 
themselves through the use of virtual screening in conjunction with molecular 
dynamics and site directed mutagenesis. 
Our analysis of compounds targeting the extracellular surface of the 
receptor identified three compounds which inhibited CXCR4 at 10 IJM or less. 
ECl VS 14 stands out amongst these compounds as a selective inhibitor of 
CXCR4 with minimal cytotoxicity. Subsequent QSAR analysis of EClVS14 
revealed that although conversion of the hydrazine-alkyl linker group increased 
anti-CXCR4 activity, it also increased cytotoxicity. lengthening of the hydrazine-
alkyl linker moiety was found to reduce anti-CXCR4 activity, as did removal of the 
1-BPMAM moiety. Modification of the terminal benzene group by addition of 
electronegative substituents also decreased the anti-CXCR4 activity of the parent 
compound. EClVS14 is unique in its inability to modify calcium signaling, a 
characteristic that is not shared by any other CXCR4 inhibitors [289-291], 
including T140 [195] and AMD3100 [275]. 
Our five ns molecular dynamics simulations have allowed us to gain a 
finer mechanistic understanding of the interaction between CXCR4 and 
EClVS14. We have found that EClVS14 drives CXCR4 into a unique 
conformation which seems to be more open at the extracellular surface than 
seen in the native conformation, but less open than seen in the N119S 
conformation. 
Targeting the interface between the intracellular surface of CXCR4 and 
the G protein subunit Gai with virtual screening allowed us to identify twenty-four 
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compounds which significantly inhibited CXCR4-mediated chemotaxis. This initial 
hit rate of 64.9 % at 50 IlM represents a significant increase over contemporary 
virtual screening and high-throughput studies. Ten of these compounds inhibited 
CXCR4 mediated chemotaxis at 10 IlM or less, and only 5 of these compounds 
displayed any activity in fellow class A GPCR BL T1 demonstrating that the 
compounds were highly selective for the intracellular interface of CXCR4. Three 
of the ICLGa compounds were also found to inhibit tumor cell proliferation, an 
intriguing result, as a CXCR4 inhibitor need not be cytotoxic to function as a 
metastatic agent, for instance ICLGa36 inhibits chemotaxis but does not affect 
metastatic cell proliferation. 
Molecular dynamics analysis revealed that several of the compounds 
interacted with components of the side chains and backbones of ICL 1 and ICL2, 
suggesting that the compounds could act as bridging elements between these 
two regions, stabilizing their position and preventing signal transduction or 
producing a more closed intracellular surface potentially incapable of binding Gai. 
Interaction by the compounds with the C-terminal region could potentially 
stabilize TM?, or interfere with the interface between the C-terminus and Gai. 
This could be especially true in the case of ICLGa28, where interposition of the 
compound between the C-terminus and ICL3 could restrict the movement of both 
regions and directly impede the cleft which would be occupied by bound Gai. 
This study represents the first attempt of structure based drug design to 
successfully target the intracellular surface of a GPCR. Further, we demonstrate 
that selective inhibition of GPCR function need not only target the extracellular 
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CXCl12 interface, as has been the objective of all other anti-CXCR4 compound 
development, but rather that CXCR4 can be effectively inhibited by interfering 
with the entire sequence of events of its signal transduction apparatus. 
Further examination of CXCR4 structure through in silico mutation of 
target site residues identified by our virtual rescreening protocol determined that 
while the receptors predominantly maintained in the inactive native conformation 
several significant differences between native and mutant structures were 
detected. These differences were corroborated by our admittedly limited in vitro 
analysis of mutations of the target site residues produced by site directed 
mutagenesis. All but two of these mutants displayed reductions of chemotaxis 
and calcium mobilization by 50% or greater when compared to the wild type 
receptor. The remaining two mutants were hypersensitive to CXCl12 
administration, producing elevated chemotaxis and calcium mobilization 
responses. This suggests that the target sites selected are essential for CXCR4 
function and that compound interactions modulating these sites, could potentially 
alter the CXCR4 phenotype. 
Perhaps the most important findings of this dissertation came in the in vivo 
testing of three of the most active anti-CXCR4 compounds, ECl VS 14, IClGa28 
and IClGa36 in a mouse model of pulmonary metastasis. In finding that 
IClGa28 and IClGa36 both decreased both tumor incidence and tumor burden 
by 50 %, we demonstrated for the first time that the anti-CXCR4 compounds 
targeting the intracellular surface could inhibit metastasis to the same extent as 
extracellular inhibitors of CXCR4 AMD3100, CTCE-9908 and T140 derivative, 
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4F-Benzoyl-TN140003. In addition, the almost 80% decrease of tumor incidence 
and tumor burden produced by ECl VS 14 represented highly significant inhibition 
of tumor burden and incidence, a 60% increase over the inhibition produced by 
the most advanced CXCR4 inhibitor, AMD31 00. All three of the screened 
compounds produced no detectable toxic side effects. In a clinical environment 
where there are currently limited anti-metastatic compounds in clinical trials, 
development of three non-toxic selective inhibitors of metastasis is a significant 
development. 
The findings presented in this dissertation provide insight into the process 
of SBDD targeting a GPCR. We have successfully demonstrated that metastasis 
can be inhibited by targeting multiple regions of CXCR4. We have used drug 
discovery to develop sixteen lead compounds which have great potential as 
scaffolds for inhibiting CXCR4. Building upon these results, further drug 
discovery focusing on optimization of the lead compounds could allow 
characterization of essential pharmacophores for lead compound activity. The 
impact of the compounds on different mechanisms of CXCR4 signaling could 
further characterize the mechanism of action for each of the lead compounds. 
Development of additional mutants based on the interaction residues identified in 
the molecular dynamics study could also allow us to confirm the dynamically 
determined interaction site for the compounds. Further virtual screening could 
attempt to develop CXCR4 inhibitors targeting the remaining two potential 
regions of CXCR4: the intrahelical regions of CXCR4 as well as the CXCl12 
interface with the extracellular surface of CXCR4. 
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